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Abstract 
 
NEDD8 modification of proteins is extensively studied in the recent years, and the 
ubiquitin-like molecule has been shown to be involved in numerous signalling 
pathways. In addition to its well-established roles, we showed that NEDD8 responds to 
various stress conditions, such as inhibition of the 26S proteasome, heat shock and 
oxidative stress. 
Modification of proteins with ubiquitin and ubiquitin-like molecules is involved in the 
regulation of almost every biological process. Historically, each conjugation pathway 
has its unique set of E1, E2 and E3 enzymes that lead to activation and conjugation of 
their cognate molecules. We also showed the unexpected finding that the ubiquitin E1 
enzyme Ube1 activates the ubiquitin-like molecule NEDD8. The above-mentioned 
stress conditions cause a global increase in NEDDylation. Surprisingly, this does not 
depend on the NEDD8 E1 activating enzyme but rather on Ube1. A common event in 
the tested stress conditions is the depletion of “free” ubiquitin. A decrease in “free” 
ubiquitin levels in the absence of additional stress is sufficient to stimulate 
NEDDylation through Ube1. We also performed mass spectrometric analyses to 
investigate NEDD8 chain formation under stress. We found that NEDD8 forms chains 
with itself and with ubiquitin, and these chains are recognized by proteasome receptors 
and shuttle factors. Our studies revealed an unprecedented interplay between NEDD8 
and ubiquitin pathways, operating in diverse cellular stress conditions. 
In a parallel project, we characterized the role of the deNEDDylating enzyme NEDP1 in 
response to DNA damage. The NEDP1 ortholog in C. elegans, Ulp-3 has been 
previously investigated in collaboration with Anton Gartner’s group. The enzyme has 
been found to be required for DNA damage-induced apoptosis in the worm germ line. 
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Our results in human cell lines showed that the role of NEDP1 is conserved, since 
NEDP1 knockdown resulted in impaired effector caspase activation. Moreover, we 
showed that the nedp1 gene is induced upon ionizing irradiation. In the absence of the 
enzyme, we observed increased NEDDylation that was dependent on the NEDD8 E1 
enzyme. 
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1.1. The history of ubiquitin 
Ubiquitin was first identified in 1975 as a 76 amino acid polypeptide that is expressed 
in all eukaryotic cells[1]. Shortly after, covalent attachment of ubiquitin to target 
proteins was found to be a major protein regulatory mechanism. 
The ubiquitin field was created in the late 1970s, when the ubiquitin conjugation 
pathway and its role in protein degradation were discovered. In 2004, Avram Hershko, 
Aaron Ciechanover and Irwin A. Rose were awarded with the Nobel Prize in Chemistry 
for these discoveries. In the initial experiment, they noted that proteins added to 
reticulocyte extract became attached to ubiquitin and subsequently degraded by a 
protease in an ATP-dependent manner[2, 3]. In a paper in 1980, they speculated for the 
action of a conjugation machinery, the protease function that degrades proteins and the 
recycling machinery (deubiquitinating enzymes), which amazingly proved to be 
correct[4]. Later on, the E1, E2 and E3 enzymes were isolated and characterized[5, 6], 
and the ATP-dependent protease was shown to be the 26S proteasome[7].  
The first biological functions for the ubiquitin system were discovered in Alexander 
Varshavsky’s laboratory between 1984-1990. They showed that ubiquitin conjugation 
was essential for protein degradation in vivo[8], required for cell viability and the 
regulation of stress responses, cell cycle, protein synthesis and DNA repair[9-11]. The 
first protein identified to be modified by ubiquitin in cells was histone H2A[12] (the 
role of histone ubiquitination is further discussed in Chapter 1.3). 
These early discoveries were followed by the characterization of the enzymes involved 
in ubiquitin conjugation and the different polyubiquitin chain topologies that play role 
in distinct cellular processes. Malfunctions of the ubiquitin system have been shown to 
be linked to disease and aging, making the pathway an attractive therapeutic target. 
 19 
Nowadays pharmaceutical companies invest a lot in gaining a mechanistic insight into 
the system and develop compounds that target components of the pathway. The 
ubiquitin system is still one of the most dynamic and fastest expanding fields in 
biological sciences. 
1.2. Ubiquitin conjugation system 
In mammals, ubiquitin is encoded in 4 genes, either as polyubiquitin precursors or as a 
protein fused to ribosomal proteins L40 or S27a (Figure 1.1). 
 
Figure 1.1: Human ubiquitin genes and their chromosomal locations. 
Ubiquitin is encoded by 4 genes, and is transcribed and translated either fused to the C-
terminus of ribosomal proteins, or as a linear fusion of multiple ubiquitins. Adapted 
from:[13] 
 
C-terminal hydrolases catalyse cleavage of the fusions, exposing the diglycine motif on 
ubiquitin that can be activated by one of the two ubiquitin activating enzymes, Ube1 or 
Uba6[14]. These enzymes share a region of sequence homology with the bacterial 
enzyme MoeB that catalyse similar reaction. Structural studies on MoeB in complex 
with MoaD -the small protein in bacteria displaying the ubiquitin-fold and the Gly-Gly 
motif- provided insight into the mechanism of ubiquitin activation by the E1 
enzyme[15].  
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Ubiquitin E1s consist of three functional parts: an adenylation domain that binds to 
ubiquitin and ATP, the catalytic cysteine domain and the ubiquitin-fold domain (UFD), 
which binds to E2 enzymes [15-17]. The E1 enzymes have distinct preferences for E2 
charging, and ubiquitin E2s discriminate between Ube1 and Uba6 by the recognition of 
differences in their UFDs[18]. 
In the first step of activation, a ubiquitin C-terminal acyl-adenylate formation is 
catalysed by the E1 enzyme, which binds to ATP-Mg2+ and ubiquitin. Next, the C-
terminal carboxyl group of ubiquitin forms a thiolester bond with the catalytic cysteine 
residue in the E1 enzyme. The activated ubiquitin is then transferred to the catalytic 
cysteine of E2 conjugating enzymes[14]. E2s share a conserved globular domain and 
some of them also have N- or C-terminal extensions, which may regulate E3 association, 
intrinsic E2 activity, or substrate recognition[19]. E2s can determine the type of the 
polyubiquitin chain linkage by orienting the ubiquitin to expose the desired Lys residue 
to its active site[20]. Ubiquitin is then transferred to the ε-amino group of the substrate 
lysine via the aid of E3 ligases that contain both E2 and substrate binding sites[21]. One 
class of the E3s is the HECT domain (homologous to E6-AP carboxy terminus; an 
approximately 350-amino-acid C-terminal region) containing ligases. Ubiquitin is 
transferred from the E2s to the catalytic cysteine of the HECT-type E3s; therefore these 
ligases are directly involved in catalysing substrate ubiquitination[22]. E6-AP, the first 
E3 ligase discovered in humans belongs to this class of enzymes. It has been shown to 
target the tumor suppressor p53 for degradation together with the E6 protein encoded by 
human papillomaviruses[23]. Another predominant class of the E3s is the family of the 
RING-finger (really interesting new gene)/U-box ligases. RING E3s contain a RING 
motif (a short motif of Cys3HisCys4) that coordinates a pair of zinc ions. RING and U-
box E3s provide the platform where charged E2s and substrates can bind to close 
proximity[24]. Recently, two papers have shown that RING/U-box E3s catalyse 
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ubiquitination by triggering E2-Ub to shift to a more closed, active conformation[25, 
26]. 
Under certain circumstances, E4 ubiquitin ligases can extend ubiquitin chains in 
conjunction with E3 ligases[27, 28]. 
 
Figure 1.2: The ubiquitin conjugation cascade. 
Ubiquitin is activated by the E1 enzyme, then transferred onto the catalytic cysteine of 
an E2 conjugating enzyme. Through the action of E3 ligases, ubiquitin is covalently 
attached to substrate lysine residues. Polybiquitin chains are often formed on substrates. 
Adapted from[14] 
Ubiquitination is a reversible process: deubiquitinating enzymes (DUBs) are responsible 
for cleaving the isopeptide bond between ubiquitin and its target protein. By processing 
polyubiquitin chains, they have the potential to alter the fate of the substrates (rescue 
proteins from degradation). On the other hand, once the ubiquitinated protein is 
recognized by the 26S proteasome, the removal of ubiquitin from substrates by the 
DUBs is required for protein degradation and recycling of free ubiquitin[29] (Figure 
1.3). 
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Figure 1 | Diverse functions of ubiquitin-like proteins. a | The canonical conjugation pathway for ubiquitin (Ub).  
The E1 enzyme ubiquitin-activating enzyme 1 (UBA1) reacts with ubiquitin to form a ubiquitin~adenylate intermediate  
(the tilde (~) represents a high-energy bond between the carboxy-terminal carboxylate of the ubiquitin and AMP). Ubiquitin 
is transferred to a Cys in the catalytic domain of UBA1 to form the activated ubiquitin~UBA1 complex. A second molecule of 
ubiquitin binds to the adenylation domain and is converted to ubiquitin~adenylate. The doubly loaded E1 complex is then 
recognized by a cognate E2 ubiquitin-conjugating enzyme, which receives ubiquitin to form a ubiquitin-charged E2. 
E2 enzymes recognize E3 enzymes that are associated with substrates and transfer ubiquitin to the substrate. Multiple 
cycles of binding to charged E2 enzymes leads to the formation of ubiquitin chains, which are recognized by the 26S 
proteasome, facilitating substrate degradation. b | Enzymatic mechanism of the ubiquitin activation and conjugation cycle. 
For ubiquitin, the E1 enzyme is UBA1. Ub(A) represents ubiquitin that is associated non-covalently at the adenylation active 
site, and Ub(T) represents ubiquitin that is covalently linked to the catalytic Cys of UBA1 through a thioester bond. Step 1 
shows adenylate formation, step 2 shows thioester formation, step 3 shows double ubiquitin loading of E1 and step 4 shows 
ubiquitin transfer to E2. Step 2 is repeated on the E1 Ub(A)~adenylate generated in step 4 to continue the cycle. c | The 
pathways that use the 17 ubiquitin-like proteins (UBLs; yellow) that are known to be conjugated to other molecules through 
their C-terminal Gly residue are arranged around the phylogenetic tree. E1 enzymes (purple) for specific UBLs can be 
monomeric (UBA1, UBA6 (also known as UBE1L2) and UBE1L (also known as UBA7), heterodimeric (SAE1–UBA2 and 
NAE1–UBA3), or homodimeric (UBA4, ATG7 and probably UBA5) (ATG7 is autophagy-related protein 7, NAE1 is neuronal 
precursor cell-expressed developmentally downregulated protein 8 (NEDD8)-activating enzyme 1 and SAE1 is small 
ubiquitin-related modifier (SUMO)-activating enzyme 1). E2 enzymes (green) associate with E1 proteins and receive the 
activated UBL through a trans-thioesterification reaction. E2s then transfer their UBLs to substrates (orange), typically 
through association with an E3 ubiquitin ligase (magenta). Ahp1, alkyl hydroperoxide reductase 1; GABARAPL, 
gamma-aminobutyric acid receptor-associated protein-like; ISG15, interferon-stimulated gene 15; MAP1LC3, microtubule-
associated protein 1 light chain 3; RBX1, RING-box protein 1; UBC, UBL-conjugating enzyme; UFC1, UFM1-conjugating 
enzyme 1; UFM1, ubiquitin-fold modifier 1; URM1, ubiquitin-related modifier 1.
REVIEWS
320 |.": |70-6.&  www.nature.com/reviews/molcellbio
)''0DXZd`ccXeGlYc`j_\ijC`d`k\[%8cci`^_kji\j\im\[
!
	  	  
	  
 22 
Nature Reviews | Molecular Cell Biology
Ub
UBB
UBC Ub Ub Ub Ub Ub Ub Ub Ub
Ub Ub Ub
UBA52 Ub
UBA80 Ub
L
S
Ub
Ub
a  Precursor processing
d  Recycling
b  Rescue from
     degradation
c  Removal of
non-degradative
ubiquitin signal
e
f  Editing
Protein
Protein
Ub
Ub
Ub
Ub
Ub
Ub
Ub
UbDegradativesignal
Degradation
Non-degradative
signal
Protein
Protein
Protein
Ub
UbUbUbUbUbUbUbUb
Ub
Ub
Ub
Ub
Ub
UbUb
Free ubiquitin pool
DUB UbiquitinUb
Acyl intermediate
An intermediate in the Cys 
DUB reaction mechanism, in 
which the DUB is covalently 
bound to the C terminus of the 
distal ubiquitin. A sulphur acyl 
bond is formed between the 
C-terminal Gly of ubiquitin and 
the catalytic Cys of the DUB.
Oxy-anion hole
Found next to the catalytic Cys 
of a DUB, this environment 
stabilizes the negative charge 
that is created during the 
transition state before  
the formation of the acyl 
intermediate, by supplying 
hydrogen-donating amide 
groups, for example on Asn  
or Gln.
A detailed understanding of the reaction mechanism 
of Cys proteases has been gained from studies of the 
plant protease papain10. A feature of this mechanism is 
a catalytic acyl intermediate, in which the carboxyl group 
is covalently bound to the catalytic Cys after the amino 
group has been cleaved. The negatively charged trans-
ition state is stabilized by hydrogen-donating residues, 
which form an oxy-anion hole nearby. In a second step, a 
water molecule hydrolyses the acyl-Cys intermediate to 
complete the catalytic cycle (see Supplementary inform-
ation S1 (figure)). Strikingly, all Cys protease DUB 
families have divergent folds, but their catalytic residues 
superpose with only small deviations when bound to 
the ubiquitin C terminus9. The binding of ubiquitin 
to DUBs also imparts conformational order to otherwise 
unstructured loops.
Structural dynamics of USP domains. USP domains 
consist of three subdomains that have been likened to 
the palm, thumb and fingers of a hand11 (FIG. 4). The 
catalytic centre lies at the interface between the Palm 
and Thumb subdomains, and the Fingers subdomain 
grips the distal ubiquitin. Note that distal refers here and 
hereafter to the relative position of ubiquitin moieties in 
a ubiquitin chain; in a ubiquitin dimer this corresponds 
to the ubiquitin molecule that is conjugated through its 
C-terminal Gly.
Some apo-USP domains — that is, USP domains 
not bound to a substrate — are predominantly in non-
productive catalytic configurations, but undergo con-
formational changes when ubiquitin binds. This can be 
considered as shifting an equilibrium between active and 
inactive conformations, towards the active state. This is 
well characterized for USP7 (also known as Herpes virus-
associated USP (HAUSP)), for which ubiquitin binding 
is required to bring the catalytic Cys in range of the His 
residue11,12 (FIG. 4a). By contrast, the catalytic triads of 
USP14 and USP8 (also known as UBPY) are properly 
aligned for catalysis in the absence of ubiquitin, but 
ubiquitin-binding surface loops occlude the active site13,14. 
For USP14, ubiquitin binding leads to translocation of 
these loops, allowing access of the ubiquitin C terminus 
to the active site13. In USP8, which has so far only been 
crystallized in the apo form, the Fingers subdomain is 
retracted, further blocking the ubiquitin-binding site14 
(see Supplementary information S2 (figure)). However, 
inactive conformations are not a global feature of USPs: 
the USP domain of the cylindromatosis-associated DUB, 
CYLD, is both poised for catalysis and accessible15 (see 
Supplementary information S2 (figure)).
The linear amino acid sequence of USP domains can 
be disrupted by large polypeptide insertions138, which 
can fold into independent domains, such as the B-box 
domain in CYLD15 (FIG. 1; see Supplementary information 
S2 (figure)) and the UBA domains in USP5 (also known 
as ISOT) and USP13 (also known as ISOT3)12. The UBA 
domains of USP5 constitute additional ubiquitin-binding 
sites and affect enzyme activity12, whereas the B-box in 
CYLD influences subcellular localization15. Several USP 
insertions are predicted to adopt UBL folds, although no 
clear function has been assigned to these8 (FIG. 1).
OTU domains — variations of the catalytic triad. OTU 
domains can be phylogenetically divided into three sub-
classes: the Otubains (present in OTUB1 and OTUB2), 
the A20-like OTUs (present in A20, valosin-containing 
protein p97/p47 complex-interacting protein p135 
(VCIP135; also known as VCPIP1), OTU domain- 
containing protein 7B (OTUD7B; also known as Cezanne) 
and ubiquitin thioesterase ZRANB1 (also known 
as TRABID)) and the OTUs5 (FIG. 2). Representative 
structures for each class are available (FIG. 4b; see 
Supplementary information S3 (figure)).
The structure of yeast Otu1 covalently bound to 
ubiquitin has revealed that a large surface loop, which 
is disordered in the apo-structures of OTUB2, OTUB1 
and A20 (REFS 9,16–18), forms the bulk of ubiquitin 
interactions19. Superposition of the ubiquitin-bound 
structure of Otu1 onto the structure of A20 suggests 
that the binding site for a distal ubiquitin moiety must 
have diverged in A20, because a helical domain blocks 
access to this site. As with USPs, the catalytically inactive 
conformations have been determined; for example, in 
the apo-form of OTUB1, the catalytic His residue is not 
productively aligned with the Cys residue16.
Figure 3 | General roles of DUBs. a \ Ubiquitin is encoded by four genes (UBC, UBB, 
UBA52 and UBA80) and is transcribed and translated as a linear fusion consisting of 
multiple copies of ubiquitin or ubiquitin fused to the amino terminus of two ribosomal 
proteins, 40S ribosomal protein L40 (L) and 60S ribosomal protein S27a (S). Note that  
the polyubiquitin genes encode an extension one or several amino acids long at their 
carboxyl terminus (shown in yellow). Generation of free ubiquitin from these precursors 
is a key function of deubiquitinases (DUBs; also known as deubiquitylating or 
deubiquitinating enzymes). b \ Deubiquitylation can rescue proteins from degradation.  
c \ Alternatively, deubiquitylation can remove a non-degradative ubiquitin signal.  
d \ DUBs have a crucial role in maintaining ubiquitin homeostasis and preventing 
degradation of ubiquitin together with substrates of the 26S proteasome and lysosomal 
pathways (recycling of ubiquitin). e \ Disassembly of ubiquitin chains generated by en bloc 
removal from substrates ensures that recycled ubiquitin re-enters the free ubiquitin pool. 
f \ Some DUBs might function to edit ubiquitin chains and thereby help to exchange one 
type of ubiquitin signal for another.
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Figure 1.3: The different roles of the deubiquitinating enzymes (DUBs). 
(a) DUBs are responsible for the generation of free ubiquitin from the precursors. (b) 
They also catalyse ubiquitin chain removal from substrates, therefore rescui g them 
from degradation. Polyubiquitin chain removal prior to substrate degradation by the 26S 
proteasome, and the trimming of the ubiquitin chains are required for the maintenance 
of the free ubiquitin pool, and are also catalysed by DUBs (d-f). Adapted from: [29] 
The human genome encodes around 100 DUBs. Among them, there are 4 classes of the 
cysteine proteases: ubiquitin-specific proteases (USPs), ubiquitin C-terminal hydrolases 
(UCHs), Machado-Joseph domain proteases and the ovarian tu or-related (OTU) 
proteases. They rely on a catalytic diad or triad for their activity (the catalytic Cys, a 
nearby His and an Asn or Asp residu )[29]. The fifth class of DUBs, the JAMM-motif 
proteases are zinc m talloprotea es. They coordinate two zinc ions that are important 
for their catalytic mechanism of action[30]. Most of the DUBs catalyse a proteolytic 
reaction between the ε-amino group of lysine an  a carboxyl group on the C-terminus f 
ubiquitin or ubiquitin-like molecule (ubl). 
DUBs possess different types of ubiquitin-binding domains (UBDs) in their structures 
that mediate protein-protein interactions. The Ile36 patch (Ile36, Leu71 and Leu73) on 
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ubiquitin has been shown to be important for recognition by DUBs[31]. The enzymes 
display specificity both to ubiquitin chain types and to substrates and possess a great 
influence on the outcome of ubiquitin signalling. 
 
1.3. Ubiquitin chain linkages and the biological outcome 
of ubiquitination 
Ubiquitination on proteins can serve as signal for diverse cellular processes. Depending 
on whether it is conjugated as a monomer or chain of different linkages, it can target 
substrates to distinct fates.  
The first protein identified to be modified by ubiquitin in cells is histone H2A[12]. A 
single ubiquitin attachment to H2A or H2B has been shown to play critical roles in 
transcription regulation and DNA repair (reviewed in[32]). Monoubiquitination or 
multiple monoubiquitination on proteins can also signal for destruction by the 
lysosomes. Several ion channels and signal-transducing receptors are 
monoubiquitinated in response to an extracellular signal, and ubiquitination regulates 
their endocytic transport[33, 34]. Modification by a single ubiquitin also has a crucial 
role in maintaining genomic integrity, since monoubiqitination of FANCD2 is essential 
for the Fanconi anemia tumor suppressor pathway to function[35]. Additionally, single 
ubiquitin attachment has been reported to be important for virus budding[36]. 
Ubiquitin contains seven lysines (which are Lys6, Lys11, Lys27, Lys29, Lys33, Lys48 
and Lys63) and all of them can serve in the formation of polyubiquitin chains. Ubiquitin 
can form polymers in homotypic (the chain contains only one type of linkage) or 
heterotypic (chains with different types of linkages) ways. Heterotypic chains can be 
branched when ubiquitin is modified on two or more sides[37] (Figure 1.4).  
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The assembly of the different chain types can be oriented by E2s or E3s. In the case of 
the RING or U-box domain containing E3 ligases, the linkage specificity is most likely 
determined by the E2s. For instance the SCF ligases use the Lys48-specific E2 Ube2R1 
to Lys48-polyubiquitinate substrates[38], while the anaphase-promoting complex 
(APC/C) uses the Lys11-specific Ube2S to produce Lys11-linked chains[39]. Some E3s 
can synthetize different chains depending on the E2 enzymes they pair up with: for 
example BRCA1-BARD1 assembles Lys48 linkages with Ube2K, but Lys63 linkages 
when bound to Ube2N-Uev1A[40]. On the contrary, HECT-type E3 ligases display 
linkage specificity. NEDD4 synthesises Lys63-linked chains, while E6-AP assembles 
Lys48-linked chains[41]. 
The most studied linkage types are Lys48 and Lys63. Lys48 chains play role in the 
regulation of proteasomal degradation. This is the only essential lysine on ubiquitin in 
yeast[42], and the most abundant linkage type in all tested organisms[43, 44]. Lys63-
linked chains can trigger proteolysis by targeting substrates to lysosomes[45]. However, 
they have non-proteolytic functions as well, such as roles in trafficking, signaling, DNA 
damage response and in the immune system (reviewed in[46]). Roles of the other 
linkages are starting to emerge: Lys11 polyubiquitin chains are linked to proteasomal 
degradation of specific proteins involved in cell cycle progression[47]. The abundance 
of this type of linkage increases when the APC/C anaphase-promoting complex (or 
cyclosome) is active[48]. Lys11 chains might be involved in the NF-kB signaling 
pathway, as c-IAP1 and UbcH5 have been shown to assemble Lys11-linked ubiquitin 
chains on RIP1 in the TNFR1 complex [49]. The BRCA1- BARD1 complex was 
reported to assemble Lys6 linked chains on itself that can be recognized by RAP80, 
linking this type of modification to DNA repair and DNA damage response[50]. Lys29 
linkages are enriched following proteasome inhibition[44, 51], and are formed on 
substrates of the ubiquitin-fusion degradation pathway[52]. Lys27 and Lys33 may be 
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assembled during stress response by U-box E3 ligases[53]. Lys27 chains were linked to 
mitochondrial biology, since this type of polyubiquitination occurs on several 
mitochondrial proteins by the E3 ligase parkin after mitochondrial damage[54]. In 
addition, Lys33 and Lys29 have been reported to inhibit kinase activity of members of 
the AMPK (AMP-activated protein kinase)-related protein kinases[55]. 
Additionally, the C-terminal glycine residue (Gly76) of ubiquitin can be linked on Met1 
of the distal ubiquitin, forming linear chains. So far only one E3 ligase complex, the 
linear ubiquitin chain assembly complex (LUBAC) has been shown to assemble such 
chains[56]. Met1-linked chains play crucial roles in NF-kB signaling[57-59]. 
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Structural work is getting closer to elucidating the 
mechanisms underlying chain specificity in HECT 
domains. The structure of the NEDD4 HECT domain 
bound to ubiquitin-charged UBE2D revealed a direct 
interaction between the donor ubiquitin and the HECT 
domain56, and this interaction is mediated by the Ile36 
patch of ubiquitin and the HECT C-lobe. This com-
plex seems to be poised for transthiolation by placing 
the HECT and E2 catalytic residues in close proximity56 
(FIG. 2c).
It was already known that the N-lobe of HECT 
domains can non-covalently interact with ubiquitin, 
but it was unclear whether this interaction promoted 
or inhibited chain elongation57,58. The crystal struc-
tures of Rsp5 and NEDD4L HECT domain in complex 
with ubiquitin provide a molecular description of the 
ubiquiti n-binding site in the N-lobe, and this non-
covalen t binding site was shown to be essential for ligase 
processivity59,60. However, the N-lobe ubiquitin-binding 
site is remote from the catalytic Cys and unlikely to bind 
the acceptor ubiquitin directly. It is possible that a third 
ubiquitin bridges the gap between the N-lobe and the 
donor ubiquitin, and this third ubiquitin, which could 
interact with the specificity-determining C terminus, 
might serve as the real acceptor in a chain assembly 
reaction (FIG. 2c). This is reminiscent of E2 enzymes that 
harbour an additional ubiquitin-binding site, which is 
important for chain assembly but is too remote to be 
targeted by the E2 in cis44. Further structural insights are 
required to fully understand HECT domain-mediated 
specificity.
RBR E3 ligases. E3 ligases of the RBR family comprise 
a canonical RING domain, an in-between RING (IBR) 
domain and a RING2 domain, and this module is pre-
sent in 18 human enzymes61. The best studied proteins 
in this family include parkin, an E3 ligase that is involved in 
Parkinson’s disease and mitochondrial maintenance (see 
below)62, and HOIP (haeme-oxidized IRP2 ubiquiti n 
ligase 1L (HOIL1L)-interacting protein; also known as 
RNF31), which is the catalytically active component of 
the linear ubiquitin chain assembly complex (LUBAC; 
see below)63. LUBAC exclusively assembles linear ubiq-
uitin chains in an E2-independent fashion as it is able 
to override the intrinsic specificity of, for example, the 
Lys48-specific E2 enzyme UBE2K64.
Mechanistic insights into RBR ligase-mediated 
chain assembly come from the finding that some RBR 
E3 ligases, including HHARI (human homologue of 
ariadne; also known as ARIH1), act as RING–HECT 
hybrids. For these ligases it was found that the first RING 
domain of the RBR module does not directly discharge 
an E2-bound ubiquitin onto a substrate but instead onto 
a Cys residue in the RING2 domain34 (FIG. 2d). The con-
servation of the RING2 domain that often contains a 
suitable acceptor Cys suggests that most RBR domains 
follow such a hybrid mechanism.
Therefore, an RBR~ubiquitin intermediate can 
act in an E2-independent fashion just like a HECT 
domain. We currently lack molecular insights into 
RBR ligase mechanisms, as members of this ligase 
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Figure 1.4: Lysines on ubiquitin and ubiquitin linkage types. 
a, The seven lysine residues, Met1 and the C-terminus are shown in stick representation 
on the ubiquitin structure. Blue spheres indicate the amino groups that are modified 
during ubiquitin chain formation. b, Ubiquitin can modify substrates as a monomer or 
polymer of different linkage types. Adapted from:[60] 
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The signals created by ubiquitin chains are decoded by specific receptors in the cells 
that contain ubiquitin-binding domains (UBDs). UBDs bind non-covalently to ubiquitin 
signals. The interaction is linkage specific and directs proteins to cellular fates such as 
degradation or translocation. Linkage specificity of the domains is achieved by either 
the recognition of the linker region between two ubiquitin moieties or the detection of 
the spatial distribution and positioning of the units of the ubiquitin chain[61]. Most of 
the UBDs bind to the hydrophobic patch around Ile44 on ubiquitin (Leu8, Ile44, 
Val70); therefore this patch is essential for signalling. To what extend this patch is 
exposed depends on the type of the chain conformation that is determined by the 
linkages: Lys63-linked chains adopt an extended structure that exposes the patches, 
whereas Lys48 chains are in a compact conformation in solution, therefore the 
hydrophobic patch is buried. However, under physiological conditions this 
conformation oscillates between the open and packed structure[62]. Structural work has 
revealed that UBD binding to ubiquitin changes the conformation of ubiquitin[63]. The 
length of the chain is also an important determinant of the UBD-ubiquitin interaction: it 
has been shown that at least 4 Lys48-linked ubiquitin moieties are required for 
recognition by receptors associated with the 26S proteasome[64]. Binding affinities of 
individual UBDs for ubiquitin are generally low. Proteins containing multiple UBDs or 
multiple ubiquitin-binding surfaces in single domains make high-avidity interactions 
possible[65]. 
Several distinct UBDs have been described so far that are different in structures but 
non-covalently bind to ubiquitin. The most commons contain a single or multiple α-
helices in their structure. This fold can be found for example in the ubiquitin-associated 
domains (UBAs) that are present in several proteins involved in ubiquitin-mediated 
proteolysis[66], such as in shuttle factors that deliver ubiquitinated substrates to the 26S 
proteasome (Figure 1.5).  Shuttle proteins include HHR23A/B and PLIC1-4 (Dsk2 in 
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yeast)[67]. UBA domains generally bind Lys48-linked chains in strong preference to 
monoubiquitin[68]. The ubiquitin interacting motif (UIM) also folds into α–helical 
structures. It was first identified in an intrinsic ubiquitin receptor of the 26S proteasome, 
Rpn10/S5a[69]. Another types of UBDs contain zinc finger folds to engage in ubiquitin 
binding. The ubiquitin-binding zinc finger (UBZ) domains have been found in many 
proteins regulating DNA repair and have been shown to be crucial for recruiting 
proteins to the sites of DNA damage[70]. For example, PCNA monoubiquitination in 
response to DNA damage recruits the Y family DNA polymerases that recognize 
ubiquitin through their UBZ domains. This provides a high-affinity interaction and is 
essential for the successful repair of the damaged DNA[71] The pleckstrin-homology 
(PH) fold (such as the pleckstrin-like receptor for ubiquitin (PRU)) can be found in the 
other intrinsic proteasomal ubiquitin receptor, Rpn13[72]. E2 and E3 enzymes also have 
to bind to ubiquitin through their UBDs to fulfil their functions. The Ile36/ 
Leu71/Leu73 patch on ubiquitin has been described to be important for the interaction 
with the E2/E3 complex[73]. 
The so-called UBL (ubiquitin-like) fold can be also found in several proteins, including 
ubiquitin-like modifiers, or as a part of a multidomain structure in proteins that cannot 
be conjugated to substrates. Protein shuttle factors have UBL domains through which 
they can interact with the 26S proteasome[67] (see also Figure 1.5). Additionally, USP 
enzymes and E3 ligases have been predicted to possess such folds[74]. 
UBDs themselves can be regulated by posttranslational modifications: 
monoubiqitination of Rpn10 controls the receptor availability to bind ubiquitinated 
proteins[75]; and phosphorylation of the UBA domain of p62 enhances its binding to 
Lys63-linked chains and in turn regulates autophagy[76]. 
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Figure 1.5: Examples of UBD-containing proteins and their domain structures.  
The figures depict the human forms of the proteins, except for Ddi1. The 
Saccharomyces cerevisiae orthologs and human paralogs of the ubiquitin receptors are 
indicated in the grey table. ‘Intrinsic’ receptors indicate authentic proteasome receptors, 
while ‘shuttling’ receptors are reversibly associated with the proteasome. Apart from 
ubiquitin, all proteins and domains are drawn to scale. Adapted from: [77] 
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1.4. The 26S proteasome  
The 26S proteasome is an over 2.5 MegaDaltons machinery that degrades proteins that 
are labelled with ubiquitin in an ATP-dependent manner[64]. The 26S proteasome is 
localized in the nucleus and the cytoplasm, and mainly degrades substrates processively. 
In some cases however, regulatory proteins are activated by the proteasome through the 
removal of inhibitory domains, a process called partial proteolysis[77]. 26S 
proteasomes are composed of a regulatory subunit (RP, 19S particle) and a core particle 
(CP, 20S particle) that is responsible for proteolysis (Figure 1.6). The CP has a barrel-
like structure and its 28-subunits are arranged into four heteroheptameric rings[78]. The 
RP controls substrate entry to the CP by opening the substrate translocation channel. It 
consists of a lid and a base part. Since substrate degradation by the proteasome is ATP-
dependent, six ATPase subunits are located on the base and help unfold the proteins to 
direct them to the CP through the translocation channel[79]. Receptors that recognize 
ubiquitin are associated with the lid: Rpn10 and Rpn13 are intrinsic subunits; Rad23, 
Dsk2 and Ddi1 are proteasome-associated proteins. The latter proteins contact the 
proteasome through their UBL (ubiquitin-like) domain, and their function is to shuttle 
polyubiquitinated proteins to the proteolytic complex[77]. Rpn10 is the first identified 
and best-characterized ubiquitin receptor, and is essential in mice. It recognizes 
ubiquitin through its two UIMs at the C-terminus[80], and has a VWA (von Willebrand 
A) domain on the N-terminus that is important for proteasome structure. hRpn13 is a 
~42 kDa protein with an N-terminal Pru domain and a C-terminal domain that serves as 
the receptor site for the proteasome-associated DUB, Uch37[77]. 
Through the action of the RP and CP particles, proteins are hydrolysed into peptides 
that can be presented on the cell surface in complex with the major histocompatibility 
(MHC) class I molecule[81]. Therefore the proteasome plays role in adaptive immunity. 
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Alternatively, peptides can be further degraded to single amino acids by cytosolic 
peptidases. 
The proteasome also contains deubiquitinating enzymes (DUBs) that cleave ubiquitin 
from substrates, the process required for effective degradation. The function of the 
Rpn11 DUB is critical for proteasome function in human and yeast[82]. Once proteins 
“committed” for degradation, Rpn11 removes chains at once due to its proximal 
specificity. 
Apart from Rpn11, two other deubiquitinating enzymes are located on the RP: Usp14 
(Ubp6 in yeast) and Uch37. These DUBs can trim ubiquitin chains prior to the 
commitment for degradation; therefore the substrate can be rescued from the 
proteasome. Their function has been proposed to be to suppress the breakdown of 
lightly ubiquitinated proteins[83]. Ubp6 has also been shown to play an important role 
in the ubiquitin homeostasis. In its absence, ubiquitin is rapidly depleted[84]. In yeast, 
free ubiquitin depletion induces the UBP6 gene that in turn results in increased ubiquitin 
recycling[85]. 
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Figure 1.6: Structure of the proteasome holoenzyme. 
The core, base and lid particles of the 26S proteasome are indicated. The image was 
generated by averaging of electron micrographs of negatively stained Xenopus laevis 
proteasomes. Adapted from[77] 
 
1.5. NEDD8 and the NEDDylation pathway 
NEDD8 (Neural Precursor Cell-Expressed Developmentally Downregulated-8) was 
first identified in the early 1990s among other genes that are downregulated in neural 
precursor cells during mouse brain development[86]. It is highly conserved in all 
studied eukaryotes (Figure 1.7), and essential for the viability of Schizosaccharomyces 
pombe, Caenorhabditis elegans, Drosophila, Arabidopsis and mouse[87]. 
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Figure 1.7: NEDD8 is highly conserved through species 
Sequence alignment between Homo sapiens NEDD8 (accession number: NP_006147), 
Macaca mulatta (XP_001113390.1), Canis lupus familiaris (XP_537389.2), Bos taurus 
(NP_777189.1), Mus musculus (NP_032709.1), Rattus norvegicus (NP_620233.1), 
Danio rerio (NP_001002557.1), Drosophila melanogaster (NP_609919.1), Anopheles 
gambiae str. PEST (XP_317573.3), Caenorhabditis elegans (NP_492717.1), 
Schizosaccharomyces pombe (NP_595955.1), Magnaporthe oryzae (XP_365042.2), 
Neurospora crassa (XP_964486.1) was performed using ClustalX 2.0.12 software.  
An * (asterisk) indicates positions which have a single, fully conserved residue.  A : 
(colon) indicates conservation between groups of strongly similar properties.  A . 
(period) indicates conservation between groups of weakly similar properties. The 
residues are coloured according to their physicochemical properties (red: small + 
hydrophobic; blue: acidic; magenta: basic; green: hydroxyl + sulfhydryl + amine + G; 
grey: others). 
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1.5.1. NEDD8 conjugation 
NEDD8 is 80% homologues and 60% identical to ubiquitin; therefore it is the closest 
relative to ubiquitin among the ubiquitin-like molecules (ubls). NEDD8 is attached to 
its substrates in a similar manner to ubiquitination, but historically, NEDDylation is 
thought to be catalysed by a unique set of enzymes (Figure 1.8). 
NEDD8 is synthetized as a precursor that needs to be cleaved at the C-terminal in order 
to expose the diglycine motif, through which it is covalently attached to substrate lysine 
residues. NEDP1 (also called SENP8 due to its sequence similarity to SUMO-specific 
proteases) has been shown to catalyse the maturation step with high specificity towards 
NEDD8[88-90]. It can also remove NEDD8 from substrates, the process called 
deNEDDylation. Additionally, a ubiquitin C-terminal hydrolase, UCH-L3 has been 
reported to process NEDD8 as well as ubiquitin[91, 92]. 
The NEDD8 E1 and E2s (Ubc12 and Ube2F) are specific for NEDD8 conjugation and 
distinct from the ubiquitin activating and conjugating enzymes[93, 94]. The NEDD8 
activating enzyme (NAE) first adenylates the C-terminal glycine of NEDD8 in an ATP-
dependent manner, and transfers it to the catalytic cysteine to form a thiolester bond. 
NAE is a heterodimer, composed of APPBP1 and Uba3 that are similar to the N-
terminal and the C-terminal part of the ubiquitin E1, respectively[95-97]. The selectivity 
of the NEDD8 E1 that prevents misactivation of ubiquitin is determined by arginine 190 
in Uba3 and alanine 72 in NEDD8 (arginine in ubiquitin)[97]. After activation, NEDD8 
is transferred onto E2 enzymes, forming another thiolester bond. Ubc12 and Ube2F are 
E2 enzymes that contain a unique N-terminal domain that specifically docks within a 
conserved groove in Uba3 that is not found in other E1 enzymes. Therefore, it ensures 
optimal and specific transfer of NEDD8 from E1 to E2[98]. Although there is a 
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remarkable selectivity at the E1 and E2 level for NEDD8 activation and transfer, 
redundancy for E3-ligases and deconjugating enzymes has been observed. Dcn1 is a 
specific E3-ligase for NEDD8 conjugation[99-101], whereas Mdm2, c-Cbl and IAPs 
can conjugate both ubiquitin and NEDD8[102-104]. Other NEDD8 E3 ligases are 
closely associated with CRL functions, such as Rbx1 and Rbx2, and SCFFBX011[105]. 
There have been a few studies suggesting that NEDD8 can form chains in vivo on 
Lys11, Lys22, Lys48 and Lys60[106, 107], These studies mainly used a mass-
spectrometry-based approach to identify diglycine remnants on NEDD8 peptides after 
tryptic digestion, that is a sign of ubiquitin or NEDD8 chain formation (the caveats of 
this approach is discussed in Chapter 4.1). NEDD8 chains have been shown to build up 
on the catalytic cysteine of Ubc12 prior to conjugation to Cul1[108].  
NEDD8 can be removed from its targets by deconjugating enzymes such as the 
NEDP1/SENP8/DEN1 protease and the COP9 signalosome (CSN)[91, 92]. The 
catalytic component of the 8-enzyme-complex CSN is CSN5 that is a zinc 
metalloprotease with high affinity towards NEDDylated cullins[109]. Overexpression 
of NEDP1 leads to deNEDDylation of cullins but endogenous NEDP1 is inefficient in 
cullin deNEDDylation and probably involved in NEDD8 cleavage from non-cullin 
substrates (discussed in details in Chapter 5.1). Other proteases, such as UCH-L3, 
UCH-L1[110], Ataxin-3[111] and PfUCH54[112] show dual activity for NEDD8 and 
ubiquitin. Usp21 has been also shown to be an isopeptidase for NEDD8[113], however, 
a recent study identified residues on NEDD8 that preclude interaction with this 
protease[114]. 
The NEDD8 ultimate baster 1 (NUB1) has been shown to bind NEDD8 and target 
NEDDylated substrates to degradation by the 26S proteasome. It has been reported to 
interact with the proteasomal subunit S5a[115, 116]. It possesses a UBL (ubiquitin-like) 
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domain at the N-terminal region and two UBAs (ubiquitin-associated domain) at the C-
terminal region. It is induced by interferons and mainly localizes in the nucleus. NUB1 
overexpression has been shown to lead to reduction of NEDD8 monomers and 
conjugates[117]. 
 
Figure 1.8: The NEDD8 conjugation cascade 
NEDD8 processing from the precursors is catalyzed by NEDP1 or UCH-L3. NEDD8 is 
activated by the hetero dimeric E1 APPBP1-UBA3, then transferred onto the catalytic 
cysteine of Ubc12 or UBE2F, the NEDD8-specific E2 conjugating enzymes. E3 ligases 
catalyze the final step of NEDDylation. NEDD8 can be removed from substrates 
through the action of deNEDDylating enzymes. 
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1.5.2. Biological consequences of NEDDylation 
The first identified substrate for Rub1 (the NEDD8 ortholog in yeast) was cdc53, a 
component of SCF E3 ligase complex in Saccharomyces cerevisiae[95, 118] and Cul4A 
in humans[119]. However, deletion of Rub1 in cerevisiae does not cause lethality, 
contrary to other organisms, such as S. pombe, D. melanogaster and mice, where 
NEDD8 is required for viability. The inactivation of the temperature-sensitive NAE 
gene in the ts41 CHO cell line has been shown to cause cell cycle arrest at S-
phase[120]. In Arabidopsis thaliana, downregulation of the NEDD8 pathway results in 
reduced auxin response[121]; whereas RNAi knockdown of NED-8 or enzymes of the 
conjugation pathway in C. elegans causes developmental abnormalities[122, 123] and 
hypersensitivity to ENU-induced germ cell apoptosis[124]. 
The cullin family of proteins are structurally related, and function as molecular 
scaffolds in assembling the Cullin RING Ligases (CRLs). CRLs are multi-component 
ubiquitin E3 ligase complexes, consisting of a cullin scaffold and Rbx1 or Rbx2, the 
catalytic RING subunits[125]. The members of the family are Cul1, 2, 3, 4A, 4B, 5, 7 
and PARC and Apc2 in human cells, however, only Cul1-5 assemble CRL 
complexes[126]. Substrate recognition requires the assembly of the cullins with their 
own dedicated substrate receptor proteins, through an adaptor protein (Figure 1.9). The 
receptors bind to specific sequences of the substrates.  
The CRL1 is also referred to as SCF ligase complex. It consists of Cul1, Rbx1 RING 
subunit; the adaptor protein Skp1 and a substrate receptor F-box protein. Skp1 is docked 
to Cul1 near to its N-terminus, while Rbx1 is on the C-terminal domain. Structural 
studies have shown similar architectures in the case of CRL2 and CRL5. They share a 
common adaptor: Elongin BC, through which substrate receptors such as the von 
Hippel-Lindau (VHL) tumor suppressor are recruited. CRL4A utilizes the 127 kDa 
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DDB1 (damaged DNA binding protein 1) as its adaptor, and DCAFs (DDB1 and Cul4A 
associated factors) or DWDs (DDB1-binding WD40 proteins) as substrate receptors. 
The BTB domain proteins have been shown to be both adaptors and substrate 
recognition modules for CRL3[127]. 
CRLs are regulated through different mechanisms, including NEDDylation on a 
conserved lysine near the C-terminus of cullins. NEDD8 modification stimulates the 
ligase activity by a) enhancing binding to the ubiquitin-loaded E2, b) enhancing 
ubiquitin transfer from the catalytic cysteine of the E2 to the substrate, c) positioning 
the E2 active site adjacent to the substrate, d) precluding binding of the cullin inhibitor 
CAND1[128]. Additionally, NEDD8 modification of Cul3 has been shown to promote 
dimerization of the scaffold proteins (where NEDD8 covalently modifies one Cul3 
molecule while non-covalently interacts with the second one)[129]. Rbx1 and Ubc12 
NEDDylate Cul1, 2, 3 and 4, whereas Cul5 NEDDylation is mediated by Rbx2 and 
Ube2F[130]. Furthermore, Dcn1 has been shown to enhance cullin NEDDylation[131]. 
DeNEDDylation of cullins occurs through the action of the COP9 signalosome (CSN). 
The catalytic component of the 8-subunit enzyme complex is CSN5, a JAMM-
metalloproteinase. Interestingly, the COP9 signalosome structurally resembles the 
proteasome lid. The enzymatic activity of CSN is also analogous to that of the lid, and 
Csn5, like Rpn11, carries the metalloprotease active site[132]. There have been studies 
suggesting that the lid can be replaced by CSN[133, 134]. 
In the absence of NEDD8 modification, CAND1 (Cullin-Associated and Neddylation-
Dissociated 1) binds to cullins and inhibits their activity[135]. The C-terminus of the 
bound CAND1 excludes adaptor and substrate receptor protein binding, while the N-
terminus binds to the NEDD8 acceptor lysine[105]. 
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A recent study using the NEDD8 E1 inhibitor MLN4924 has demonstrated in a 
quantitative proteomics approach that most of the cullins bind to adaptors, and the 
abundance of the adaptors determine CRL activity, rather than their NEDDylated status 
or the binding of CAND1[136]. It has been also observed in several studies that 
CAND1 is required for intact CRL activity[137, 138]. Recent data from Raymond 
Deshaies and Dieter Wolf group seem to solve the CAND1 paradox: they have shown 
that CAND1 is responsible for Cul1-Fbox disassembly for the rearrangement of the new 
SCF complex. This process is controlled by cullin deNEDDylation by CSN5, an event 
regulated by the presence or absence of substrate (ZOMES VII meeting, 2012, oral 
presentation). 
Interestingly, a bacterial mechanism for inhibiting NEDD8 conjugation has been shown 
recently: CHBP or Cif, the bacterial effector deamidase promotes deamidation of Gln40 
of NEDD8 that results in decreased CRL activity[139]. This is an interesting example 
how pathogens can target ubiquitin-like conjugation pathways and could be important 
for drug development. 
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Figure 1.9: Composition of the Cullin RING E3 Ligases. 
Adapted from: [105]. Cul1-5 (green) are in complex with Rbx1/2 (red). Adaptors are 
shown in light blue, while substrate receptors are highlighted in magenta color. The 
ubiquitin is presented in orange, while the E2 conjugating enzyme in yellow color. 
 
Other important substrates for NEDD8 are the tumor suppressor p53, and its main 
regulator, the ubiquitin and NEDD8 E3 ligase Mdm2. NEDD8 modification on p53 
increases its stability, and in addition it inhibits its transcriptional activity. Mdm2 itself 
is NEDDylated, and the modification significantly increases its protein stability[102]. 
p53 NEDDylation can be also mediated by FBX011, a member of the F-box protein 
family and a component of the SCF (Skp1.Cullin1.F-box) complex[140]. p53 fused 
with NEDD8 at the C-terminus has been found exclusively in the nucleus[141]. NUB1, 
a NEDD8 interacting protein was shown to inhibit p53 NEDDylation and stimulate 
mono-ubiquitination, resulting in nuclear export of the tumor suppressor[142]. A 
regulator of the p53-Mdm2 pathway, Tip60 acetyltransferase was shown to 
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preferentially inhibit Mdm2-mediated p53 NEDDylation, but not ubiquitination[143], 
and this activity was related to the ability of Tip60 to relocalise p53 to PML bodies. 
Mdm2 also mediates NEDDylation of TAp73 (full-length p73), resulting in the 
cytoplasmic localization of the protein. Transcriptional activity of TAp73 has been 
shown to increase in the ts41 CHO cell line at the non-permissive temperature, 
indicating that NEDDylation inhibits its transcriptional activity[144]. 
VHL (von Hippel-Lindau) protein, a component of the Cul2-based CRL has been also 
shown to be NEDDylated, and the modification prevents its interaction with cullin 2 
and promotes VHL association with fibronectin. Point mutations that prevent 
NEDDylation of VHL are associated with von Hippel-Lindau disease and lung 
cancer[145]. 
NEDDylation has been shown to increase the efficiency of EGFR ubiquitination by the 
shared NEDD8 and ubiquitin E3 ligase, c-CBL, and facilitates its lysosomal 
degradation[103].  
Endogenous breast cancer-associated protein 3 (BCA3) has been shown to be modified 
by NEDD8 on multiple lysine residues. Moreover, NEDP1 knockdown increased BCA3 
NEDDylation, indicating that the deNEDDylating enzyme regulates the protein in vivo. 
Modification of BCA3 by NEDD8 promotes SIRT1 recruitment and therefore 
suppresses NF-κB-dependent transcription[146]. 
Ribosomal proteins are a large class of NEDD8 substrates. NEDDylation of L11 is 
required for its stability, and it also regulates its localization. In the event of nucleolar 
stress, caused by low doses of Actinomycin D (which preferentially inhibit RNA 
Polymerase I and rRNA production), L11 relocalises to the nucleoplasm. The 
translocation results in binding to Mdm2, repression of Mdm2-mediated ubiquitination 
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of p53, and leads to increased level of the tumor suppressor protein and cell cycle 
arrest[147]. It has been shown that the NEDDylated form of L11 localises in the 
nucleolus. Upon low doses of ActD treatment, NEDDylation of L11 decreases, causing 
relocalization of L11 from the nucleolus to the nucleoplasm, which provides a signal for 
p53 activation[148]. 
PINK1 and parkin have been recently found as novel NEDD8 targets. The 
modification results in increased parkin E3 ligase activity and stabilized PINK1[149]. 
Recently, NEDD8 has been reported to regulate the transcription factor E2F-1, in a 
manner analogous to p53 regulation. One study showed that the modification increases 
E2F-1 stability, decreases its transcriptional activity and slows cell growth[150]. 
Another group reported that NEDDylation of E2F-1 determines its target specificity and 
might play important role in promoting apoptosis upon DNA damage[151]. 
Additional substrates for NEDD8 that play role in DNA repair, chromatin remodeling, 
replication and mRNA splicing have been identified by proteomics approaches[106]. 
Further characterizations of these proteins are needed to specify the role of NEDD8 
modification in their regulation. 
 
1.6. Ubiquitin-like modifiers 
Apart from ubiquitin, other polypeptides have been identified to regulate proteins 
through covalent modification of their lysine residues. These ubiquitin-like modifiers 
are attached to substrates in a reversible manner, through an enzymatic cascade that is 
distinct but evolutionally related to ubiquitination (Figure 1.11).  
Ubiquitin and ubls share the same three-dimensional structure, the β-grasp fold (Figure 
1.10). Although ubiquitin and ubls cannot be found in prokaryotes (the only exception 
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might be Pup), several proteins adopt the ubiquitin-fold, including MoaD and ThiS that 
are involved in molybdopterin and thiamin cofactor biosynthesis, respectively. The 
activation of MoaD and ThiS is also strikingly similar to that of the ubls, except that it 
results in the attachment of a sulphur atom to their C termini, and not their attachment to 
a substrate.[152]. 
©!!""#!Nature Publishing Group!
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TRANSLESION SYNTHESIS
DNA synthesis by the DNA 
polymerases ζ and η over a gap 
in DNA.
free and uses a template-switching event that involves 
the undamaged sister chromatid. On the basis of a 
combination of elegant genetic and biochemical experi-
ments that were mostly carried out in S. cerevisiae, it 
now seems that all three mechanisms of DNA repair are 
brought about by the modification of the same residue 
(K164) in the proliferating cell nuclear antigen (PCNA) 
DNA-replication processivity factor16–18 (FIG. 2a).
First, K164 is monoubiquitylated by the E2 Rad6 
and the E3 ligase Rad18 (FIG. 2b). It has been shown 
that when PCNA is monoubiquitylated, it can asso-
ciate with the translesion polymerases. However, 
as a K164R mutant of PCNA can still interact with 
the translesion polymerases, it is thought that the 
monoubiquitylated form of PCNA does not promote 
a direct interaction with the polymerases. Instead, 
the modification is thought to be important for dis-
rupting the interaction of some other PCNA-bind-
ing protein that masks the translesion-polymerase 
binding sites on PCNA. The K164-linked mono-
ubiquitin of PCNA can be extended by the addition 
of a K63-linked ubiquitin chain through the action 
of the heterodimeric E2 Ubc13–Mms2 and the E3 
Rad5 (FIG. 2c). This K63-linked-chain modified form 
of PCNA signals the error-free bypass (template 
switching) pathway. Interestingly, it seems that 
SUMO (small ubiquitin-like modifier) modifica-
tion of K164 might suppress the Rad52-dependent 
recombinational repair pathway18 (FIG. 2d).
Transcription. Ubiquitin and the ubiquitin–proteasome 
system can control transcription in several ways, some 
of which are described here. The histone code — that 
is, the post-translational modification of histones by 
ubiquitylation, methylation and acetylation — con-
trols many nuclear processes including gene expres-
sion, DNA repair and replication. In S. cerevisiae, the 
ubiquitin-conjugating enzyme Rad6 (Ubc2) mono-
ubiquitylates K123 on histone H2B, which, in turn, 
mediates the methylation of K4 on histone H3 REF. 19. 
The histone-acetyltransferase-containing SAGA/SLIK 
(Spt–Ada–Gcn5–acetyltransferase/SAGA-like) com-
plexes, which acetylate histones H3 and H2B, also 
remove ubiquitin from H2B using the deubiquitylating 
enzyme Ubp8. These complexes have recently been 
shown to include the protein Chd1 (chromodomain–
helicase-domain–DNA-binding-domain-1), which 
recognizes methylated K4 on H3 to control transcrip-
tion20. The ubiquitylation of histone H2A is carried 
out by the E3 complex human Polycomb repressive 
complex-1-like, which links H2A ubiquitylation to the 
Polycomb silencing of gene expression21.
A subcomplex of the 19S proteasome regulator 
(ATPases independent of 20S (APIS)) functions in a 
non-proteolytic manner to control RNA-polymerase-II-
dependent transcription22. RNA polymerase II also 
seems to be physically linked to the 26S proteasome. 
The 26S proteasome might associate with transcrip-
tional termination sites to facilitate termination and 
with stalled elongation complexes to facilitate the 
degradation of proteins in these stalled complexes23.
Transcription factors are also post-translationally 
modified as part of the intricate management of gene 
function. For example, the F-box protein Dsg1/Mdm30 
is required for the ubiquitylation of the S. cerevisiae 
transcription factor Gal4. Dsg1/Mdm30 stimulates 
Gal4 turnover and therefore affects its transcriptional 
activity24.
In mammals, oestrogen receptors are ubiquitylated 
and degraded by the 26S proteasome as part of the 
cyclical regulation of oestrogen-sensitive promoters, 
which enables responses to changes in oestrogen con-
centrations in a cell25. Another well studied example 
of the post-translational modification of a mam-
malian transcription factor is the tumour suppressor 
p53. Among other modifications, the ubiquitylation, 
sumoylation and neddylation of a group of lysine resi-
dues at the C terminus of p53 control the stability and 
biological activities of this protein26,27.
Signal transduction. The nuclear factor (NF)-κB sig-
nalling pathway is used here to exemplify the many 
ways in which ubiquitin and the ubiquitin–proteasome 
system can control signal transduction.
The transcription of NF-κB-dependent genes is 
induced in response to several stimuli. For example, 
tumour necrosis factor-α (TNFα) and the RANK 
Box 1 | The ubiquitin superfold and ubiquitons
Ubiquitin and its relatives are related primarily by the 
ubiquitin superfold, which is a β-grasp fold. Sequence 
homology between the proteins can be extensive or 
absent. There is a need for an encompassing term for 
ubiquitin and all of the ubiquitin-like proteins to 
acknowledge the importance of the superfold, and the 
term used is ‘ubiquiton’121. In the course of evolution, 
ubiquitons have evolved to give the present repertoire 
of small proteins with distinct functions TABLE 1. 
Ubiquitons can not only be covalently at ached but ca  
also be genetically incorporated into much larger 
proteins, for example, Raf kinase90.
The figure shows an overlay of ubiquitin (blue; Protein 
Data Bank (PDB) accession code P62988), SUMO-1 
(green; PDB accession code P63165) and NEDD8 
(red; PDB accession code Q15843), and was made in 
Molscript by T. Wilkinson, University of York, UK. 
NEDD8, neuronal-precursor-cell-expressed 
developmentally downregulated protein-8; SUMO, 
small ubiquitin-like modifier.
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Figure 1.10: The ubiquitin superfold. 
The figure shows an overlay between ubiquitin (blue), SUMO (green) and NEDD8 
(red). Adapted from:[153] 
 
An interferon-induced gene product, ISG15 was the first ubl discovered, four years 
after the discovery of ubiquiti . Its primary sequence consists of 2 domains that share 
significant homology with ubiquitin. The components of the ISG15 conjugation 
pathway are also induced by interferons. UBE1L is a specific E1 for ISG15, and 
UBCH8 is a shared E2 with ubiquitin. A few E3s have been identified for ISG15, 
including estr ge -responsive finger pr tein (RING-type) and Herc5. USP18 has been 
shown to reverse ISGylation. 
Hundreds of proteins have been identified as targets for ISG15. In a recent study, a 
proteomics approach has revealed that ISG15 conjugation is restricted to newly 
synthesised proteins, including newly translated viral proteins in infected cells, causing 
disruption in viral particle assembly[154]. 
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The small ubiquitin-like modifier SUMO family includes three members, SUMO-1, -2 
and -3. They share a similar three-dimensional structure, but only approximately 20% 
sequence identity with ubiquitin. SUMO-2 and -3 only differ by three amino acids in 
their mature form and they are only 50% identical in sequence to SUMO-1[155]. 
SUMO is activated by a heterodimeric E1, and conjugated through the action of the E2 
enzyme Ubc9 and E3 ligases, including RanBP2, PIAS family members, Pc2 and 
Topors[156, 157]. SUMOylation is a reversible modification, SUMO-specific proteases 
include SENP1, SENP2, SENP3, SENP5 and SENP7[158]. 
The first identified role for SUMO-1 was the modification of RanGap1 that targets it to 
the nuclear pore[159, 160]. Since then, SUMOs have been shown to play role in diverse 
stress responses, including heat shock, osmotic and oxidative stress[161]. SUMO 2/3 
have been shown to form chains on target proteins that recruit SIM (SUMO interacting 
motif)-containing effector proteins, providing important regulatory mechanisms[162]. 
Poly- SUMO chains can act as a signal for recognition by ubiquitin E3 ligases to target 
the substrates for proteasomal degradation. An important example is the degradation of 
the PML protein. PML was identified in promyelocytic leukemia to be fused to retinoic 
acid receptor-α (RARα) and dispersed into small nuclear bodies. SUMOylation of PML 
recruits the SIM-containing ubiquitin E3 ligase, RNF4 that subsequently ubiquitinates 
the fusion and targets it to degradation[163]. Additional roles for SUMOylation include 
regulation of transcription[164], nucleo-cytoplasmic transport, neuronal survival[165], 
DNA replication and repair[166], cancer development and cell cycle progression[157]. 
 
Urm1 (ubiquitin-related modifier 1) was discovered as a protein showing sequence 
similarity to the bacterial sulphur carriers ThiS and MoaD. It is activated by Uba4, a 
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Ube1 related protein[167, 168]; and modifies a handful of proteins identified in a recent 
proteomics study[169]. It does not only attach to proteins, but also acts as a sulphur 
carrier in tRNA thiolation[170]. 
 
FAT10, also called diubiquitin, contains two ubiquitin-like domains in tandem[171]. It 
is covalently attached to substrate lysine residues similarly to ubiquitination, and serves 
as a signal for proteasomal degradation. Its degradation is accelerated by interaction 
with NEDD8 ultimate buster-1L (NUB1L)[172]. NUB1L is a splice variant of NUB1 
possessing an extra UBA domain, and it was first described as a NEDD8 interacting 
protein[115]. However, it has higher affinity towards FAT10 than NEDD8. FAT10 and 
ubiquitin share an E1 activating enzyme, Uba6. USE1 (UBA6-specific E2 enzyme) is a 
recently identified E2 for FAT10 that is self-FATylated[173]. E3 ligases for the 
modification still remain to be found. FAT10 covalently modifies p53[174] and the 
ubiquitin activating enzyme Ube1[175]. In a recent study, the autophagosomal receptor 
p62/SQSTM1 (p62) was also found to be a genuine substrate for the modification [176]. 
FAT10 is induced by the proinflammatory cytokines IFN-γ and TNF-α in most cell 
lines, and constitutively expressed in B cells and mature dendritic cells[177-179]. 
 
ATG8 and ATG12 are induced by starvation, and are essential for autophagosome 
formation, hence their name: autophagy-related ubiquitin-like modifier. Autophagy 
mediates the degradation of long-lived proteins and protein aggregates through the 
formation of a double-membraned vesicle in the cytoplasm, followed by fusion with the 
lysosome and hydrolysis of its contents. ATG12 is activated and conjugated by the E1-
and E2-like enzymes ATG7 and ATG10, respectively[180, 181]. ATG5 is a substrate 
for ATG12, and its modification has been shown to be required for the elongation of the 
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isolation membrane to form autophagosome. 
During autophagy, ATG8 (LC3) is crucial for the so-called ‘lipidation’, autophagosome 
maturation. It is covalently conjugated to the common membrane phospholipid, 
phosphatidylethanolamine to promote membrane association of the protein[182]. Unlike 
ATG12, ATG8 needs to be processed by ATG4 to expose the C-terminal glycine 
residue. ATG8 shares the E1 enzyme ATG7 with ATG12. This was the first example of 
a shared activating enzyme between two ubiquitin-like modifiers. ATG3 is the E2 
conjugating enzyme for ATG8, and ATG4 has been identified to be responsible for 
deconjugation as well[182]. 
 
UBL5 is an unconventional ubiquitin-like molecule. It is highly conserved, but poorly 
characterized in higher eukaryotes. Most of the functional studies have been done on the 
Saccharomyces cereviseae homolog, Hub1 (homologous to ubiquitin-1). Budding yeast 
Hub1 deletion mutants are viable, while the corresponding Schizosaccharomyces pombe 
mutant is lethal. Hub1 is not conjugated covalently to proteins, and possesses a C-
terminal dityrosine (YY), instead of the diglycine[183, 184]. The role of Hub1 in 
alternative splicing has been recently demonstrated in yeast: it modifies the spliceosome 
in a way that enables it to use certain non-canonical 5’ splice sites[185]. It has been also 
shown to be involved in the mitochondrial unfolded protein response[186], cell cycle 
progression and polarized growth[187]. 
 
Even though prokaryotes lack the ubiquitin proteasome system, Mycobacterium 
tuberculosis (Mtb) has analogous proteolytic machinery. Pup (prokaryotic ubiquitin-
like protein) is a 64-residue protein that has been shown to modify proteins and to target 
them for degradation by the mycobacterial proteasome[188]. Pupylation involves the 
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action of an enzymatic cascade that is analogous to the ubiquitin E1-E2-E3, and 
proteins with ‘depupylase’ activity have been described as well[189, 190]. Pup is 
attached to substrate lysine residues through its C-terminal glutamate, which is 
converted from the original glutamine before substrate conjugation. The pupylation 
cascade and the Mtb proteasome itself are promising drug targets against the pathogen. 
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Figure 1 | Overview of the enzymatic cascade involved in ubiquitin-like protein (UBL) conjugation and the  
ubiqitin–proteasome system (UPS). a | Ubiquitin-activating enzyme (UAE) binds ATP and ubiquitin (Ub) to form a 
ternary complex consisting of E1–ubiquitin thioester with ubiquitin–AMP bound (see text for details). The thioester-bound 
ubiquitin is then passed to one of several E2 conjugating enzymes through a transthiolation reaction. The 
ubiquitin-charged E2 then forms a complex with an E3 ligase and a protein substrate to transfer ubiquitin to a lysine 
residue on the substrate. To mark substrates for degradation, multiple ubiquitins are similarly recruited to produce a 
K48-linked polyubiquitin chain. Following release from the E3, the proteasome recognizes the polyubiquitin chain, and 
the substrate is deubiquitylated and destroyed. Substrates marked with ubiquitin chains linked through lysines 6, 11, 27, 
29 and 33 also seem to be primarily destined for degradation. Alternatively, substrates marked with monoubiquitin, linear 
ubiquitin chains or K63 ubiquitin chains are involved in signalling functions that are independent of the proteasome.  
A second E1 (ubiquitin-like modifier activating enzyme 6 (UBA6)) also activates ubiquitin, but the function(s) of this 
pathway are unknown. b | Nine classes of UBL and eight E1 activating enzymes participate in diverse biological pathways 
in humans. E1s, E2s and UBLs are structurally and mechanistically related but are unique to each pathway. Ubiquitin and 
some E2s are exceptions in that they can be used by both the UAE and UBA6 pathways. Ufl1 and C20orf166 were recently 
identified and reported by Tatsumi et al139. DUB, deubiquitylating enzyme; NAE, NEDD8-activating enzyme; PPi, inorganic 
pyrophosphate; SAE, SUMO-activating enzyme.
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Figure 1.11: Ubiquitin-like molecules and their enzymes. 
Nine classes of ubls are shown in the figure, each of which are conjugated through their 
cognate enzymatic cascade. Except for ubiquitin that can be activated by UAE (Ube1) 
and Uba6 as well. Adapted from[191]. 
 
Crosstalks between these modifications enhance the complexity of protein regulation by 
ubls. A single lysine residue can undergo different types of modifications; for example 
p53 and Mdm2 have similar lysine requirements for either ubiquitination, SUMOylation 
or NEDDylation[192]. Other proteins such as HIF-1α, IκBα, CREB, PCNA, and 
Huntingtin can be SUMO or ubiquitin modified with different biological 
outcomes[193]. An example is the coordination of DNA replication by SUMO and 
ubiquitin on the proliferating cell nuclear antigen (PCNA). Ubiquitination in response to 
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DNA damage is required for the bypass of replication-blocking lesions, while SUMO 
modification contributes to the Srs2 helicase recruitment to replication forks[194]. The 
earlier-mentioned PML degradation coordinated by sequential SUMO and ubiquitin 
modification is one of the several examples of close interaction between the pathways. 
Another crosstalk has been studied in great details is the activation of the Cullin RING 
ubiquitin E3 ligases by NEDD8. It has been also shown that proteins can be 
simultaneously modified by different ubls. Moreover, there are a few examples where 
ubls share E1, E2 or E3 enzymes that initially thought to be specific for a distinct ubl 
conjugation pathway. For instance, FAT10 is activated by the ubiquitin E1 enzyme 
Uba6; ISG15 shares an E2 enzyme, UBCH8 with ubiquitin; and NEDD8 conjugation 
can be coordinated by ubiquitin E3 ligases Mdm2, c-Cbl and XIAP. 
 
1.7. Stress response 
Cells have to maintain their viability under a wide variety of stressful conditions. 
Transcription, translation and protein degradation are all parts of the stress response, 
and dynamic protein regulation by the ubiquitin and ubiquitin-like pathways have been 
also shown to play important roles in cell survival. 
1.7.1. Heat stress: 
Cells sense elevated temperatures by proteins, since their proper structure and folding is 
only achieved in a small temperature range. A few degrees of difference from the 
optimal growth can result in unfolded and damaged proteins that are sensed by the cells. 
There have been many different ways evolved to react to these conditions: chaperons, 
heat shock proteins are induced to help proper refolding, or ultimately damaged proteins 
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are removed by different ways: proteases, lysosomes or the proteasome. Heat shock also 
results in damage of the structural parts of the cells: the cytoskeleton, microtubules etc. 
Elimination of aggregates and damaged proteins is essential for survival, and 
malfunctioning of this process is associated with disease and aging[195]. 
Bacteria respond to heat stress by inducing many genes that encode proteases that 
eventually degrade proteins[195]. In yeast several proteases and component of the UPS, 
including ubiquitin are also induced[196]. Apart from ubiquitin, the involvement of the 
small ubiquitin-like modifier in the heat shock response has been also well established. 
Increased SUMO attachment to targets after heat shock has been shown to help 
solubilize the proteins[197]. Moreover, the vast SUMO-2/3 conjugation in response to 
heat stress also defends cells from hyperthermic cytotoxicity[198]. 
1.7.2. Oxidative stress: 
Cells are exposed to reactive oxygen-species (ROS) from environmental oxidizing 
agents and H2O2 that arise as a by-product of aerobic metabolism[199]. ROS exposure 
results in oxidization damage of proteins, DNA and lipids, and has been linked to aging 
and disease such as diabetes, neurodegeneration and cancer. In response to oxidizing 
agents, cells normally arrest and induce genes involved in restoring redox balance. 
ROS has been shown to cause perturbation in the SUMO and the ubiquitin conjugation 
pathways. In the presence of H2O2, SUMO conjugates including modified transcription 
factors disappear, due to the inhibition of the conjugating enzymes: the SUMO E1 
forms a disulfide bond with Ubc9[200].  In yeast, the ubiquitin E2 enzyme Cdc34 is 
sequestered through a disulfide complex with Uba1 in response to oxidation. This in 
turn causes stabilization of its target, Sic1 that results in a delay in cell cycle 
progression[201]. 
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1.7.3. Ubiquitin stress: 
An interesting paradigm is the so-called ubiquitin stress. In yeast, the sensitivity to 
many environmental conditions can be linked to the exhaustion of the ubiquitin pool. 
Such conditions include heat shock, cadmium, canavanine, cycloheximide, anisomycin, 
chloramphenicol, trichodermin, methotrexate, 4NQO, and methylmethanesulfonate[202, 
203]. A low level of ubiquitin is dangerous since ubiquitination is critical in cell cycle 
regulation, DNA repair, protein sorting and quality control, apoptosis and other 
important processes. 
 
1.8. Ubiquitin and ubiquitin-like molecules in disease 
The ubiquitin-proteasome system and ubl pathways are essential for the maintenance of 
cellular homeostasis. Their malfunctions are associated with numerous types of disease, 
including cancers, neurodegenerative diseases, heart failure and viral diseases. Due to 
the involvement of UPS and ubls in important regulatory processes, they have the 
potential to be targeted by small-molecule inhibitors that influence distinct proteins. 
Several enzymes involved in ubiquitin and ubl conjugation are associated with disease 
(for examples, see Table 1.1). The development of drugs target different parts of the 
system. The least selective are the proteasomal inhibitors that block degradation of 
many proteins. Several studies indicate that inhibition of the proteasome influences a 
wide range of pathways that eventually lead to anti-tumor effects. In the absence of 
intact proteasome, apoptosis is upregulated, while factors of angiogenesis, growth and 
survival are downregulated[204] (Figure 1.12). 
 50 
The first clinically validated drug was bortezomib (velcade), an inhibitor of the 26S 
proteasome for anticancer treatment, developed by Millenium Pharmaceuticals. It is in 
clinics to treat multiple myeloma and mantle cell lymphoma. It targets the 20S 
proteasome, and is slowly reversible[191]. Disruption of the NF-κB signaling pathway, 
activation of ER stress, hypoxic response deregulation and mTOR inhibition are some 
of the mechanisms by which bortezomib has been implicated in killing cancer cells.  
Interestingly, there might be a new therapeutic application of bortezomib: initial 
experiments suggest that it could be used to deplete normal antibody-producing plasma 
cells in transplant patients to prevent from antibody-mediated rejection[205].  
Second generation inhibitors for different parts of the proteasome are also being 
developed for greater drug pharmacology. 
 
 
Figure 1.12: Effects of the proteasome inhibition. 
The diagram is a schematic represenatation of the effect of proteasome inhibition on 
different pathways that contribute to cancer prevention. Adapted from: [204] 
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Several studies have linked the NEDD8 pathway to cancer. First of all, CRLs regulate 
the activity of proteins involved in cell cycle regulation and subsequently in 
tumorigenesis, and components of the ligase complex are often mutated, overexpressed 
or amplified in several cancers[206]. Elevated NEDD8 conjugation has been observed 
in oral squamous cell carcinoma and melanoma cell lines[207]. Among other substrates 
for NEDD8, tumor suppressors and oncoproteins can be found. 
In order to block a specific ubl, the cognate E1 enzyme can be targeted. This results in 
specific inhibition of the ubl. The best example is MLN4924, the selective and potent 
inhibitor for the NAE[208]. It has also been developed at Millenium Pharmaceuticals, 
as a result of a screen for selective NAE inhibition. It is a competitive ATP inhibitor of 
NAE, an adenosine sulphamate analogue that forms a NEDD8-MLN4924 adduct and 
binds tightly to the nucleotide-binding site of Uba3, inhibiting its enzymatic activity. 
The covalent NEDD8-MLN4924 adduct is formed in situ through a mechanism called 
substrate assisted inhibition. First NEDD8-AMP is formed, followed by the thiolester 
bond between NEDD8 and the catalytic cysteine of NAE. MLN4924 binds to AMP 
binding site of the loaded NAE and attacks the thiolester bond between the Uba3 
subunit and NEDD8, forming the adduct[209] (Figure 1.13.). 
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Figure 1.13: Schematic representation of the enzymatic mechanism of NAE-
dependent NEDD8 activation and NEDD8-MLN4924 adduct formation. 
Step 1: MgATP and NEDD8 bind to the enzyme. The reaction yields in a NEDD8-AMP 
formation and release of inorganic pyrophosphate (PPi). 
Step 2: NAE-NEDD8 thioester is formed and AMP is released. 
Step 3: A second ATP and NEDD8 bind NAE and a second NEDD8-AMP is formed 
that occupies the adenylation domain of NAE. This form of NAE transthiolates NEDD8 
to Ubc12.  
Step 3’: MLN4924 binds to the nucleotide binding pocket of the NAE-NEDD8 thioester 
form of NAE and forms a NEDD8-MLN4924 adduct with the thioester-bound NEDD8.  
Adapted from: [209] 
 
As a result of NAE inhibition, CRL activity is inhibited, and subsequent stabilization of 
the targets, eg. CDT1, p27 and NRF2 are achieved, upstream of the proteasome. 
MLN4924 is now in clinical phase II trial for the treatment of acute myeloid leukemia 
(AML), since CRL targets are essential for AML cell survival. In response to the 
treatment, AML cells undergo increased apoptosis mainly due to the disruption of 
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cellular redox status[210]. Since the range of NEDD8 substrates include tumor 
suppressors and oncogenes, MLN4924 may be a promising drug for other types of 
cancers too. Similar adducts to inhibit the ubiquitin- and SUMO activating enzymes are 
being tested to target specifically the ubl pathways. 
Inhibition of the proteasome or E1 enzymes affect a wide range of substrates. On the 
other hand, E3s are thought to possess substrate specificity. Therefore screening for 
ligase inhibitors is a popular method for developing therapeutic agents. There have 
already been a few examples proven that some E3s are associated with disease, and they 
can be mechanistically targeted. Table 1.1 shows the most common E3s associated with 
disease and their inhibitors. 
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E3 ligase Substrate Disease association 
Inhibitor/intervention 
investigated 
HDM2 p53, p27 
Breast and lung 
cancer, oesophageal 
carcinomas, 
glioblastomas and 
malignant 
melanomas 
Nutlins and 
RITA promote p53 
stabilization, 
Parthenolide promotes 
ubiquitination 
CRLSKP2/βTRCP/FBW7 
p21, p27, cyclinD, 
β-catenin, IκBα 
Multiple cancers and 
other disorders 
linked to the NF-κB 
pathway 
NAE inhibitor 
IAP 
Substrates involved 
in apoptosis and 
signalling 
Oesophageal, liver 
and lung cancers, 
ovarian carcinoma 
and MALT 
lymphoma 
SMAC mimetics 
promote IAP 
degradation 
E6-AP p53 
Cervical cancer; 
mutations associated 
with Angelman’s 
syndrome 
Expression of mRNA 
decay factor TTP 
stabilizes p53 through 
E6-AP targeting in 
HPV-transformed 
cervical cancer 
VHL HIF1α, HIF2α 
VHL syndrome; 
renal cell carcinoma 
Bioengineered VHL 
protein to increase HIF 
degradation 
Parkin Synphilin 1, Parkin Parkinson’s disease 
Nitric oxide inhibits 
E3 activity 
Table 1.1. Examples of E3 ligases associated with human disease.  
Adapted and modified from:[191] 
 
Although there are only about 100 DUBs identified so far, their biological roles make 
them attractive to further study them and develop inhibitors that can be applied in 
pharmaceutical interventions. Small molecule drugs have been suggested to be good 
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inhibitors for metalloproteases. However, in the case of the larger class of DUBs, the 
cysteine proteases, finding inhibitors that can be used as drugs has been problematic, 
since the currently available inhibitors do not get into the cells[191]. Regardless, there 
have been efforts to turn these inhibitors into drugs, because individual DUBs are 
associated with pathways involved in specific diseases, such as USP1 in the Fanconi 
anaemia DNA repair pathway[211] or USP7 with non-small cell lung 
adenocarcinoma[212]. Parkinson’s disease was also linked to the loss of the 
deubiquitinase activity of UCH-L1[213]. 
Interestingly, bacteria and viruses have been also shown to interfere with the 
ubiquitin/ubl conjugation system on the DUB level. Host cell encoded proteases can be 
manipulated by pathogens during infection. Additionally, there are pathogen-encoded 
proteases with ubiquitin/ubl specific activities that target the host cells. Targeting these 
enzymes for therapeutic interventions is important, since many infectious diseases are 
still not curable (reviewed in [214]). 
The ubiquitin-proteasome system plays a major role in degrading neuronal proteins. The 
malfunctioning of the UPS is associated with the accumulation of insoluble protein 
aggregates in neurons, the phenomenon observed in age-related and chronic 
neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s, amyotrophic 
lateral sclerosis and dementia with Lewy bodies. Interestingly, polyubiquitin conjugates 
also accumulate in these disease conditions, and NEDDylation has been found to be 
deregulated in Alzheimer’s disease[215, 216]. 
In Huntington's disease, the spinocerebellar ataxias can promote the formation of 
protein aggregates that are resistant to degradation by the proteasome and impair 
proteasome function[217]. Similarly in Alzheimer's disease, the formation of 
neurofibrillary tangles and plaques associated with amyloid-β protein aggregation 
and/or ubiquitinated TAU accumulation can impair proteasome function[218]. 
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Ubiquitin and SUMO have been also linked to cardiovascular diseases[219]. For 
example, cardiomyopathies are associated with deregulated UPS functions and 
accumulation of ubiquitinated proteins[220]; and ischemic myocardial injury is linked 
to the deficiency of the ubiquitin ligase CHIP[221]. 
 
1.9. DNA damage, apoptosis and the regulation by the 
ubiquitin pathway 
1.9.1. DNA damage and ubiquitin 
DNA damage can result from stochastic errors in replication or recombination, 
endogenous reactive oxygen species or from environmental and therapeutic genotoxins. 
To ensure the integrity of genomic DNA and prevent tumor formation, the cell is able to 
detect the damage and signal to elicit cellular responses that include DNA repair, cell 
cycle arrest, senescence and apoptosis[222]. 
The ubiquitin pathway has been widely implicated in the various types of DNA damage 
responses. Recently, large-scale proteomics studies identified that many ubiquitination-
mediated processes are engaged in promoting cellular responses to genotoxic stress[44, 
51]. The most recent one quantified ~6,700 ubiquitination site changes in response to 
ultraviolet irradiation[223]. 
An example of the DNA damage regulation by the ubiquitin system is that the 
replication licensing factor Cdt1 has been shown to be regulated by the Cul4A-DDB1 
ubiquitin ligase and by CRL1. Degradation failure of Cdt1 results in re-replication and 
G2/M DNA damage checkpoint activation[224, 225]. The NAE inhibitor MLN4924 has 
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been shown to induce apoptosis by blocking Cul4A NEDDylation that in turn 
deregulates Cdt1 turnover[226]. 
PCNA is involved in checkpoint control and DNA repair, and its roles are also regulated 
by its ubiquitination status. Monoubiquitination of the protein facilitates translesion 
synthesis, while polyubiquitination is required for postreplicational repair[222]. 
In addition, monoubiquitination of FANCD2 by UBE2T and the FA core complex is 
required for the intact DNA damage response by the Fanconi anemia pathway[227]. The 
modified form of the protein recruits the FAN1 DNA repair nuclease to DNA damage 
sites[228]. 
An important step of the DNA damage response is the recruitment of the ubiquitin E3 
ligase RNF8 to DNA damage sites. The enzyme promotes the formation of Lys63 
polyubiquitin chains on a target yet to be identified. This signal recruits RNF168 that 
promotes monoubiquitination of H2A and H2AX that is primed for Lys63 chain 
formation and recruitment of further effectors[229]. 
The SUMO pathway is also engaged in the DNA damage response. All three SUMO 
paralogs accumulate at DNA damage sites[230]. A recent example is the report on the 
SUMO-targeted ubiquitin E3 ligase RNF4 that is recruited to sites of damage by 
SUMOylated MDC1. The ligase recognizes the SUMOylated protein through its SUMO 
interacting motifs. Absence of RNF4 results in delayed clearance of DNA damage 
factors from the foci and defective loading of replication proteins[231]. 
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1.9.2. Apoptosis 
Apoptosis (programmed cell death, PCD) has been recognized as a possible outcome of 
DNA damage in 1980[232]. Our understanding on the mechanism derives from the 
investigation of apoptosis that occurs during the development of the nematode 
Caenorhabditis elegans, in which 131 cells die invariantly between worms at particular 
points during the development process[233]. Programmed cell death occurs during 
development, aging, as a homeostatic mechanism to maintain cell populations in tissues, 
or when cells are damaged. Cancer chemotherapy or irradiation result in DNA damage 
that can lead to apoptotic death through a p53-dependent pathway. 
Inappropriate apoptosis contributes to many human conditions including 
neurodegenerative diseases, autoimmune disorders and many types of cancers. 
Apoptosis is a coordinated and often energy-dependent process that involves a complex 
cascade of events. Two main apoptotic pathways have been discovered so far: the 
extrinsic or death receptor pathway and the intrinsic or mitochondrial pathway (Figure 
1.14). They have been also shown to be linked and influence each other, and they both 
converge at the execution phase where caspases activate cytoplasmic endonucleases that 
degrade nuclear material and proteases that degrade cytoskeletal and nuclear proteins. 
Caspases (cysteinyl aspartic acid protease) are conserved cysteine proteases that are 
widely expressed in an inactive proenzyme form that require proteolytic cleavage for 
activation. Functionally, they can be divided into two groups: the initiator caspases, 
such as caspase 8 and 9 and the effector caspases, such as caspase 3 and 7.  
An additional pathway has been described that involves perforin-granzyme-dependent 
cell death and T-cell mediated cytotoxicity[234] (Figure 1.14). 
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Figure 1.14: Apoptotic pathways 
The two main pathways are the extrinsic and intrinsic apoptotic pathways as well as a 
perforin/granzyme pathway. Each is triggered by specific signals that result in the 
activation of their own initiator caspase, which in turn activates caspase-3. The 
perforin/granzyme pathway also works in a caspase-independent manner. In the final 
steps of apoptosis, characteristic cytomorphological changes can be observed such as 
chromatin condensation, formation of apoptotic bodies etc. Adapted from:[234] 
 
The extrinsic pathway begins with the direct interaction of extracellular ligands with the 
death receptors located on the cell membrane of the cells destined for apoptosis. Ligand 
binding to death receptors such as TNF (tumor necrosis factor) receptors like Fas or 
CD95, and TRAIL (TNF related apoptosis inducing ligand) receptors result in the 
assembly and activation of the death receptor complex [235]. The complex consists of 
adapter proteins such as FADD (Fas-associated death domain) and the initiator caspase 
8 that is activated through autoproteolytic cleavage [236]. Caspase 8 in turn activates 
caspase 3 and caspase 7, leading to subsequent apoptosis. 
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The tumor suppressor p53 has a crucial role in inducing the intrinsic pathway in 
response to genotoxic stress. p53 regulates the Bcl-2 family of proteins that govern the 
membrane permeability of the mitochondria. Bcl-2 proteins can be either pro-apoptotic 
(Bax, Bak, etc.) or anti-apoptotic (Bcl-2, Bcl-x, etc.). Once the pro-apoptotic proteins 
are activated, cytochrome c is released from the mitochondria, binds to and activates 
Apaf-1, forming an “apoptosome”[237]. Apoptosome formation results in a 
multicomponent adaptor complex that serves as a catalyst for caspase-9 oligomerization 
and mediates its auto-activation. The activated caspase 9 interacts with and activates 
caspase 3 [238]. Smac (small mitochondria-derived activator of caspases) is also 
released from the mitochondria, and it has been shown to suppress the action of IAPs 
(inhibitors of apoptosis proteins). IAPs (such as XIAP and survivin) are conserved 
proteins, which bind to both initiator and effector caspases and inhibit their proteolytic 
activity by covering the active site of the caspases and blocking the substrate entry [239, 
240]. 
Interestingly, another cell death-inducing platform, termed ‘Ripoptosome’ was 
discovered recently. It assembles in response to genotoxic stress-induced depletion of 
IAPs, and forms independently of the extrinsic and intrinsic apoptotic pathways. It can 
stimulate both caspase-8-mediated apoptosis and caspase-independent necrosis[241]. 
The activation of the execution caspases results in cleavage of various substrates, 
including PARP, cytokeratins, and the endonuclease CAD. CAD is also released from 
the mitochondria in a later phase of apoptosis, along with AIF and endonuclease G that 
cause DNA fragmentation. Caspase-3 induces cytoskeletal reorganization as well. 
The last stage of apoptosis is the phagocytic uptake of the cells in response to the 
externalization of phosphatidylserine on the surface of apoptotic cells [234]. 
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1.9.3. Regulation of apoptosis by ubiquitination 
The ubiquitin pathway regulates every phase of the programmed cell death through 
mono-or polyubiquitination of important factors. Ubiquitin expression has been found 
to be upregulated during apoptosis in the intersegmental muscle of insects and mature 
lymphocytes[242]; while the 26S proteasome controls the degradation of pro-and anti-
apoptotic proteins. The Bcl-2 family of proteins are known targets for the UPS; 
degradation of pro-apoptotic factors such ad Bax and Bak has been shown to promote 
survival, while elimination of Bcl-2 and Bcl-x by the proteasome is required for 
apoptotic progression[242]. 
Caspase activity needs to be tightly regulated by subcellular localization, protein 
synthesis or ubiquitination. The IAP proteins possess RING domains and have been 
identified as ubiquitin E3 ligases for the effector caspases. In mammals, caspase 3 and 7 
are monoubiquitinated through c-IAP (cellular IAP), which results in allosteric 
conformational impairment of the catalytic pocket of the caspase and steric interference 
with substrate entry. The Drosophila DIAP1 has been also shown to directly bind and 
ubiquitinate both the initiator caspase DRONC and the effector caspases drICE and 
DCP-1. Moreover, DIAP1 levels are also regulated by auto-ubiquitination that has been 
reported to be assisted by the SCF ligase complex[243]. 
Another RING E3 ligase, Mdm2 is involved in the regulation of apoptosis through the 
suppression of p53. Under non-apoptotic conditions, p53 is ubiquitinated by Mdm2, 
exported to the cytosol and degraded by the UPS[244]. However, under pro-apoptotic 
circumstances, p53 ubiquitination is rapidly recovered by the action of the 
deubiquitinating enzyme HAUSP. In stress conditions, Mdm2 autoubiquitination and 
degradation is favored. Furthermore, p14ARF, an alternate reading frame protein 
expressed from the INK4a locus, interacts with Mdm2, which leads to the relocalization 
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of Mdm2 from the nucleoplasm to the nucleolus, blocking the nuclear export of p53 by 
Mdm2 that is required for the degradation of the tumor suppressor protein[245]. 
Recently, several new studies emerged that link NEDD8 to apoptosis. MLN4924, the 
NEDD8 E1 inhibitor has been shown to induce apoptosis in several types of cancer, 
including liver cancer and head and neck cancers[246, 247]. In addition, the Drosophila 
inhibitor of apoptosis protein DIAP1 has been identified as a NEDD8 E3 ligase that 
NEDDylates itself, however, the functional consequences of the self-NEDDylation have 
not been determined yet[104]. 
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1.10. Aims 
My PhD project was aiming to further investigate the role of NEDD8 in diverse stress 
responses. The characterization of the ubiquitin-like modifier under proteasome 
inhibition and the utilization of the NEDD8 E1 inhibitor MLN4924 led us to the 
unexpected finding that the ubiquitin activating enzyme Ube1 activates endogenous 
NEDD8 in vivo. We characterized this phenomenon extensively, and showed that 
NEDD8 responds to heat shock and oxidative stress through the ubiquitin conjugation 
pathway. 
We also investigated the NEDD8 chain formation upon MG132 treatment. One of our 
goals was to identify NEDD8 and NEDD8/ubiquitin mixed chains unambiguously by 
mass spectrometry. We achieved it by applying two different approaches. We have also 
shown that NEDD8 is present in the chains that are recognized by ubiquitin-binding 
domains. 
In a parallel project, we aimed to characterize the role of the deNEDDylating enzyme 
NEDP1 in response to DNA damage. The NEDP1 ortholog in C. elegans, Ulp-3 has 
been previously investigated in collaboration with Anton Gartner’s group and the 
enzyme has been found to be required for DNA damage-induced apoptosis in the worm 
germ line. We investigated whether the role of NEDP1 is conserved in human cell lines, 
and assessed its mechanism of action in the DNA damage-induced apoptosis pathway. 
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Chapter 2: Materials and Methods 
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2.1. Chemicals and suppliers: 
Commonly used chemicals were of analytical grade, supplied by VWR and Sigma 
Aldrich. MG132 was purchased from Calbiochem, lactacystin from Enzo Life Sciences, 
MLN4924 from Millenium Pharmaceuticals, doxorubicin from Enzo Life Sciences, and 
actinomycin D and staurosporine were from Sigma. Lysyl endopeptidase C was 
purchased from Wako Chemical, and trypsin from Promega. 
To investigate the effects of DNA damage induced apoptosis, cells were treated with 2-
10 Gy of gamma irradiation using a Cs137 (IBL 437C, CIS bio international). 
Centrifugation was done with a Heraeus Biofuge Pico Centrifuge with #3328 rotor. 
2.2. Tissue culture and cellular assays 
2.2.1. Cell lines and growth conditions 
MCF7 human breast adenocarcinoma cells, U2OS human osteosarcoma cells, HeLa 
cervical cancer cells, HEK 293 human embryonic kidney cells and HCT116 colorectal 
carcinoma cell lines were cultured in Dulbecco's Modified Eagle's Medium (DMEM, 
Gibco) with 50 U/ml Penicillin, 50 µg/ml Streptomycin and 10 % FCS (fetal calf serum) 
at 37°C, 5 % CO2. 
H1299 human non-small cell lung carcinoma cells were cultured in RPMI-1640 
medium (Gibco) with 2 mM L-glutamine, 50 U/ml Penicillin, 50 µg/ml Streptomycin 
and 10 % FCS (fetal calf serum) at 37°C, 5 % CO2. 
~90 % confluent cells were treated with trypsin-EDTA and replated to the desired 
confluency. Cells were used until they reached passage ~25. 
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PBS (phosphate buffered saline, Gibco) was used to wash the cells. 
2.2.2. Generation of stable cell lines 
For stable cell lines expressing His-NEDD8, a lentivirus vector generated by Liu Geng 
was used. HCT116 or U2OS cells were seeded in a 6-well plate. 80 µl of the lentiviral 
supernatant was added to the cells in the presence of 4 µg/ml polybrene. Medium was 
replaced with DMEM with 10 % FCS the next day. 2-3 days later 5 µg/ml puromycin 
was added to the medium. The stable cell lines were maintained in DMEM medium 
with 5 µg/ml of puromycin and the expression of His6-NEDD8 was verified.  
2.2.3. Long-term storage of cells 
To prepare stocks for long-term storage, cells were grown to 90 % confluency, detached 
by trypsin, washed with PBS, and transferred to a 15 ml falcon tube. Cells were pelleted 
at 1000 rpm for 2 min in a Beckman centrifuge. The pellet was resuspended in FBS+ 10 
% DMSO, and transferred to cryotubes (3 vials/ 75cm flask). The cells were first frozen 
at -80°C, before transferring them to liquid nitrogen storage. To recover cell lines, a vial 
was thawed in a 37°C water bath, and immediately plated in a flask with the adequate 
medium. Once cells settled, medium was changed to remove the DMSO.  
2.2.4. Transfections 
2.2.4.1. Cell plating 
24 hrs before transfection, cells were washed twice with PBS, trypsinized and 
resuspended with RPMI or DMEM with 10 % FCS and antibiotics. Cell number was 
counted using a Hemocytometer. 
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2.2.4.2. Plasmid transfection with calcium-phosphate method 
H1299 cells were transfected using the calcium-phosphate method. 1 hr prior 
transfection, RPMI media was replaced with DMEM to increase transfection efficiency. 
This is done as RPMI has high salt concentrations and interferes with the calcium-
phosphate method. DNA solution (up to 20 µg of DNA in 437.5 µl ddH2O) was mixed 
with 62.5 µl 2 M CaCl2 in a tube. 500 µl 2X HBS (280 mM NaCl, 10 mM KCl, 1.5 mM 
Na2HPO4·2H2O, 12 mM dextrose, 50 mM HEPES, pH 7.05) was added on a well of a 6 
well plate. The DNA solution was added on the HBS dropwise and DNA/Ca3(PO4)2 
precipitates were monitored under microscopy before pipetted on the cells. 24 hrs after 
transfection media was replaced to RPMI. Cells were normally harvested 48 hrs after 
transfection. 
2.2.4.3. Fugene transfection 
All cell lines except H1299 were transfected with plasmid DNA using the Fugene HD 
Transfection Reagent (Roche) in 3:2 ratio of Fugene: DNA (µg). Cells were seeded on 6 
well plates to reach 80-90 % confluency by the time of transfection. DNA was diluted 
in Opti-MEM serum-free medium. Fugene HD transfection reagent was added to the 
tube containing the DNA, vortexed and incubated for 15 min at RT. After incubation, 
the solution was added on the cells and incubated for 24-48 hrs prior harvesting. 
2.2.4.4. siRNA transfection 
siRNAs were purchased form Dharmacon as ON-TARGETplus SMARTpools (each 
pool contained 4 individual siRNAs targeting different parts of the gene of interest). 
Non-targeting siRNA from Dharmacon was used as a control. Prior to transfection, cells 
were seeded in 6-well plates with 2 ml DMEM and incubated overnight. 3.3 µl 
Lipofectamine RNAiMAX (Invitrogen) was diluted in 200 µl Optimem (Gibco), and 
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this was added to 0.5 µl of 20 µM siRNA in 200 µl Optimem, and then incubated for 20 
mins at room temperature. The cells were harvested 48-72 hrs after the transfection. For 
the experiments with NEDP1 siRNA, 24 hrs after the transfection, the wells of the cells 
were trypsinized and split into 2 wells. The siRNA transfection was repeated the next 
day, and cells were harvested 4-5 days after the first transfection. 
2.2.5. Ni2+-NTA pulldown 
Cells were grown on 10 cm culture dishes. Before harvesting, cells were washed twice 
with 3 ml ice cold PBS, and then scraped into 1 ml PBS. 200 µl of the sample was 
pelleted at 13000 rpm for 1 min and lysed in 200 ml 2X SDS (5 % m/v sodium dodecyl 
sulphate, 25 % glycerol, 150 mM Tris-HCl pH 6.8, 0.01 % m/v bromophenol blue). 
Lysates were passed through a 21 G needle 20 times and were boiled for 5 mins. 800 µl 
of the sample was lysed in 6 ml of 6 M GuaCl (6 M Guanidinium-HCl, 10 mM Tris-
HCl, 0.1 M Na2HPO4/NaH2PO4, pH 8.0) with 10 mM imidazole and 10 mM β-
mercaptoethanol. 50 µl of Ni2+-NTA-agarose beads were added to the lysates and 
incubated for 4 hrs at room temperature or overnight in cold room. Beads were pelleted 
at 1500 rpm for 5 mins and were washed once with 750 µl 6 M GuaCl with 10 mM 
imidazole and 10 mM β-mercaptoethanol; four times with 750 µl 8 M Urea pH 6.3 (8 M 
Urea, 0.1 M Na2HPO4/NaH2PO4, 0.01 M Tris-HCl) with 10 mM imidazole and 10 mM 
β-mercaptoethanol and 0.1 % Triton X-100. After each wash, beads were spun down at 
7500 rpm for 1-2 min and the washing buffer was removed. 100 µl of 250 mM 
imidazole in 8 M Urea (pH 6.3) was added, and samples were incubated for 30 mins at 
RT, then spun at 13000 rpm for 10 min. The supernatant was collected, the eluate was 
mixed with 2X SDS and analysed by SDS-PAGE. His6-NEDDylated proteins for mass 
spectrometry were isolated as described above, except that samples were eluted in 8 M 
Urea (pH 8.0) containing 200 mM imidazole. The second elution was digested in 
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solution with Lys-C for 12 hrs at room temperature. TAP-NEDD8 purification and 
proteomics analysis was done as described in[106]. 
2.2.6. Immunoprecipitation 
U2OS or HEK 293 cells were cultured in 10 cm plates and transfected with HA-Ube1 or 
pcDNA3 plasmid using Fugene HD Transfection Reagent (Promega). Cells were lysed 
in 1% SDS, 5 mM EDTA, 10 mM iodoacetamide, 15 U/ml DNase I (Sigma) and 
protease inhibitors (Roche). After incubation at 95oC for 5 min, the lysate was diluted 
10 fold with non-denaturing lysis buffer (20 mM Tris pH 8, 150 mM NaCl, 1 % NP-40, 
2 mM EDTA, protease inhibitors), and passed through a syringe. Anti-HA antibody 
coupled to sepharose beads (Sigma) was used for immunoprecipitation. Proteins were 
eluted with pH 2.8 elution buffer (Thermo). Eluates were split and in one set DTT (200 
mM) was added. Samples were mixed with 8 M Urea and 2X SDS loading buffer and 
analysed by western blotting. 
2.2.7. RNA isolation and Quantitative PCR (qPCR) 
For detection of gene expression, RNA from the cells from 6-well plates was isolated 
using the Promega SV Total RNA Isolation system. cDNA was made using the 
Invitrogen SuperScript® III First-Strand Synthesis SuperMix for qRT-PCR  with 300 
ng of RNA. The cDNA was diluted with H2O (1:20 dilution) and 2 µl were used in 12 
µl qPCR reaction with appropriate primers and TaqMan Gene Expression Master Mix 
(in case of the NEDD8 and NEDP1 detection) or SYBR Green PCR Master Mix 
(Applied Biosystems). Experiments were performed at least 3 times and data represent 
mean values +/- standard deviation. 
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2.2.8. Chromatin Immunoprecipitation (ChIP) and Sequential 
ChIP Assay  
Cells were grown on 10 cm dishes. After harvesting, cross-linking was performed by 
incubating cells with 1 % formaldehyde for 10 min at room temperature. A final 
concentration of 125 mM glycine was added to terminate the reaction and incubated for 
5 min at room temperature. Cells were washed twice with ice-cold PBS. Nuclei were 
isolated by incubation in cell lysis buffer (10 mM Tris-HCl pH 8.1, 10 mM NaCl, 0.2 % 
Nonidet P-40,) containing for 10 min on ice, followed by centrifugation for 2 min at 
600 g. Nuclei were lysed in nuclei lysis buffer (50 mM Tris-HCl pH 8.1, 10 mM EDTA, 
1 % SDS) containing Protease Inhibitor cocktail tablets (Roche) for 10 min at 4°C. The 
lysate was sonicated up to ~500 bp chromatin fragment and checked by agarose gel 
electrophoresis. After centrifugation at 16000 g for 10 min, soluble chromatin was 
diluted with immunoprecipitation (IP) dilution buffer (20 mM Tris-HCl pH 8.1, 150 
mM NaCl, 2 mM EDTA, 0.01 % SDS, 1 % Triton X-100) at a 1:10 ratio of nuclei lysis 
buffer to IP dilution buffer. Chromatin was then pre-cleared by incubation with at least 
equal amount of preimmune serum or equal amount of control IgG for 2 hrs. Protein A 
was added and incubated for at least 2 hrs. Aliquots of pre-cleared samples (input) were 
saved. Remaining sample was incubated with 2.5 µg of anti-p53 (DO1) antibody per 1 
ml IP reaction for 16 hrs at 4°C. Immune complexes were collected by incubation with 
pre-blocked Protein A Sepharose (Sigma) for 2 hrs at 4°C. Sepharose beads were 
washed twice with 0.5 ml of IP wash buffer 1 (20 mM Tris-HCl pH 8.1, 50 mM NaCl, 2 
mM EDTA, 0.1 % SDS, and 1 % Triton X-100), once with IP wash buffer 2. Immune 
complexes were eluted twice with 150 µl of IP elution buffer (0.1 M NaHCO3 and 1 % 
SDS). Cross-links were reversed by adding RNase A (3.3  g/ml) and NaCl (0.3 M) and 
incubating for 6 hrs at 65°C. Samples were digested with proteinase K (0.2 mg/ml) for 
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at least 2 hrs at 45°C. DNA was column purified by using ChIP DNA Clean and 
Concentrator Kit (Zymo Research). 
Samples were analysed by qPCR. 2 µl of each eluate was used in a 12 µl reaction with 
appropriate primers. Primer sequences can be found in Table 2.1. Each experiment was 
performed at least 3 times and data represent mean values +/- standard deviation.  
 
Real time PCR primers/ probes 
 Sense primer Antisense primer Probe 
NEDD8 
Obtained from Applied Biosystems as a validated mix of forward/reverse 
primers and probe 
Actin CAACTCCATCATGAAGTGTGA CAGGGCAGTGATCTCCTTCTG - 
NEDP1 
Obtained from Applied Biosystems as a validated mix of forward/reverse 
primers and probe 
ChIP primers 
NEDP1 
promoter 
TGAACAGGAGGGCATGACAAG CTTTTTGTTGCCTCTATCTTATTTTAACTG 
p21 promoter GTGGCTCTGATTGGCTTTCTG CTGAAAACAGGCAGCCC 
BAX promoter TAATCCCAGCGCTTTGGAAG TGCAGAGACCTGGATCTAGCAA 
Table 2.1. Primers used in gene expression and ChIP experiments 
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2.2.9. Caspase activity assays 
A 5-days double treatment of NEDP1 or NT siRNA was performed in HCT116 cells. 6 
hrs before harvesting, cells were either left untreated, or exposed to 7 Gy ionizing 
irradiation or 1 µM staurosporine. Caspase activity was measured using Caspase-Glo 
3/7, 8 or 9 Assays (Promega), according to the manufacturers instructions. 
Luminescence signals were measured on luminometer (Berthold Microlumat Plus 
LB96V). 
2.3. Bacteria and plasmid preparation 
2.3.1. Media 
LB (Luria-Bertani) media (1 % w/v bacto-tryptone, 0.5 % w/v bacto-yeast extract, 1 % 
w/v NaCl, pH 7.0), and LB Agar (LB +1.5 % bacto agar) plates with the appropriate 
antibiotic were prepared by the media services, MSI/WTB/JBC complex, University of 
Dundee and CRBM, Montpellier. 
2.3.2. Preparation of chemically competent DH5α cells 
5 ml LB medium was inoculated with a single colony of E.coli from a freshly streaked 
agar plate and incubated overnight at 37°C. This starter culture was used to inoculate 
500 ml 2YT media. Once the culture reached OD600 =~ 0.6, it was chilled on ice for 5 
min. The cells were collected by centrifugation at 2500 rpm for 10 min at 4°C. Bacterial 
pellet was then resuspended in 25 ml cold TSB (LB pH 6.1, 10 % w/v PEG, 5 % 
DMSO, 10 mM MgCl2, 10 mM MgSO4). 2.5 ml sterile glycerol was added and the cells 
were incubated on ice for 10 min. The aliquots were snap-frozen in liquid nitrogen and 
stored at -80°C.   
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2.3.3. Transformation of chemically competent DH5α cells 
5X KCM buffer (0.5 M KCl, 0.15 M CaCl2, 0.25 M MgCl2) was mixed with 1 µg of 
DNA and ddH2O to a final volume of 100 ml at 1X KCM final. 100 ml E. coli DH5α 
competent cells were added, mixed and incubated first on ice for 20 min, followed by 
10 min incubation at room temperature. 1 ml pre-warmed LB media was added to the 
cells and incubated for 1 hr at 37°C prior to plating on LB agar plates in the presence of 
appropriate selective antibiotic.  
2.3.4. Plasmid DNA amplification and purification 
5 ml LB with appropriate selective antibiotic (Amplicillin 100 mg/ml, Kanamycin 
50 mg/ml) was inoculated with a single colony for small-scale plasmid purification. For 
“maxiprep”, 250 ml LB media was inoculated overnight at 37°C with the 5 ml 
overnight culture. QIAprep Spin Miniprep Kit (Qiagen) and QIAGEN Plasmid Maxi 
Kit (Qiagen) were used for 5 ml and 250 ml culture respectively. The procedure was 
carried out according to the manufacturer’s instructions.  
2.3.5. Plasmid DNA quantification 
DNA concentration was measured by spectrophotometer (eppendorf BioPhotometer) at 
OD260. The purity of DNA was determined by the ratio of OD260 and OD280. 
2.3.6. DNA sequencing 
DNA templates (20 ng/ml, min. volume 15 ml) and primers (3.2 pmol, min. volume 10 
ml) were sent to The Sequencing Service, MSI/WTB/JBC complex, University of 
Dundee. 
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In the case of the NEDD8 mutants, sequencing was performed by Eurofins MWG 
with T7 primers. 
2.3.7. Site-directed mutagenesis 
Site-directed mutagenesis was performed with Phusion High-Fidelity polymerase (New 
England Biolabs). The reaction mixture was composed of 1X PCR buffer (NEB), 0.25 
mM dNTPs, 0.4 µM forward primer, 0.4 µM reverse primer, 0.5 U DNA polymerase 50 
ng DNA template, 1 % DMSO. ddH2O was added to make up the final volume to 50 ml. 
PCR was performed with the following cycling parameters: initial denaturation at 98°C 
for 30 sec; 18 cycles of subsequent denaturation at 98°C for 10 sec, annealing at 60°C 
for 20 sec, and extension at 72°C for 2 min; final extension at 72°C for 7 min. Primers 
used for mutagenesis are shown in Table 2.2. 
After the PCR was finished, 1 ml  DpnI (20000 U/ml) was added to each PCR tube and 
incubated at 37°C for 2 hrs. DpnI only cleaves at methylated sites, hence it only digests 
the plasmid from bacteria but not from PCR products. 5 µl of the digested reaction was 
run on gel and compared to the undigested parental plasmid (they show different band 
pattern). 5 ml of each reaction was used for transformation and DNA isolated from 
miniprep was sequenced to confirm the mutation. 
2.3.8. Agarose gel electrophoresis 
DNA was resolved using 0.8-1 % w/v agarose gels (depending on the size of the DNA 
fragments of interest) in TAE buffer (40 mM Tris, 0.114 % glacial acetic acid, 1 mM 
EDTA pH 8.0) and 1X GelRed Nucleic Acid Stain (Biotium) (10,000X stock). Samples 
were mixed with 5X gel loading buffer (30 % Glycerol, 0.2 % w/v Orange G) and 
loaded on the gel, along with a 100 bp or 1 Kb DNA ladder (NEB). The gel was run at 
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60 V at room temperature and DNA was visualised using a transilluminator UV 
lightsource.  
2.3.9. Plasmids 
Eukaryotic expression plasmids used in this thesis can be found in Table 2.2. 
Name Template PCR primers Sources 
HA-UBE1   Gift 
His6-NEDD8   Our lab 
HA-NEDD8   Our lab 
His6-ubiquitin   Our lab 
Mdm2   Our lab 
Myc-Cullin4A   Our lab 
NEDP1   Our lab 
p53   Our lab 
pcDNA3   Our lab 
HA-NEDD8 L2A HA-NEDD8 
F:CGCTTCCCTTGGATCCGCCATTAAAGTGAAGACGC 
R:GCGTCTTCACTTTAATGGCGGATCCAAGGGAAGCG 
 
HA-NEDD8 K4A HA-NEDD8 
F:CCTTGGATCCCTAATTGCCGTGAAGACGCTGACC 
R:GGTCAGCGTCTTCACGGCAATTAGGGATCCAAGG 
 
HA-NEDD8 K6A HA-NEDD8 
F:GATCCCTAATTAAAGTGGCCACGCTGACCGGAAAGG 
R:CCTTTCCGGTCAGCGTGGCCACTTTAATTAGGGATC 
 
HA-NEDD8 T7A HA-NEDD8 
F:GATCCCTAATTAAAGTGAAGGCCCTGACCGGAAAGGAGATTG 
R:CAATCTCCTTTCCGGTCAGGGCCTTCACTTTAATTAGGGATC 
 
HA-NEDD8 K11A HA-NEDD8 
F:GAAGACGCTGACCGGAGCCGAGATTGAGATTGAC 
R:GTCAATCTCAATCTCGGCTCCGGTCAGCGTCTTC 
 
HA-NEDD8 E12A HA-NEDD8 
F:CGCTGACCGGAAAGGCCATTGAGATTGACATTG 
R:CAATGTCAATCTCAATGGCCTTTCCGGTCAGCG 
 
HA-NEDD8 I13A HA-NEDD8 
F:GCTGACCGGAAAGGAGGCCGAGATTGACATTGAAC 
R:GTTCAATGTCAATCTCGGCCTCCTTTCCGGTCAGC 
 
HA-NEDD8 D16A HA-NEDD8 
F:GAAAGGAGATTGAGATTGCCATTGAACCTACAGACAAG 
R:CTTGTCTGTAGGTTCAATGGCAATCTCAATCTCCTTTC 
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HA-NEDD8 Q40A HA-NEDD8 
F:GAATCCCCCCACAAGCCCAGAGGCTCATCTAC 
R:GTAGATGAGCCTCTGGGCTTGTGGGGGGATTC 
 
HA-NEDD8 Y45A HA-NEDD8 
F:CACAACAGCAGAGGCTCATCGCCAGTGGCAAGCAGATGAATG 
R:CATTCATCTGCTTGCCACTGGCGATGAGCCTCTGCTGTTGTG 
 
HA-NEDD8 S46A HA-NEDD8 
F:GCAGAGGCTCATCTACGCCGGCAAGCAGATGAATG 
R:CATTCATCTGCTTGCCGGCGTAGATGAGCCTCTGC 
 
HA-NEDD8 K48A HA-NEDD8 
F:GGCTCATCTACAGTGGCGCCCAGATGAATGATGAGAAG 
R:CTTCTCATCATTCATCTGGGCGCCACTGTAGATGAGCC 
 
HA-NEDD8 D52A HA-NEDD8 
F:GCAAGCAGATGAATGCCGAGAAGACAGCAGC 
R:GCTGCTGTCTTCTCGGCATTCATCTGCTTGC 
 
HA-NEDD8 G64A HA-NEDD8 
F:GATTACAAGATTTTAGGTGCCTCAGTCCTTCACCTGGTG 
R:CACCAGGTGAAGGACTGAGGCACCTAAAATCTTGTAATC 
 
HA-NEDD8 V66A HA-NEDD8 
F:GATTTTAGGTGGTTCAGCCCTTCACCTGGTGTTGG 
R:CCAACACCAGGTGAAGGGCTGAACCACCTAAAATC 
 
HA-NEDD8 L69A HA-NEDD8 
F:GGTTCAGTCCTTCACGCCGTGTTGGCTCTGAG 
R:CTCAGAGCCAACACGGCGTGAAGGACTGAACC 
 
HA-NEDD8 K6R HA-NEDD8 
F:GATCCCTAATTAAAGTGCGTACGCTGACCGGAAAGG 
R:CCTTTCCGGTCAGCGTACGCACTTTAATTAGGGATC 
 
HA-NEDD8 K11R HA-NEDD8 
F:GACGCTGACCGGAAGGGAGATTGAGATTG 
R:CAATCTCAATCTCCCTTCCGGTCAGCGTC 
 
Table 2.2. Plasmid DNA information 
For the plasmids constructed in the thesis, the template DNA with the PCR primers 
are shown. Plasmids were in pcDNA3 vectors, except HA-UBE1, which was in 
pCMV. This plasmid was a gift from Dr. Thimo Kurz. For other plasmids, sources 
are indicated. For PCR primers, both forward (F) and reverse (R) primers are 5’3’. 
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2.4. Protein expression from bacteria 
Construct name Gene Gene modification Species Vector Tag Cloning site 
mRpn13 (1-407)-
pGEX-4T1 Rpn13 wt mouse 
pGEX-
4T1 GST BamHI-XhoI 
S5A (1-377)-pGEX-
4T1 Rpn10 wt human 
pGEX-
4T1 GST XhoI-XhoI 
hHR23A-UBA1-
pGEX-4T1 Rad23 UBA1 human 
pGEX-
4T1 GST 
BamHI-
BamHI 
hHR23A-UBA2-
pGEX-4T1 Rad23 UBA2 human 
pGEX-
4T1 GST 
BamHI-
BamHI 
hHR23B-UBA1-
pGEX-4T1 Rad23 UBA1 human 
pGEX-
4T1 GST 
BamHI-
BamHI 
hHR23B-UBA2-
pGEX-4T1 Rad23 UBA2 human 
pGEX-
4T1 GST 
BamHI-
BamHI 
hPLIC2 (UBA)-
pGEX-4T1 PLIC2 UBA human 
pGEX-
4T1 GST 
BamHI-
BamHI 
pGEX-KG-UBA 
(Dsk2) Dsk2 UBA S. cerevisiae  GST  
Table 2.3. Constructs used for recombinant protein expression 
All plasmids were constructed by and obtained from Dr. Koraljka Husnjak, except the 
Dsk2 UBA, which was a gift from Mark Laurence. 
 
2.4.1. Transformation of chemically competent BL21 (DE3) 
Codon Plus cells 
The list of bacterial expression vectors encoding the different UBA domains used in this 
thesis can be found in Table 2.3. Plasmids were transformed into 100 µl BL21-
CodonPlus® Competent Cells and incubated on ice for 30 mins. The bacteria were heat 
shocked at 42°C water bath exactly for 2 mins, before being placed on ice for a further 
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minute. 1 ml prewarmed LB media was added and cells were incubated at 37°C before 
being plated on LB-ampicillin agar plates. 
2.4.2. Protein expression 
Single colony was picked to inoculate 5 ml LB with appropriate selective antibiotic 
(Amplicillin 100 mg/ml, Kanamycin 50 mg/ml) and incubated overnight at 37°C. This 
was further used to inoculate 200 ml LB media at 37°C, for 2-3hrs. Once OD600 reached 
0.6-0.8, the culture was chilled on ice water for 10 min. Expression was induced with 
the addition of IPTG to a 100 µM final concentration and the culture was agitated at 
20°C overnight.  
2.4.3 Protein purification and coupling to Glutathione Sepharose 
beads 
The overnight culture was pelleted at 5000 rpm for 20 min at 4°C, and the pellets re-
suspended in 10 ml PBS with protease inhibitor (complete EDTA-free, Roche). 10 µl of 
100 mg/ml lysozyme was added and incubated on ice for 30 min. Triton-X was added to 
1 % final concentration and lysates were sonicated 3X 30s with 50 % amplitude on ice 
(Branson Digital Sonifier). Samples were centrifuged at 12,000g for 30 min at 4°C.  
The supernatant was incubated with Glutathione Sepharose beads (GE Heatlhcare) 
overnight at 4°C. Beads were spun at 1500 rpm, 2 min at 4°C, washed three times with 
PBS and 0.1% Triton-X and once with PBS only. GST-tagged proteins coupled to beads 
were stored as a 50% slurry in PBS and 0.02% NaN3 at 4°C. 
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2.5. Pulldown with GST-tagged UBA domains or UBA 
domain containing proteins 
H1299 cells were grown in 15 cm dishes to ~90% confluency. Cells were either treated 
with the 30 µM MG132 for 4 hrs, or heat shocked at 43oC incubator for 1 hour, or left 
untreated, as indicated. Before lysis, cells were washed twice with ice cold PBS, 
scraped off, and the pellet was resuspended in 50 mM Tris pH 7.4, 150 mM NaCl, 1% 
NP40, 10% glycerol, 10 mM EDTA, protease inhibitor and 50 mM iodoacetamide. The 
lysis was performed by syringing and incubation on ice. The lysate was cleared by 
centrifuging at 14,000 rpm, 10 min at 4 oC. 250 µl of the lysate per conditions was 
incubated with the different UBA domains overnight at 4 oC. Beads were washed 5 
times with lysis buffer and proteins were eluted by boiling the samples in 60 µl 2X 
SDS. 20 µl was loaded on a 4-12% gel and analysed by western blotting with anti-
ubiquitin and anti-NEDD8 antibodies. After western blotting, the membrane was 
stained with coommassie blue reagent to visualize the total proteins loaded. 
2.6. Biochemical techniques 
2.6.1. In vitro NEDD8 processing assay 
For NEDD8 processing by NEDP1 or ULP-3, recombinant MBP-His-NEDD8-Ub 
fusion and the wild type and mutant enzymes were expressed and purified previously in 
the lab. The reaction was performed in 10 µl containing 600 ng of MBP-His-NEDD8-
Ub, 50 mM Tris, pH 7.5, 100 mM NaCl, 5 mM MgCl2, 5 mM β-mercaptoethanol and 
200 ng NEDP1 or MBP-ULP-3 wt or MBP-ULP-3 Cys. Reactions were incubated for 
10, 30 or 60 mins at 37°C and terminated by the addition of SDS loading buffer 
containing β-mercaptoethanol. 
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2.6.2 BCA protein assay  
Protein concentration was measured by BCA Protein Assay (Thermo scientific). 
Reagent A and Reagent B was mixed in a 50:1 volume ratio and applied to dilute 
protein samples. Protein samples were incubated for 25 min in a 60°C water bath until 
the colour became light purple. The samples cooled down to room temperature and 
OD562 was measured by spectrophotometer. The protein concentration was determined 
from a standard curve using BSA. 
2.6.3 SDS-polyacrylamide gel electrophoresis 
Proteins were resolved with Invitrogen NuPage 12% or 4-12% Bis-Tris gels 
(Invitrogen) in Invitrogen Xcell SureLock Mini-Cell apparatus, which was filled with 
500ml 1X MOPS running buffer (MOPS 50 mM, Tris base 50 mM, SDS 0.1%, EDTA 
1 mM, pH 7.7). Alternatively, MES running buffer (MES pH 7.2 50 mM, Tris base 50 
mM, SDS 0.1%, EDTA 1 mM, pH 7.3) was used to resolve low molecular weight 
proteins. 
2.6.4 Coomassie staining 
Polyacrylamide gel was incubated in Coomassie blue stain solution (0.1% w/v 
Coomassie Brilliant Blue, 40% v/v methanol, 7% v/v glacial acetic acid) followed by 
washes in Coomassie destain solution I (40% v/v methanol, 7% v/v glacial acetic acid) 
for 30min and three washes in Coomassie destain solution II (5% v/v methanol, 7% v/v 
glacial acetic acid) for several hours. 
Coomassie staining of PVDF membrane was performed by incubation in Coomassie 
blue stain solution for 10 min, followed by several washes in ddH2O. 
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2.6.5 Western immunoblotting 
Proteins resolved by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) gels (Invitrogen) were transferred onto PVDF membrane (Millipore) using the 
Bio-Rad Mini Trans-Blot apparatus filled with 1L transfer buffer (0.2 M Glycine, 25 
mM Tris, 20% methanol). Transfer was carried out at 25 mA overnight or at 70 V for 90 
mins on ice. 
Membranes were blocked by shaking with 5% milk solution (PBS with 5% skimmed 
milk and 0.1% Tween-20, boiled and filtered with dental napkins) for 1 hr at room 
temperature. Primary antibodies were diluted and stored in TBS 0.1% Tween-20 with 3 
% BSA and 0.1% NaN3 at 4°C and incubated with the membranes overnight at 4°C. 
Membranes were washed with 2X 10 mins PBS 0.1% Tween-20 prior to the incubation 
of the corresponding secondary antibodies (Sigma Aldrich), which were diluted 1:2000 
in 5% milk solution, at room temperature for 1 hour. Membranes were washed with 4X 
10 mins PBS 0.1% Tween-20 followed with 2X 5 mins PBS.  
Detection was performed with ECL Western Blotting Detection Reagents (Amersham) 
prepared by mixing equal volumes of Reagent I and Reagent II. Membranes were 
incubated with the reagent solution mix for 1min, prior to being exposed to Medical 
Film (Konica Minolta) for an appropriate exposure time before being developed. 
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Name Species Stock Concentration 
Dilution for 
WB Sources 
β-actin Mouse  1:25000 Calbiochem 
Cullin1 Mouse  0.5 µg/ml In house 
Cullin 4A Rabbit 85 mg/ml 1:1000 Abcam 
Cullin 3 Rabbit  1:1000 Gift 
Flag Mouse 3 mg/ml 1:3000 In house 
HA Mouse  1:3000 In house 
His Mouse  1:3000-5000 Clontech 
Myc Mouse 0.2 mg/ml 1:200 Santa Cruz 
Mdm2 (4B2) Mouse 2 mg/ml 1:2000 In house 
NEDD8 Rabbit  1:1000 Epitomics 
NEDP1 Sheep  1:1000 In house 
Ubiquitin E1 Ube1 Rabbit 1 mg/ml 1:2000 Abcam 
Uba6 Rabbit  1:2000 Gift 
UbcH5 Sheep  1:20,000 In house 
Cyclin E Mouse   Gift 
p53 (DO1) Mouse 0.25 mg/ml 1:250-500 In house 
p21 Mouse 0.2 mg/ml  Santa Cruz 
SUMO-2/3 Sheep  1:2000 In house 
α-Tubulin Mouse  1:1000 Cell Signaling 
Ubiquitin  Rabbit  1:2000 DAKO 
Ubc12 Rabbit  1:2000 In house 
 
Table 2.4. Primary antibodies used in the thesis.  
WB: western blotting. Cullin 3 antibody was a gift from Matthias Peter, ETH 
Zurich. 
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2.7. Mass Spectrometric Analysis 
The Lys-C-digested peptides were desalted on StageTips[248] and analyzed by LC-
MS/MS on an LTQ-Orbitrap Velos mass spectrometer (Thermo Fisher Scientific, 
Germany) coupled to a nanoflow HPLC (EASY-nLC system, Proxeon, Odense, 
Denmark). Only peptides with charge state equal or higher than 3 for the trypsin 
experiment, and 4 for the Lys-C experiment were fragmented by CID and recorded in 
the orbitrap analyser.  Samples from the TAP-NEDD8 experiment were analysed on an 
LTQ-Orbitrap Classic instrument by Dr. Ivan Matic. Processing of raw MS data and the 
quantitative analysis were performed with the MaxQuant software[249, 250]. Mass 
additions of GG and LRGG were considered as variable modifications in “trypsin” 
experiments. Spectra were manually validated and assigned. 
 
2.8. Handling of S. pombe and C.elegans 
2.8.1 Schizosaccharomyces pombe strain, growth and media 
Strain ID: FY7093, genotype: h+, ade6-M210 was used for the heat shock 
experiment. YES (YE+supplements) rich medium was prepared according to[251]. 
2.8.2 Heat shock and small scale protein extraction from S. pombe 
Starter culture was inoculated from a freshly streaked plate and incubated for 1 day with 
agitation. A 150 ml YES medium was inoculated from the starter culture and incubated 
overnight, until OD600 has reached 0.3-0.6. This was split into 25 ml liquid cultures and 
incubated at 37-39°C for the indicated time periods. After centrifugation at 3000 rpm, 2 
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mins at 4°C, pellet was washed with ice-cold water and resuspended in lysis buffer (50 
mM Tris pH7.5; 150 mM NaCl; 10 mM EDTA; 1% NP40; 10% glycerol, Roche 
protease inhibitor cocktail tablet and 50 mM iodoacetamide). After addition of 200 µl 
glass beads, cells were broken up in a FastPrep TM-24 beater (with a Hi Prep adapter 48 
X 2 ml samples) beater for 3-times 40 sec, with 5 min rest in between. The tube was 
punctured with a heated needle, placed into a clean tube and spun at maximum speed 
for 10 sec. The insoluble pellet was removed by spinning for a further 5 min at max 
speed. Supernatant was mixed with equal amount of 2X SDS and boiled at 95°C for 5 
min. 
2.8.3 Heat shock and protein extraction from C. elegans 
Bleached-synchronized L1 larvae stage worms were grown at 20°C on NGM agar plates 
seeded with E. coli HT115 strain. After reaching the L4 larvae stage, worms were 
subjected to a heat shock by transferring agar plates to 30°C for 5 hrs. Total protein was 
extracted by bead beating (Zirconia beads 0.7 mm, Biospect Products) in lysis buffer 
(50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-40, 5 mM EDTA), clarified by 
centrifugation and boiled in SDS sample buffer. Protein were analysed by western Blot 
analysis.  
2.9. Statistical analysis 
Statistical analysis was performed using GraphPad software. The two-tailed p values 
were determined using Student’s t-test. Values p<0.05 were considered to represent 
statistically significant difference. 
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Chapter 3: NEDD8 responds to stress 
conditions via the ubiquitin pathway 
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3.1. Introduction 
The ability of cells to adapt to environmental changes is essential for their survival. 
Diverse mechanisms have been evolved to protect cells from external or internal stress 
conditions. Upon stress stimuli, several cellular responses are coordinated by 
posttranslational modifications (PTMs), which alter the conformation and 
physicochemical properties of the target proteins. Regulation by PTMs provides a 
powerful and quick response to environmental changes, as the kinetics for PTMs 
control is faster than the regulation of protein expression levels. 
The roles of ubiquitin and SUMO in stress responses have been extensively 
investigated. These modifications can alter protein properties such as stability, activity, 
localization and interaction with other proteins. One of the best-characterized and 
evolutionally conserved defence mechanisms is the heat shock response. In yeast, the 
ubiquitin gene is induced upon heat stress, enabling the organism to eliminate misfolded 
proteins via increased proteasomal degradation[252, 253]. Although higher eukaryotes 
have sophisticated repairing and refolding mechanisms [195], elimination of 
irreversibly damaged proteins through protein degradation is also part of the response 
[254]. Similarly, generation of reactive oxygen species can also cause protein damage 
and the proteasome is responsible for the removal of these damaged proteins. 
Furthermore, the activity of the proteasome itself is subject to oxidative inactivation that 
may result in the accumulation of ubiquitinated proteins [255]. SUMO conjugation is 
also induced upon cellular stresses, such as heat shock, osmotic stress and 
hibernation[256, 257]. Accumulation of SUMO conjugates upon proteasome inhibition 
have been previously noted[258], and a recent study provided insight into the role of 
SUMO in response to the accumulation of misfolded proteins[259]. The NEDD8 
pathway has been well-characterized under homeostatic conditions (cullin-dependent 
 87 
role), and more recently in ribosomal stress through regulation of ribosomal proteins 
[148]. However, the response of NEDDylation under broader environmental stress 
conditions remains unknown, especially with endogenously expressed proteins. 
Historically ubiquitin-like molecules are thought to be activated and conjugated by their 
cognate enzymes. Recently examples of cross-activation have been emerged, unveiling 
another layer of regulation of ubls[102, 103]. Most of the ubl enzymes have striking 
affinity towards their cognate molecule, indicating that they must fulfill a rather specific 
role in the cells. The ubiquitin conjugating enzymes and E3 ligases however have been 
shown to regulate not only ubiquitin conjugation, but in certain circumstance other ubls 
too. The ubiquitin pathway appears to be a general, main regulator of many different 
cellular processes, while ubls are dedicated to a less broad range of functions.  
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3.2. Results 
NEDD8 is 57 % identical and ~80 % similar to ubiquitin in sequence. The asterisks on 
the sequence alignment in Figure 3.1. show the amino acids that are identical in NEDD8 
and ubiquitin. Moreover, their three-dimensional structure shares similarity as well 
(Figure 1.10), therefore it is likely that many ubiquitin-interacting proteins can also 
recognize NEDD8. 
            * * ******* * :::**:*.:*.:* ::::******:*****::***::* :* :**:*   *.***** ****     
NEDD8 MLIKVKTLTGKEIEIDIEPTDKVERIKERVEEKEGIPPQQQRLIYSGKQMNDEKTAADYKILGGSVLHLVLALRGGGGLRQ    81
ubiquitin MQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGG     76
   1.......10........20........30........40........50........60........70........80.
 
Figure 3.1: ClustalX aligment of human NEDD8 (accession number: NP_006147) 
and human ubiquitin (accession number: P62988) 
An * (asterisk) indicates positions which have a single, fully conserved residue.  A : 
(colon) indicates conservation between groups of strongly similar properties.  A . 
(period) indicates conservation between groups of weakly similar properties. The 
residues are coloured according to their physicochemical properties (red: small + 
hydrophobic; blue: acidic; magenta: basic; green: hydroxyl + sulfhydryl + amine + G; 
grey: others). 
3.2.1. Effect of the proteasome inhibitor MG132 on the NEDD8 
signal 
Previous studies using either overexpression of NEDD8 or cell lines stably expressing 
tagged NEDD8 showed that inhibition of the proteasome with MG132 results in 
increased NEDD8 conjugation to substrates[106]. We performed a shorter and longer 
time course experiment with the proteasome inhibitor, to investigate the phenomenon 
under endogenous conditions (Figure 3.2). MCF7 cells were treated with 30 µM 
MG132 for the indicated time intervals, directly lysed in 2X SDS and analysed by 
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western blotting. We found that the NEDD8 pathway responds to MG132 very rapidly 
(~5 min), and it is manifested mainly by an increase in high molecular weight 
conjugates. However, accumulation of NEDD8 conjugates does not lead to significant 
depletion of the free NEDD8 pool (see also data obtained with mass spectrometry 
(Figure 4.5) on the quantification of unconjugated NEDD8). We addressed the 
possibility that MG132 might affect NEDD8 at the transcriptional or translational level. 
Quantitative real time PCR using RNA from untreated or MG132 treated MCF7 cells 
shows no effect of MG132 on the levels of NEDD8 mRNA (Figure 3.3.a). Furthermore, 
inhibition of protein synthesis by cyclohexamide has no effect on the accumulation of 
NEDD8 conjugates upon MG132 treatment (Figure 3.3.b). Therefore, we concluded 
that the increase in NEDDylation by MG132 is a post-translational effect. It is also 
possible that NEDD8 itself  may be a substrate for proteasomal degradation. 
To detect NEDD8 signal in western blot analysis, we used a monoclonal NEDD8 
antibody from Epitomics, which was initially developed by Millenium 
Pharmacheuticals. A synthetic peptide corresponding to residues in the N-term of 
human NEDD8 was used as immunogen. The antibody was also validated by Hjerpe et 
al. and showed no cross-reactivity with ubiquitin[260]. 
For the detection of ubiquitinated substrates, we used the polyclonal antibody from 
Dako, which has also been characterized by Hjerpe et al. and showed no cross-reactivity 
with NEDD8. 
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Figure 3.2: NEDD8 accumulates upon MG132 treatment.  
MCF7 cells were treated with 30 µM MG132 for the indicated time intervals. Total cell 
extracts were analysed by western blotting with ubiquitin and NEDD8 antibodies. 
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Figure 3.3: Increase in NEDDylation by MG132 does not depend either on 
transcription or translation. 
(a) MCF7 cells were treated with 30 µM MG132 for 4 hrs. Quantitative real-time PCR 
for NEDD8 was carried out as described in Materials and Methods. The experiment was 
performed in triplicates; data are represented as mean +/-STDEV. (b) MCF7 cells were 
treated with 100 µM cycloheximide (CHX) just before treatment with 30 µM MG132 
and harvested at the time points indicated. Total cell extracts were analysed by western 
blotting with NEDD8 antibody. 
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3.2.2. Increase in NEDD8 signal upon MG132 does not depend 
on the NEDD8 E1 
Next, to investigate the specificity of the observed immunoreactivity and the regulation 
of NEDDylation we used either MLN4924, a specific inhibitor of NAE that blocks 
NEDDylation, or transfected cells with NEDD8 siRNAs [208, 209]. MCF7 cells were 
treated with non-targeting or NEDD8 siRNA for 48 hrs before harvesting. MLN4924 
was applied in 1 µM concentration for 16 hrs. Under unstressed conditions, as expected, 
treatment with MLN4924 or knockdown of NEDD8 dramatically decreased 
NEDDylation in MCF7 cells (Figure 3.4.). However, under these experimental 
conditions, NEDDylation of cullins was not affected dramatically by NEDD8 
knockdown. As cullins are the most efficient NEDD8 targets, we assume that the 
residual NEDD8 in cells is sufficient to support cullin NEDDylation[148]. The data also 
suggest that there is an excess of free unconjugated NEDD8 in cells. It is also possibly 
that there is a pool of NEDD8 in cells that can not be knocked down efficiently under 
the conditions used.  
Treatment with 30 µM MG132 for 4 hrs causes a dramatic increase in NEDDylation. 
Surprisingly, inhibition of NAE by MLN4924, while it blocked cullin NEDDylation 
had no effect on the accumulation of additional NEDDylated species (Figure 3.4.). 
Under these conditions, knockdown of NEDD8 dramatically decreased the observed 
immunoreactivity, confirming the identity of these species as NEDD8 conjugates. The 
data suggest that upon proteasomal inhibition, NEDD8 conjugation is dramatically 
increased through an NAE independent pathway. 
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Figure 3.4: NAE-independent increase of NEDDylation.  
MCF7 cells were transfected with non-target or NEDD8 siRNAs for 48 hrs, then treated 
or untreated with 1 µM MLN4924 for 16 hrs. 4 hrs before harvesting, cells were treated 
with 30 µM MG132 where indicated. Total cell extracts were analysed by western 
blotting. 
 
3.2.3. The ubiquitin E1 enzyme Ube1, but not Uba6 mediates 
increase in NEDD8 conjugates upon proteasome inhibition 
The data suggest that NEDD8 modification of certain substrates could occur through an 
alternative conjugation pathway, independent of NAE activation. Since NEDD8 shares 
57 % identity to ubiquitin, and previous in vitro studies showed that NEDD8 could be 
activated by the ubiquitin E1, Ube1[261], we tested whether the ubiquitin activating 
enzymes are responsible for mediating protein NEDDylation in vivo. We performed the 
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experiment described in Figure 3.4., this time transfecting MCF7 cells with siRNA 
against Ube1 or Uba6, the two known E1 ubiquitin activating enzymes[14]. 
Knockdown of Ube1 had no effect on the NEDD8 profile under homeostatic conditions, 
however, NEDD8 accumulation upon MG132 treatment was dramatically reduced upon 
Ube1 knockdown (Figure 3.5. a). To confirm the result, we performed the experiment in 
different cell lines. Figure 3.5. b shows the same experiment performed in HeLa cells. 
Similar effects were observed with individual siRNAs targeting different parts of the 
Ube1 mRNA sequence (Figure 3.6.). On the other hand, decrease in Uba6 levels did not 
have any effect on protein NEDDylation in any tested conditions, suggesting that this 
enzyme doesn’t play role in NEDDylation (Figure 3.7.). Interesting to note that Ube1 
siRNA did not have detectable effect on ubiquitin conjugates. It is possible that Ube1 is 
in excess in cells, and the remaining enzymes are still sufficient to activate ubiquitin, 
but not the ’poor’ substrate, NEDD8. Detecting changes in high-molecular weight 
ubiquitin conjugates on western blot is difficult, since the signal is saturated, and the 
species the antibody detects under these conditions might be aggregates. In this case, 
our method would not be suitable to detect changes in ubiquitination upon Ube1 
knockdown.  
Next we aimed to confirm that the Ube1-mediated increase in NEDD8 conjugation is 
indeed triggered  by proteasome inhibition and not due to other effects MG132 might 
have in cells. Therefore we used a more specific inhibitor of the proteasome, lactacystin 
(Figure 3.8.) [262]. We observed similar effects to MG132, although the NEDD8 
response to MG132 treatment was stronger than to lactacystin. This suggests that 
MG132 probably has some off-target effects as well, but also shows that NEDD8 
responds to a more specific proteasome inhibitor. 
These results indicate that there is an increase in protein NEDDylation upon proteasome 
inhibition, which depends on Ube1, but probably not on Uba6. 
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Figure 3.5: Ube1 activates NEDD8 in vivo upon proteasome inhibition.  
(a) MCF7 cells were transfected with non-target or Ube1 siRNAs for 48 hrs, then 
treated or untreated with 1 µM MLN4924 for 16 hrs. 4 hrs before harvesting, cells were 
treated with 30 µM MG132 where indicated. Total cell extracts were analysed by 
western blotting. (b) HeLa cells were transfected with non-target or Ube1 siRNAs for 
48 hrs, then treated or untreated with 1 µM NAE inhibitor (MLN4924) for 16 hrs. 4 hrs 
before harvesting, cells were treated with 30 µM MG132 where indicated. Total cell 
extracts were analysed by western blotting. 
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Figure 3.6: Test of individual Ube1 siRNAs 
MCF7 cells were transfected with individual Ube1 siRNAs for 48 hrs. 4 hrs before 
harvesting, cells were treated with 30 µM MG132 where indicated. Total cell extracts 
were analysed by western blotting. 
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Figure 3.7: Uba6 knockdown experiment suggests that Uba6 does not play a role in 
NEDDylation.  
Experiment performed as in Figure 3.5. with the exception of using Uba6 siRNA 
instead of Ube1. 
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Figure 3.8: Lactacystin induces NEDD8 accumulation.  
MCF7 cells were transfected with non-target or Ube1 siRNAs for 48 hrs, then treated or 
untreated with 1 µM MLN4924 for 16 hrs. 4 hrs before harvesting, cells were treated 
either with 30 µM MG132 or 300 µM lactacystin where indicated. Total cell extracts 
were analysed by western blotting. 
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3.2.3. NEDD8 response to MG132 treatment upon knockdown of 
Ubc12, UbcH5a and Mdm2 
We tested whether the best-characterised NEDD8 E2 Ubc12 and Mdm2, the dual 
ubiquitin/NEDD8 E3 ligase have an effect on the observed increase in NEDD8 
conjugation upon MG132. Cells were treated with Mdm2 or Ubc12 siRNAs for 48 hrs 
before exposed to MG132 treatment for 4 hrs. Cells extracts were analysed by western 
blotting. The result suggests that Mdm2 and Ubc12 knockdown do not abolish 
increased NEDD8 conjugation (Figure 3.9). 
We also tested whether the knockdown of a single ubiquitin E2 enzyme, UbcH5a would 
inhibit NEDD8 response to MG132. UbcH5a is a very diverse ubiquitin E2 that controls 
ubiquitination of many targets. However, in our experiment it did not affect the NEDD8 
response to MG132 (Figure 3.10). Important to note that the knockdown of UbcH5a 
was not very efficient in this experiment. Additionally, there might be a specific subset 
of substrates the are NEDDylated in a UbcH5a-dependent manner, but their 
disappearance can not be visualised from total cell extract. In the paper of Hjerpe et al. 
the authors showed that NEDD8 can form a thiolester bond with several ubiquitin E2s 
in vitro[260], suggesting that multiple ubiquitin E2 conjugating enzymes are 
responsible for NEDD8 conjugation under stress. 
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Figure 3.9: Effects of Mdm2 and Ubc12 knockdown on the NEDD8 response to 
MG132.  
MCF7 cells were transfected with non-target, Mdm2 or Ubc12 siRNAs for 48 hrs, then 
treated or untreated with 1 µM MLN4924 for 16 hrs. 4 hrs before harvesting, cells were 
treated or not with 30 µM MG132. Total cell extracts were analysed by western 
blotting. 
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Figure 3.10: Effects of UbcH5a knockdown on the NEDD8 response to MG132. 
MCF7 cells were transfected with non-target or UbcH5a siRNAs for 48 hrs, then treated 
or untreated with 1 µM MLN4924 for 16 hrs. 4 hrs before harvesting, cells were treated 
or not with 30 µM MG132. Total cell extracts were analysed by western blotting. 
 
3.2.4. NEDD8 responds to heat shock in a Ube1-dependent 
manner 
Ubiquitin and ubiquitin-like molecules respond to a variety of environmental stresses as 
part of the cellular response. However, while the role of NEDDylation is well-
documented under unstressed conditions, there is little knowledge upon stress 
conditions. Our data have revealed that upon proteasome inhibition NEDD8 conjugation 
is dramatically increased, unexpectedly through the ubiquitin E1 activating enzyme 
Ube1. We then determined whether this is an unique phenomenon, or NEDD8 responds 
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to other environmental stresses such as heat shock and oxidative stress in a similar 
manner. MCF7 cells were shifted from 37oC to 43oC for different intervals, and total 
cell extracts were analysed with a NEDD8 specific antibody. We found that 
NEDDylation rapidly increases in heat shocked cells (within 10’), compared to the 
unstressed cells (Figure 3.11). We also looked at the recovery period of heat shock: 
cells were shifted to 43oC for 60’ followed by incubation at 37oC for 120’ to recover. In 
this case, we observed a decrease (recovery) in NEDDylation, suggesting that the 
NEDD8 response to heat shock is a regulated process (Figure 3.11). Inhibition of NAE 
by MLN4924 had no effect on the NEDD8 response to heat shock, indicating that the 
increase in NEDDylated species is NEDD8 E1-independent (Figure 3.12). However, 
when cells were transfected with Ube1 siRNA, the NEDD8 response to high 
temperature was no longer observed (Figure 3.12). The data reveal a physiological 
stress condition where NEDD8 responds through Ube1. 
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Figure 3.11: NEDD8 responds to heat shock. 
MCF7 cells were grown under normal condition (37oC). For the indicated periods of 
time, cells were shifted to 43oC or left at 37oC. After heat shock, cells were either 
immediately harvested, or let to recover at 37oC for 2 hrs. Total cell extracts were 
immuno-blotted with the indicated antibodies. The two NEDD8 blots represent a longer 
and a shorter exposure of the same blot. 
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Figure 3.12: Heat shock triggers increased NEDD8 conjugation in an Ube1-
dependent fashion.  
MCF7 cells were transfected with non-target or Ube1 siRNAs for 48 hrs, then treated or 
untreated with 1 µM MLN4924 for 16 hrs. Before harvesting, cells were either left 
untreated (37°C) or exposed to heat shock (43°C). Total cell extracts were analysed by 
western blotting. 
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3.2.5. NEDD8 responds to oxidative stress 
Another commonly studied cellular stress is the response to reactive oxygen species. 
Previous studies have shown that while ubiquitin conjugates are not severely affected 
by oxidative stress caused by H2O2, SUMO conjugation is reduced [200]. We found that 
H2O2 causes a dramatic increase in NEDD8 conjugation at concentrations (1 mM) 
where SUMO-2/3 conjugates are decreased (Figure 3.13). Similarly to proteasomal 
inhibition and heat shock, the observed increase in NEDD8 conjugates does not depend 
on NAE but rather on Ube1 (Figure 3.14). The above data demonstrate that NEDD8 
responds to a variety of cellular stress conditions but surprisingly NEDD8 conjugation 
is mediated through the ubiquitin E1 activating enzyme Ube1.  
 
Figure 3.13: NEDD8 responds to H2O2 treatment.  
MCF7 cells were treated with increasing doses of H2O2 for 1 hr and total cell lysates 
were analysed by western blotting. 
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Figure 3.14: Oxidative stress results in increased NEDD8 conjugation in an Ube1-
dependent fashion.  
MCF7 cells were transfected with non-target or Ube1 siRNAs for 48 hrs, then exposed 
to H2O2 for 1 hr. Whole cell lysates were analysed by western blotting. 
 
3.2.6. Ubiquitin depletion is sufficient to allow NEDD8 activation 
by the ubiquitin E1 activating enzyme Ube1 
Early biochemical studies and as presented in a paper by Hjerpe et al., show that in 
vitro, Ube1 has a very low activity towards activating NEDD8 compared to 
ubiquitin[260, 261]. However in vivo, our data show that this activation occurs under 
defined cellular stress conditions. A common feature of the above characterised cellular 
insults is that they all result in depletion of free ubiquitin, therefore altering the ratio 
between the unconjugated pools of NEDD8 and ubiquitin that are available for the E1 
enzymes. Studies have suggested that free ubiquitin in cells constitutes a cellular signal 
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and its depletion initiates a stress response [11, 263]. We therefore tested whether free 
ubiquitin depletion alone in the absence of any stress would allow NEDD8 to be 
conjugated through Ube1. MCF7 cells were transfected with siRNAs against ubiquitin 
for a relatively short period of time (15 hrs) so that there are no perturbations in cell 
growth. Knockdown of ubiquitin in the absence of any additional stress is sufficient to 
cause the increase of NEDD8 conjugates that depends on Ube1 (Figure 3.15). SUMO-
2/3 conjugation that also increases upon proteasome inhibition and heat shock is not 
affected by ubiquitin knockdown (Figure 3.15). The data suggest that decrease in 
ubiquitin levels is at least part of the mechanism that allows NEDD8 conjugation 
through Ube1. 
 
Figure 3.15: Decrease in free ubiquitin level triggers increased NEDD8 
conjugation through Ube1.  
MCF7 cells were transfected with non-target or Ube1 siRNAs for 48 hrs and ubiquitin 
(UBB) siRNA for 15 hrs, lysed and immunoblotted with the appropriate antibodies. 
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3.2.7. Ubiquitin overexpression does not prevent the NEDD8 
response to MG132 
Even though little work has been done to investigate the effects of free ubiquitin 
depletion, a paper from Hanna et al. has shown that ubiquitin overexpression provides 
resistance to stress conditions that are associated with free ubiquitin depletion[202]. If 
free ubiquitin depletion is the only event that is required for Ube1-mediated NEDD8 
activation, we reasoned that overexpression of ubiquitin would rescue this phenotype. 
Different amounts of ubiquitin construct were transfected in MCF7 cells for 48 hrs 
before MG132 treatment and harvesting. Analysis of the total cell lysates by western 
blotting with NEDD8 antibody showed that NEDD8 responds to MG132 treatment, 
even when 2 µg of ubiquitin-coding plasmid was used (Figure 3.16). This result can be 
interpreted in different ways. It is possible that the ubiquitin system prefers to engage in 
NEDD8 conjugation under stress conditions, even when there is sufficient amount of 
ubiquitin available. If this is true, free ubiquitin depletion must be only part of the 
mechanism that triggers NEDD8 activation and the depletion of ubiquitin may create a 
stress response that would promote activation of NEDD8 by Ube1. Another explanation 
is that the exogenous ubiquitin is not used in a same way as the endogenous; hence it 
cannot rescue the phenotype. 
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Figure 3.16: Ubiquitin overexpression does not prevent the NEDD8 response to 
MG132.  
MCF7 cells were transfected with different amounts of plasmids encoding ubiquitin. 
‘Ubiquitin (µg)’ indicates the amount of plasmid transfected. 48 hrs after transfection, 
cells left untreated or treated with 30 µM MG132. Total cell extracts were analysed by 
western blotting. 
 
3.2.8. Ube1 forms a thiolester linkage with NEDD8 in vivo 
We have shown that the NEDD8 response to stress conditions is mediated through 
Ube1. In order to prove that Ube1 is indeed able to activate NEDD8 and this is the 
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mechanism by which it promotes increased NEDD8 conjugation, we tested whether 
Ube1 forms a thiolester bond with NEDD8 in cells. HA-tagged Ube1 was 
overexpressed in U2OS cells. We performed an HA immunoprecipitation in conditions 
that allowed us to preserve the thiolester bonds (non-reducing conditions, addition of 
alkylating agent to the buffer). After the elution, samples were divided, and reducing 
agent, DTT was added to half of the samples. The samples were analysed by western 
blotting, with NEDD8 or ubiquitin antibodies that detected a band of the expected size, 
which was sensitive to reducing agents (Figure 3.17. a). In a similar experiment we 
knocked down ubiquitin in HEK 293 cells to test whether it affects the thiolester 
intermediate. Surprisingly, ubiquitin siRNA treatment did not result in an increased 
thiolester formation between Ube1 and NEDD8 (Figure 3.17. b). In the 
immunoprecipitation experiments, Ube1 formed a thiolester linkage with endogenous 
NEDD8 under normal conditions, and we saw no further increase with ubiquitin 
knockdown or other stress conditions. This is probably due to the overexpression of 
Ube1. If there is more Ube1 in cells, it becomes available for NEDD8 activation. This 
also suggests that the ratio between the free NEDD8, ubiquitin, and Ube1 determines 
which ubl is activated. 
The western blot at the lowest panel of Figure 3.17.b shows the total NEDDylation. As 
mentioned above, overexpressed Ube1 forms a thiolester bond with endogenous 
NEDD8 under normal conditions. However, this alone does not result in a detectable 
increase in NEDD8 conjugation (second lane), only when it is triggered by stress 
(ubiquitin knockdown, third panel). This observation raises the possibility that changes 
in the ratio between free ubiquitin/NEDD8/available Ube1 is only part of the 
mechanism that allows NEDD8 engagement into the ubiquitin pathway. There might be 
a more specific regulation for the switch, possibly through a stress-induced 
posttranslational modification of NEDD8 or Ube1. 
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Figure 3.17: Ube1 forms a thiolester bond with NEDD8. 
(a) U2OS cells were transfected with HA-Ube1 or pcDNA3 plasmid. 48 hrs later, cells 
were lysed as described in Materials and Methods. Anti-HA antibody coupled to 
sepharose beads was used for immunoprecipitation. After elution, samples were divided 
and in one set DTT (200 mM) was added before boiling. Proteins were analysed by 
western blotting. (b) Experiment was done as in Figure 3.17. (a), except HEK 293 cells 
were treated with non-targeting or ubiquitin siRNA for 15 hrs prior to 
immunoprecipitation. 
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3.2.9. p53 is NEDDylated by Ube1 under proteasome treatment 
p53 has been shown to be modified by NEDD8, and this modification partially depends 
on the NAE under homeostatic conditions[102]. In this study, Xirodimas et al, 2004, the 
authors used a ts41 CHO cell line that has a temperature-sensitive NAE. At the 
restrictive temperature, p53 NEDDylation is largely decreased, but does not disappear 
completely (Figure 5. a in the paper). The authors’ interpretation for the above result 
was that at the restrictive temperature some residual activity of the NAE allows partial 
p53 NEDDylation. In the context of our new finding that NAE is not the only E1 
enzyme for NEDD8, we speculated that the Ube1 might be also responsible for p53 
NEDDylation. We used a cell line stably expressing His6-NEDD8 (6HisND8-MCF7) to 
assess the effect of Ube1 knockdown on p53 NEDDylation under MG132 treatment. 
Parental MCF7 cells or the stable cell line were treated with Ube1 siRNA or MLN4924, 
in combination with MG132. NEDD8 conjugates were isolated on Ni2+-agarose beads, 
and analysed by western blotting (Figure 3.18). 
NEDDylation of p53 was mainly dependent on Ube1 under proteasome inhibition. In 
contrast, the NEDD8 modification of cullin 3 was not affected by Ube1 knockdown, but 
was abolished when NAE was inhibited by MLN4924. 
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Figure 3.18: NEDDylation of p53 depends on Ube1 upon stress.  
6HisND8 MCF7 cells were transfected with non-target (-) or with Ube1 siRNA for 48 
hrs and treated with 1 µM MLN4924 for 16 hrs and 30 µM MG132 for 4 hrs as 
indicated. Cells were lysed under denaturing conditions and purification of His6-
NEDD8 conjugates was performed using Ni2+-NTA agarose beads. Isolated proteins 
and total cell lysates were analysed with the indicated antibodies. 
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3.2.10. NEDD8 responds to heat shock in C. elegans, but not in S. 
pombe 
We were interested to know whether NEDD8 responds to stress conditions only in 
human cell lines, or it is a conserved mechanism. Together with Aymeric Bailly we 
performed a heat shock experiment in C. elegans, where worms were shifted from 20oC 
to 30oC for 5 hrs and then total protein was extracted by bead beating and lysed as 
described in the Materials and Methods. Total worm extracts were analysed by western 
blotting with the human NEDD8 antibody. Since NEDD8 is highly conserved through 
species, we expected cross-reactivity with the worm NED-8. Indeed, we found that the 
antibody recognised NED-8, and the signal was increased in the heat-shocked samples, 
suggesting that the NEDD8 response to high temperature is a conserved mechanism 
(Figure 3.19 a). 
We have also used Schizosaccharomyces pombe as a model organism to investigate the 
heat shock response. Contrary to Saccharomyces cerevisiae, ned8 deletion in fission 
yeast causes lethality. We used a wild-type strain (FY7093, genotype: h+, ade6-M210) 
for our investigation. Cultures were grown at 32°C (the optimal temperature for fission 
yeast growth), until they reached OD600 =0.3-0.6 (log phase, where the culture grows 
exponentially and is most susceptible to environmental changes). At that point, they 
were shifted to 37 or 39°C for the indicated time intervals. Total proteins were extracted 
as described in the Materials and Methods section, and analysed by western blotting 
with NEDD8 antibody from Epitomics. Again, we reasoned that due to the high 
conservation of NEDD8 through species, our antibody would recognize S. pombe ned8. 
It was indeed the case since a band corresponding to NEDDylated cullins was detected 
(Figure 3.19 b). However, we did not observed accumulation of higher molecular 
weight conjugates, as it was seen in human cell lines. Our western blot analysis with the 
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ubiquitin-specific antibody showed increase of ubiquitin conjugates at 1 hr after shifting 
to 37°C, but the same conjugates did not appear at later time points or higher 
temperatures. This preliminary data suggests that the NEDD8 heat shock response is not 
conserved between humans and S. pombe. However, we cannot exclude the possibility 
that we did not detect the response due to experimental issues. It would be interesting to 
investigate the same phenomenon in a strain that contains a tagged form of NEDD8, and 
use a tag-specific antibody. Alternatively, since NEDD8 has not been well-studied in S. 
pombe in response to stress conditions, further experimental conditions such as higher 
temperature (up to 42°C), or the use of the proteasome inhibitor (in a specific strain that 
can take up the drug) should be used to draw final conclusions. 
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Figure 3.19: NEDD8 response to heat shock in C.elegans and S. pombe 
(a) Synchronised worms were grown at 20°C and shifted to 30°C at L4 larvae stage. 
Total worm extracts were analysed by western blotting with NEDD8-specific antibody. 
(b) Wild-type S. pombe was cultured at 32°C or shifted to 37 or 39°C for the indicated 
time intervals. Total protein extracts were prepared as described in Materials and 
Methods, and analysed by antibodies specific to human NEDD8, ubiquitin and α-
tubulin. 
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3.2.11. Characterization of NEDD8 surface residues required for 
Ube1-mediated activation by site-directed mutagenesis 
We characterised the activation of NEDD8 by Ube1 in different cellular stress 
conditions. Next we aimed to address the biological outcome of this new type of 
NEDDylation. The NAE-dependent NEDDylation can be specifically inhibited by 
MLN4924, and the NEDD8 siRNA largely affects the conjugates that are dependent on 
Ube1. The remaining NEDD8 appears to be efficient to modify cullins, and allows 
almost intact functioning of the CRL E3 ligases, as determined by the detection of two 
substrates, cyclinE and p21 (Figure 3.20). SCF ligases normally degrade these two 
proteins; however, inhibition of cullin NEDDylation by MLN4924 results in an increase 
of cyclinE and p21. On the other hand, partial NEDD8 knockdown does not have a 
major affect on cullin NEDDylation, and importantly, does affect SCF activity, as SCF 
substrates do not stabilize. However, complete inhibition of the Cullin Ring Ligases by 
MLN4924 perturbs the ubiquitin pathway, which is also engaged in NEDD8 
conjugation under certain conditions, therefore this drug is not an appropriate tool to 
investigate the roles of the two types of NEDDylation. 
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Figure 3.20: NEDD8 knockdown does not affect cullin NEDDylation and function 
of the SCF-ligase complex.  
The upper panel is a part of Figure 3.4. The same extracts were blotted against 
substrates of the SCF-ligase complex. While MLN4924 treatment inhibits cullin 
NEDDylation and allows accumulation of cyclin E and p21, NEDD8 knockdown does 
not affect the function of the SCF-ligase complex. 
 
To find a tool that will distinguish between the two pathways, the NAE- and the Ube1-
dependent NEDDylation, we decided to search for a NEDD8 mutant that is activated by 
NAE but not by the Ube1. Such mutant could be used to replace wild type NEDD8 in 
human cell lines or in a model organism and allow testing the role of atypical 
NEDDylation on cell survival or response to stress.  
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We were aiming to identify the residue(s) on NEDD8 that is required for the activation 
by Ube1. For this, we set up the following criteria: 
1. The amino acid has to be a surface residue 
2. Should not be required for NAE-mediated activation [97] 
Amino acids that have been published in Walden et al., as shown in Figure 3.21, to be 
in contact with NAE during activation were not included in our screen. 
 
Figure 3.21: Residues on NEDD8 required for the interaction with NAE 
(a) Sequence alignment of NEDD8, ubiquitin, SUMO1 and S. cerevisiae Apg8p with 
the identical residues to NEDD8 are shaded and the structure of NEDD8 (b) are adapted 
from[97]. The residues highlighted in red are in contact with UBA3. The residues in 
blue are in contact with APPBP1. 
 
3. Should be conserved between humans and S. cerevisiae 
Since it has been published that Ube1 activates overexpressed NEDD8 (Rub1) in S. 
cerevisiae[260], we reasoned that the essential amino acid is most likely conserved 
between the two organisms (Figure 3.22). To make our mutational analysis easier, we 
eliminated the non-conserved amino acids from our screen. 
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Figure 3.22: ClustalX sequence alignment between Rub1p (accession number: 
NP_010423.2) and NEDD8 (accession number: NP_006147) 
An * (asterisk) indicates positions which have a single, fully conserved residue.  A : 
(colon) indicates conservation between groups of strongly similar properties.  A . 
(period) indicates conservation between groups of weakly similar properties. The 
residues are coloured according to their physicochemical properties (red: small + 
hydrophobic; blue: acidic; magenta: basic; green: hydroxyl + sulfhydryl + amine + G; 
grey: others). 
 
Figure 3.23. shows the structure of NEDD8 (PDB ID number 1NDD from PDBTM) 
that was modified in MacPyMOL software to highlight the residues selected for site-
directed mutagenesis. S46 and V66 were later added to the list, based on previous 
observations that these mutants showed unexpected NEDDylation patterns. 
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Figure 3.23: The residues on NEDD8 selected for mutagenesis.  
Ribbon view of the three-dimensional structure of NEDD8 was generated by PyMOL 
v0.99. The selected amino acids are highlighted in, and the K11 residue in blue. 
 
The mutageneses to alanine (or arginine in the case of the lysine residues) were 
performed on pcDNA3 HA-NEDD8 vector, followed by verification by sequencing. 
The plasmids were overexpressed in H1299 cells, treated or untreated with MG132, and 
lysed directly with 2X SDS. The NEDDylation pattern was visualised by Western 
blotting, with HA-antibody. The conjugation profile was compared to that of the wild-
type HA-NEDD8.  Figure 3.24-25. show a few representative examples of the tested 
mutants.  
 
 
Figure 3.24: Examples of the behaviours of selected NEDD8 mutants.  
H1299 cells were transfected with wild type or mutant NEDD8 constructs. 48 hrs after 
transfection, cells were treated or not with 30 µM MG132 for 4 hrs, directly lysed in 2X 
SDS, and analysed by western blotting with the antibody specific for the HA-tag. 
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We were looking for a mutant that fulfills the following criteria: 
• expressed similarly to wild type NEDD8; 
• can be conjugated to cullins, the well-known NAE-dependent substrates; 
• the increase of the NEDD8 conjugates after MG132 treatment is impaired.  
The K11R mutant appeared to fulfill these criteria: it was expressed, was conjugated to 
cullins, but the MG132 response was impaired. We have seen the same effect when we 
mutated Lys11 to alanine. No other mutant showed the same phenotype. 
 
 
 
Figure 3.25: NEDD8 K11R mutant does not respond to MG132 treatment. 
H1299 cells were transfected with wild type or K11R mutant NEDD8 constructs. 48 hrs 
after transfection, cells were treated or not with 30 µM MG132 for 4 hrs, directly lysed 
in 2X SDS, and analysed by western blotting with HA-specific antibody. 
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Table 3.1 contains the summary of the mutations and their behavior in response to 
MG132 treatment. 
Mutation Expression Cullin NEDDylation MG132 response 
L2A ✓ ✓ ✓ 
K4A ✓ ✓ ✓ 
K6A ✗ ✗ ✗ 
T7A low weak ✓ 
K11A low weak ✗ 
E12A ✓ ✓ ✓ 
I13A low weak ✓ 
D16A ✓ ✓ ✓ 
Q40A ✓ ✓ ✓ 
Y45A ✓ ✓ ✓ 
K48A ✓ ✓ ✓ 
D52A ✓ weak weak 
G64A ✓ weak weak 
L69A low ✓ ✓ 
S46A ✓ ✓ ✓ 
V66A ✓ ✓ ✓ 
K6R low ✓ ✓ 
K11R ✓ ✓ ✗ 
 
Table 3.1: Summary of the NEDD8 mutants used in the screen 
 
These preliminary results show that K11 on NEDD8 could be potentially important 
either for the activation by Ube1, or for the chain formation.  
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3.3. Discussion 
Interplay between posttranslational modifications provides complex and diverse ways of 
regulating the proteome. It has been well documented that one ubl can be responsible 
for the regulation of other ubl conjugation machinery: Cullin RING Ligases are 
activated through NEDDylation, and SUMO chains signal for ubiquitination and 
proteasomal degradation of certain proteins. 
In this project we have discovered an unprecedented cross-talk between NEDD8 and 
ubiquitin conjugation pathways. We found that upon diverse stress conditions including 
proteasome inhibition, heat shock and oxidative stress NEDD8 conjugation dramatically 
increases in cells. Surprisingly however, NEDD8 conjugation does not depend on the 
NEDD8 activating E1 enzyme NAE but rather on the ubiquitin E1 activating enzyme 
Ube1.  The observation that Ube1 can activate NEDD8 and transfer it to ubiquitin 
E2s[260], together with the current knowledge on shared E3 ligases between NEDD8 
and ubiquitin pathways[102, 103] fundamentally changes our understanding about Ubl 
conjugation pathways. Redundancy between the cascades exists in a way that NEDD8 
can be used by two distinct pathways: through NAE that mainly controls cullin 
NEDDylation and through the Ube1 pathway that expands conjugation of NEDD8 to 
substrates that are also ubiquitinated. While our data show that the later mechanism is 
dramatically induced under diverse cellular stress conditions, we cannot exclude the 
possibility that conjugation of NEDD8 through Ube1 occurs under unstressed 
conditions. 
It is tempting to draw a paralell between SUMOylation and NEDDylation. The SUMO 
family consists of three members: SUMO-1 and SUMO-2,3. SUMO-1 shares only 
about 50 % sequence identity with SUMO-2/3, which means it is less identical to the 
other SUMO members than NEDD8 is identical to ubiquitin. The three SUMO 
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members share the same E1 activating enzyme. SUMO-1 modification appears to play 
role in protein regulation under homeostatic conditions. Its main role is the regulation of 
RanGAP1 through covalent modification that promotes RanGAP1 association with the 
nuclear envelope, to fulfill its function in nuclear protein import[159].  Recently 
SUMO-1 modification on PTEN was found to be important to increase PTEN binding 
to the plasma membrane, which is required for its tumor suppressor activity[264]. To 
our knowledge, SUMO-1 fulfills its regulatory roles by modifying its targets in a 
monomeric form. On the other hand, SUMO-2 and-3 appear to be stress-responsive 
regulators of the proteome, as it was demonstrated upon heat shock and proteasome 
stress; and they mainly represent a signal in a form of polySUMO chains. To this 
analogy, NAE-mediated NEDDylation that mainly regulates Cullin RING Ligases 
resembles homeostatic modification by SUMO-1. On the other hand, the Ube1-
mediated NEDDylation, similarly to SUMO-2/3 modifications, is engaged in protein 
modification under stress conditions. The utilization of one posttranslational modifier, 
NEDD8 through two distinct pathways in order to suit diverse cellular functions makes 
it a very versatile regulator of protein function. This is a good example of how the 
complexity of the proteome can be increased by modification through different 
ubiquitin-like conjugation pathways to compensate for the low number of genes in 
vertebrate genomes. 
We showed the first in vivo evidence that NEDD8 does not only respond to 
pharmacological inhibition of the proteasome, but also to environmental stress 
conditions such as heat shock or oxidative stress. In all tested conditions, Ube1 
mediated the NEDD8 activation. We also gained evidence on the NEDD8 response to 
heat shock in C. elegans. Very recently, Lee et al. has demonstrated a global NEDD8 
accumulation during torpor in the brains of hibernating ground squirrels by western blot 
analysis[265]. This study suggests a role for NEDD8 in ischemic stress. Even though 
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the nature of this increased NEDD8 conjugation was not addressed in the paper, their 
western blot analysis clearly resembles the pattern of the Ube1-mediated NEDD8 
response to heat shock or oxidative stress. Taken together, NEDD8 seems to act as a 
general stress response molecule to diverse environmental challenges in different 
organisms. 
In this project we also gained a mechanistic insight of Ube1-mediated NEDDylation. 
Heat shock results in exhaustion of the unconjugated ubiquitin pools by generating 
misfolded proteins, that are excellent substrates for the UPS (ubiquitin-proteasome 
system)[11, 266]. Although it is still a matter of debate to what extent the ubiquitin-
proteasome system is involved in eliminating oxidized proteins, there is increasing 
amount of studies showing the response of the ubiquitin pathway to oxidative stress 
[267]. What is also evident is that under these stress conditions the proteasome activity 
may also be compromised through depletion of ATP (heat shock) or due to dissociation 
of the 20S core particle from the 19S regulatory particle (oxidative stress) [268, 269]. A 
common phenomenon under conditions of proteasomal activity perturbations is the 
depletion of free ubiquitin. Under oxidative stress conditions our data show that while 
ubiquitin conjugates are not dramatically affected, the level of free ubiquitin is 
decreased at 1 mM H2O2 treatment. This is the exact concentration where NEDDylated 
proteins accumulate in a Ube1-dependent fashion. These observations led us to 
hyphothesise that the changes in the relative levels between NEDD8 and ubiquitin will 
provide a trigger for Ube1 to activate NEDD8. We show that a decrease in the ubiquitin 
levels (by siRNA treatment) in the absence of any additional stress, was sufficient to 
stimulate NEDD8 conjugation through the ubiquitin E1 activating enzyme. We also 
tested whether ubiquitin knockdown affects general SUMOylation, a posttranslational 
modification that responds to the same stress conditions. SUMO did not accumulate 
upon ubiquitin knockdown, suggesting the existence of differential mechanisms for 
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NEDD8 and SUMO to respond to cellular stress. In support of the model that the 
relative levels of NEDD8 to ubiquitin control the activation of NEDD8 by Ube1, Hjerpe 
et al. show that overexpression of NEDD8 results in activation and conjugation through 
the ubiquitin pathway[260]. Additionally, we speculate that an active switch may exist 
to allow activation of NEDD8 by Ube1 in vivo under stress conditions. This is 
supported from the observation that ubiquitin overexpression cannot rescue the NEDD8 
response (Figure 3.16). There are other experimental indications that the control of 
Ube1-mediated NEDD8 activation is more complex than the ratio between free 
ubiquitin/NEDD8 and Ube1. As discussed in Chapter 3.2.8 , Figure 3.17b shows that 
Ube1 overexpression alone is sufficient to allow thiolester formation between the 
enzyme and NEDD8, however, it does not result in NEDD8 conjugation in the absence 
of stress. Ube1 and NEDD8 are posttranslationally modified, which may increase the 
affinity of Ube1 for NEDD8, allowing its activation and conjugation by the ubiquitin 
pathway[270-272]. This would explain the poor activation of NEDD8 by Ube1 in vitro, 
where recombinant proteins are used[261]. 
One possible interpretation for the activation of NEDD8 by Ube1 could be that NEDD8 
and ubiquitin are used in a redundant way: when cells run low on ubiquitin, it 
substitutes with a similar modifier. Against this argument is the observation that the 
yeast polyubiquitin gene is induced upon heat shock and starvation to increase cell 
resistance to stress [11]; indicating that organisms do produce more ubiquitin, if they 
need so. However, such induction in human cells does not happen, instead, -based on 
our observations- the system prefers to involve a different modifier in the response. 
NEDD8, despite its close homology with ubiquitin has distinct biophysical and 
thermodynamic properties from ubiquitin. NEDD8 appears to be more thermolabile and 
more prone to unfolding than ubiquitin[273]. These characteristics might be biologically 
significant if NEDD8 modification on proteins is recognized and handled differently to 
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ubiquitin signals. For instance, changes in rates of degradation could give more 
opportunities for refolding of misfolded proteins, which is an energetically favourable 
mechanism in higher eukaryotes. Alternatively, the increase in NEDD8 conjugation 
observed under stress conditions could be part of a mechanism to dampen the depletion 
of ubiquitin and part of a response to restore the initial ubiquitin levels. 
Another interesting observation is that the free NEDD8 is not depleted, while the levels 
of NEDD8 conjugates increase. It would be important to test whether the reamining 
unconjugable NEDD8 is processed, or this pool consists of freshly translated, 
unprocessed form of the ubl. Is the NEDD8 processing somehow inhibited under stress 
conditions? It would be also interesting to test the subcellular localization of these 
NEDD8 species. It has been noted that ubiquitin mainly exists in the cells already 
charged on the E1 enzymes (Millenuim Pharmacheuticals, personal communication). It 
is possible that the free NEDD8 we observe on the western blot after cell lysis under 
reducing conditions is actually thiolester-bound NEDD8 in the cells, waiting for a 
trigger to be quickly transferred to E2s and substrates when a prompt response is 
required. 
To draw a conclusion on the biological significance of the Ube1-mediated 
NEDDylation, we need to distinguish between the two pathways in an unambigous 
manner. The last part of the project, which is in progress, is aiming to develop a system 
that makes this differentiation possible. By site-directed mutagenesis, we identified a 
residue on NEDD8, Lys11, that is likely to be required either for the NEDD8 activation 
by Ube1, or for chain formation. Diglycine modification on NEDD8 K11 residue has 
been identified by MS in previous studies[44, 107]. However, this is not the only 
linkage through which NEDD8 can form chains. The K11 residue can be important for 
the activation by Ube1, therefore in the future we aim to test whether the K11R mutant 
can form a thiolester bond with Ube1. Alternatively, it is possible that the activation by 
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the ubiquitin cascade is initiated by a NEDD8 dimer (or other intermediate) formation 
through K11 linkage. Once this intermediate is formed, NEDD8-ubiquitin chain can be 
built up rapidly through different linkages. This hypothesis is to be tested, but there is 
evidence suggesting that Ube1 forms thiolester mainly with NEDD8 in a dimeric form 
([260] and our observations). It would be interesting to immunoprecipitate NEDD8 with 
Ube1, break up the thiolester linkage, and identify the nature of the dimer by mass 
spectrometry. 
Utilization of a NEDD8 mutant that can only be activated by NAE will allow us to gain 
evidence on the biological significance of the Ube1-mediated NEDDylation and the 
exact cellular processes it is involved in.  
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Chapter 4: Characterization of NEDD8-
ubiquitin chains in vivo 
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4.1. Introduction 
Mass spectrometry (MS) is an ideal technique for examining chemical modifications, 
such as posttranslational modifications of proteins. By measuring the mass-to-charge 
ratios of a modified peptide and its fragment ions, MS is unique in presenting direct 
evidence of modification sites[274]. Thus, it provides the crucial starting point for 
determining the biological significance for the post-translational modification in 
question. This includes the creation of site-specific mutations on the substrate of 
interest. Phosphoproteomics has been particularly successful, and more recently, similar 
approaches have been developed to detect proteins/peptides modified by ubiquitin/ubls.  
For large-scale identification of ubiquitinated proteins, due to their low abundance, it is 
necessary to purify them for enrichment. This can be done on the protein or peptide 
levels. Purification of proteins relies on the usage of cell lines that express non-
endogenous tagged ubiquitin/ubl. The most widely used epitope tags include the short 
histidine stretches (eg.6His-Ub/NEDD8), where purification is done under denaturing 
conditions with metal ions, such as Ni2+ or Co2+. Immunoprecipitations through Myc-
tag, FLAG-tag or HA-tag are also popular. However, the native conditions used for the 
purification preserve non-covalent interactions, therefore covalent modifications have to 
be confirmed by the detection of the site of modification[275]. Tandem-affinity 
purification strategies (with TAP-tagged proteins) have been originally developed to 
study non-covalent protein-protein interactions. By introducing a lysis step under 
denaturing conditions prior to purification, it can be also applied to study proteins 
modified by ubls. This approach reduces contaminations resulting from non-covalent 
interactions, and at the same time preserves ubl-modifications by inhibiting 
proteases[276].  
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Ubiquitin-binding domains can be also used to enrich substochiometrically modified 
proteins under endogenous conditions. Reagents consisting of tandem ubiquitin binding 
domains have been developed for more efficient pulldowns[277, 278]. SUMO 
conjugates have been also purified with tandem SIM (SUMO-interacting motif) 
domains[279]. 
Trypsin, the enzyme widely used in proteomics studies to digest proteins, cleaves at the 
C-terminus of arginine and lysine (unless the lysine is modified or followed by proline 
residues). In the case of ubiquitinated proteins, there is no cleavage at the modified 
lysine, and the mass of the peptide is increased by the two glycines that remain from the 
digested ubiquitin. This provides a predictable mass shift of the precursor ion 
(+114.0429), and allows detection of peptides modified by ubiquitin[280]. 
A recently published monoclonal antibody that recognizes the isopeptides that contain 
the diglycine motif provides a powerful tool to study ubiquitination on the peptide level, 
making it possible to identify the site of modification[281]. This is critical when a 
protein is modified on multiple sites. In the recent years several different laboratories 
utilized the GlyGly antibody for proteomics studies[282-284]. In the largest study, 
around 19,000 diglycine-modified peptides within 5000 proteins have been 
identified[44]. The proteomics data have been deposited in a publicly available 
database, and can be a basis of further biological studies.  
However, ubiquitin is not the only modification that leaves the diglycine signature on 
lysine residues: tryptic digestion of NEDD8 and ISG15 provide the same mass shift. 
Due to the increasingly important regulatory roles of ubls and the several examples of 
crosstalks between the modifiers, methodological advances that distinguish 
unambiguously between ubiquitin and NEDD8 sites have to be developed in the near 
future[280]. 
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Apart from substrate identification, monitoring of the ubiquitin/ubl modified proteome 
upon cellular stimuli or in response to pharmaceutical agents is crucial to understand 
protein regulation by these pathways. However, mass spectrometry is not inherently 
quantitative. In order to monitor changes in the proteome upon stimuli, absolute or 
relative quantitation approaches can be used. The AQUA approach uses stable isotope 
labeled peptides as internal standard to study complex biological samples 
quantitatively[285]. On the other hand, the popular SILAC method (Stable isotope 
labeling by amino acids in cell culture) provides relative quantification between two cell 
populations, at the protein levels[286]. It uses the metabolic labeling of proteins with 
normal or heavy amino acid isotopes. Typically, two cell populations are grown in 
culture media that only differ from the form of a particular amino acid (in the heavy 
medium, arginine and lysine are replaced by their 13C and/or 15N carbon labeled forms, 
leading to C-terminal labeling of tryptic peptides). The incorporation of these amino 
acids into peptides lead to a known mass shift that is detectable by MS[287]. 
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Figure 4.1: An example of a SILAC workflow. 
13C labeled lysine incorporation throughout the proteome followed by Lys-C digestion 
results in a predictable mass shift of 6 Da from the light peptide. Adapted from:[288]  
 
We have shown that the ubiquitin E1 enzyme activates NEDD8 under certain 
conditions. An important question is the nature of the chains formed on substrates when 
the ubiquitin pathway uses two different modifiers at the same time. Based on in vitro 
[102, 261] and in vivo data[102, 289], substrates can be simultaneously modified with 
NEDD8 and ubiquitin. What is also evident is that within this mixture both NEDD8 and 
ubiquitin are modified, however the nature of formed chains has been unclear. 
In this project we investigated the nature of the chain formation under proteasome 
inhibition, and the recognition of the signal by ubiquitin-binding domains. 
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4.2. Results 
4.2.1. NEDD8 and ubiquitin coexist on substrates 
Our data demonstrated that pharmacologic inhibition of the proteasome causes a 
dramatic increase in NEDD8 conjugation which involves the ubiquitin conjugation 
pathway. We addressed the nature of these conjugates and more specifically the 
presence of ubiquitin. For this we used MCF7 cells stably expressing His6-NEDD8 
(MCF7-ND8) at levels similar to endogenous NEDD8 [142, 290]. Cells were either 
untreated or treated with MG132 and NEDDylated proteins were isolated under 
denaturing conditions using Ni2+ agarose beads to prevent any noncovalent interactions. 
Similarly to what is observed in parental MCF7 cells, MG132 treatment causes a 
dramatic increase of NEDD8 conjugates in the MCF7-ND8 cells (Figure 4.2.a). We 
found that upon MG132 treatment the accumulated NEDD8 conjugates are also 
enriched with ubiquitin suggesting that upon stress conditions substrate proteins can be 
simultaneously modified with NEDD8 and ubiquitin. Next we performed the reverse 
experiment: we isolated His6-ubiquitin conjugates on Ni2+-beads, and detected the 
conjugates with ubiquitin and NEDD8 antibodies. Indeed, NEDD8 was present among 
the ubiquitinated substrates under MG132 treatment, confirming that the two 
posttranslational modifiers can simultaneously modify proteins (Figure 4.2.b). 
We also looked at the endogenous NEDD8 conjugates. In proteomic approaches, where 
the aim is the identification of ubiquitin conjugates, pulldowns with proteins containing 
ubiquitin-binding domains (UBDs) or with the domain itself are frequently used[275]. 
We have expressed the recombinant UBA-domain of Dsk2 (the S.cerevisiae homologue 
of HsPlic2), and coupled to sepharose beads to isolate endogenous ubiquitin conjugates. 
MCF7 cells were treated or not with MG132 and the lysate was incubated with 
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recombinant UBA. The domain efficiently isolated ubiquitin conjugates, among which 
we detected NEDD8 signal as well from the MG132 treated samples (Figure 4.2.c). 
This result indicates that endogenous NEDD8 is present on ubiquitinated substrates.  
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Figure 4.2: Ubiquitin and NEDD8 co-precipitate in different pulldown strategies. 
(a) Parental MCF7 or MCF7 cells stably expressing His6-tagged NEDD8 (MCF7-ND8) 
were left untreated or treated with 30 µM MG132 for 4 hrs. NEDDylated proteins were 
isolated as described in the Materials and Methods, using Ni2+-NTA agarose beads. 
Whole cell lysates or purified proteins were analysed by western-blotting, using 
NEDD8 or ubiquitin antibodies. (b) Experiment was done as described at Figure 4.2.a, 
except using MCF7 cells stably expressing His6-tagged ubiquitin. (c) Pulldown of 
ubiquitinated proteins was performed by using recombinant UBA domain derived from 
Dsk2 protein. The eluates and flowthrough were analysed by western blotting. 
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4.2.2. Ubiquitin and NEDD8 chains are enriched in the 
NEDDylated fraction  
Xirodimas et al., 2008 employed a SILAC method to label HeLa cells stably expressing 
TAP-NEDD8 with medium containing either 12C-Arginine or 13C-Arginine and cells 
were either untreated (12C) or treated with MG132 (13C). As Figure 4.3.a shows, cell 
extracts were mixed in 1:1 ratio, followed by a tandem affinity purification, in gel 
digestion with trypsin and mass spectrometric analysis[106]. We re-analysed these data 
using MaxQuant software[249]. We performed a quantitative analysis on the NEDD8 
modified peptides upon MG132 treatment, by looking for NEDD8 peptides that contain 
diglycine modification on lysines. The employed labeling method allowed 
quantification of the abundance of the NEDD8 linkage at K22 and a previously in vivo 
unreported linkage at K33. The analysis showed that conjugation at both sites increases 
upon MG132 treatment (Figure 4.3.b,c and Figure 4.4. a-c) [106, 107]. We also 
identified and quantified ubiquitin peptides within the NEDD8 conjugates with 
diglycine modification on K48 and K63. The analysis showed that ubiquitin chains are 
also present in the NEDD8 pulldown and increase upon MG132 treatment  (Figure 
4.3.d,e and Figure 4.4. d, e). These results indicate that treatment with MG132 causes an 
increase in NEDD8 and ubiquitin chain formation. 
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Figure 4.3: Diglycine modified ubiquitin and NEDD8 peptides are enriched upon 
MG132 treatment within the NEDD8 proteome. 
(a) Schematic representation of the SILAC workflow. The data from a SILAC 
experiment performed in Xirodimas et al., 2008 were re-analysed using MaxQuant (see 
main text for details). MS spectra of NEDD8 peptides modified by Gly-Gly on K22 (b) 
or on K33 (c) and ubiquitin peptides modified on K48 (d) and K63 (e). The SILAC 
ratio indicates an increase of the modification for all peptides with MG132 treatment. 
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Figure 4.4: MS/MS spectra of the modified NEDD8 peptides identified in the 
SILAC experiment. 
(a) NEDD8 peptide modified by Gly-Gly on K22. (b) NEDD8 peptide modified by 
Gly-Gly on K33. (c) NEDD8 peptide modified by Gly-Gly on K33 (longer peptide, due 
to a trypsin ‘missed cleavage’). (d) Ubiquitin peptide modified by Gly-Gly on K48. (e) 
ubiquitin peptide modified by Gly-Gly on K63. 
The screen shots also contain information on the protein, the score and the method used. 
Scores: (a) 299.69; (b) 107.53; (c) 117.7; (d) 277.8; (e) 912.14. 
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4.2.3. Quantification of the unconjugated NEDD8 
Trypsin digestion of proteins occurs at the carboxyl side of lysine and arginine residues 
that are not modified or followed by proline. A common phenomenon during digestion 
is a ’missed cleavage’, which in the case of NEDD8 allows the identification of the 
extreme C-terminus NEDD8 peptide that indicates the presence of unconjugated free 
NEDD8 (Figure 4.5. a). The sequence of this peptide is not normally identified, since 
the common databases contain the sequence of the unprocessed form of NEDD8. The 
sequence of the matured form was subsequently included in the database to allow 
detection and quantitation of the last peptide, which is the direct evidence for the 
presence of unconjugated NEDD8. Our analysis identified this peptide, but interestingly 
MG132 treatment had no effect on its relative abundance (Figure 4.5.b, c). This 
observation is consistent with our western blot analysis (Figure 3.2) showing that, 
contrary to ubiquitin, free NEDD8 depletion does not occur when NEDD8 chains 
accumulate. The combination of the two analysis supports the idea that inhibition of the 
proteasome, while it increases the abundance of NEDD8 chains has no effect on the 
levels of the unconjugated NEDD8. 
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Figure 4.5: Quantification of unconjugated NEDD8. 
(a) Sequence of NEDD8. Trypsin ‘missed cleavage’ at K60 position (no cleavage at 
R74) results in a unique peptide for NEDD8 (underlined). The unconjugated diglycine 
at the C-terminus indicates the peptide derives from unconjugated, “free” NEDD8. (b) 
MS spectrum of the last peptide of NEDD8: the SILAC ratio indicates that the relative 
abundance of the free form of NEDD8 is unchanged with MG132. (c) MS/MS spectrum 
of the last peptide of NEDD8. 
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4.2.4. Identification of ubiquitin modification on NEDD8 peptides  
While the conventional strategy for the identification of diglycine motifs on lysine 
residues shows that NEDD8 forms chains in vivo, that increase upon MG132, it does 
not indicate the type of modification. This is because both NEDD8 and ubiquitin 
provide a diglycine signature upon trypsin digestion. However, it has been noted that 
due to ’missed clevage’, trypsin digestion produces the tetrapeptide LRGG as a 
modification signature on lysines[291]. Since ’missed cleavage’ in NEDD8 does not 
produce the LRGG signature, we used this approach to distinguish between NEDD8 
and ubiquitin modification (Figure 4.6.a). We isolated NEDDylated proteins from 
MCF7 His6-NEDD8 cells after MG132 treatment. The sample was digested „in 
solution” with trypsin for a short time, in order to achieve a partial digestion. LC-
MS/MS analysis was performed on a LTQ-Orbitrap Velos mass analyzer. We added 
’LRGG’ in the Andromeda search engine[250], as a posttranslational modification on 
lysine residues, and specifically searched for NEDD8 or ubiquitin peptides with this 
modification. We identified both NEDD8 and ubiquitin peptides with the LRGG 
signature on K48 (Figure 4.6. b-e). This finding provides the first in vivo evidence of 
ubiquitin modification on NEDD8.  
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Figure 4.6: NEDD8 is modified with ubiquitin in vivo. 
 (a) Sequence of the branched peptides of ubiquitin and NEDD8 when modified by 
ubiquitin on K48 residue upon complete or partial trypsin digestion. (b) MS/MS 
spectrum of the ubiquitin peptide modified by GG on K48 (m/z 487.60005; (3+); mass 
error 0.53 ppm). (c) MS/MS spectrum of the ubiquitin peptide modified by LRGG on 
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K48 (m/z 577.32844; (3+); mass error 0.1 ppm). (d) MS/MS spectrum of the NEDD8 
peptide modified by GG on K48 (m/z 513.92057; (3+); mass error 0.5 ppm). (e) 
MS/MS spectrum of the NEDD8 peptide modified by LRGG on K48 (m/z603.64897; 
(3+); mass error 0.4 ppm). 
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4.2.5. Identification of NEDD8-NEDD8 and NEDD8-ubiquitin 
branched peptides with a different strategy 
Although successful with ubiqutin, the above described strategy did not allow the 
identification of peptides modified by NEDD8. Therefore, we turned to another 
approach to distinguish between NEDD8 and ubiquitin modification: instead of trypsin 
digestion, NEDDylated proteins isolated from MCF7-ND8 cells after MG132 treatment 
were digested in solution with endoproteinase Lys-C.  This enzyme provides unique 
signatures for either NEDD8 or ubiquitin modification on lysine residues, since it 
cleaves at the C-terminus of lysine, but not arginine residues (Figure 4.7. a)[292]. We 
created a new database that included the predicted NEDD8 and ubiquitin branched 
peptides, and processed our data obtained from the mass spectrometric analysis for the 
identification of ubiquitin and NEDD8 branched peptides (Figure 4.7. b, c [293]). We 
found that ubiquitin is NEDDylated on K29 and NEDD8 is NEDDylated on K6 lysine 
residue (Figure 4.8. a, b). The combination of the two approaches (partial tryptic and 
Lys-C digestion) suggests that in cells NEDD8 forms chains with NEDD8 and ubiquitin 
as well. The detection and analysis of branched peptides in complex mixtures is 
technically very challenging [294]. Thus, based on the previous identification of 
multiple modification sites on both NEDD8 and ubiquitin[106, 107] it is highly possible 
that the identified types of modification for K48 and K6 in NEDD8 and K29 in 
ubiquitin will apply to other NEDD8/ubiquitin sites. Nevertheless, our data for the first 
time indicate the formation of mixed NEDD8-ubiquitin chains in vivo. 
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Figure 4.7: Branched peptide sequences 
(a) Sequence of the branched peptides of ubiquitin and NEDD8 on lysine residues upon 
trypsin or Lys-C digestion. While complete trypsin digestion leaves a diglycine 
signature on lysines, Lys-C digestion enables discrimination between the different 
modifiers. (X: any amino acid) (b) Sequence of the NEDD8-ubiquitin and NEDD8-
NEDD8 branched peptides and the virtual peptides. For the easy interpretation of the 
MS/MS spectrum, the cross-linked peptide is “reversed”[294].  (c) The two sequences 
show examples of the linearized version of the branched peptides added to 
database[293]. 
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Figure 4.8: NEDD8 modifies ubiquitin on Lys29 and NEDD8 on Lys6 
MCF7-ND8 cells were treated with 30 µM MG132 for 4 hrs. Isolated NEDDylated 
proteins were digested with Lys-C to enable discrimination between NEDD8 and 
ubiquitin sites. After MS analysis, peptides were identified using MaxQuant software 
and a modified database containing Lys-C digested NEDD8 and ubiquitin branched 
peptides. Figure (a) represents the high-resolution MS/MS spectrum of a ubiquitin 
peptide modified with NEDD8 on K29 (m/z 452.47996 (5+); mass error -0.3 ppm). The 
peptide was fragmented by high-energy collision-induced dissociation (HCD) and the 
fragment ions were analysed in the orbitrap analyser. Figure (b) represents the high-
resolution MS/MS spectrum of a NEDD8 peptide modified with NEDD8 on K6 (m/z 
461.29248 (5+); mass error 0.1 ppm). The peptide was fragmented by collision-induced 
dissociation and the fragment ions were analysed in the orbitrap analyser. Spectra were 
assigned manually.  
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4.2.6. NEDD8 is present on ubiquitinated substrates recognised 
by ubiquitin-binding domains that are associated with the 26S 
proteasome 
The signals created by the different types of ubiquitin chains are decoded by the 
recognition of ubiquitin-binding domains (UBDs). In order to gain insight into the role 
of Ube1-mediated NEDD8 activation, we investigated how different UBDs or UBD 
containing proteins recognize NEDD8/mixed chains. We obtained constructs of GST-
tagged Rpn10, Rpn13, and the UBA domains of Rad23A, B, and Plic2 from Dr. 
Koraljka Husnjak. These proteins are either part of the 26S proteasome (Rpn10 and 
Rpn13) or play role in recognizing ubiquitinated proteins and transferring them to the 
proteolytic machinery (Plic2, Rad23 and Sc. Dsk2). We expressed them as recombinant 
GST fusion proteins in bacteria (Figure 4.9) and used them in pull down assays with 
untreated, MG132, or heat shock treated H1299 cell extracts. Cells were lysed and 
incubated overnight with the indicated recombinant GST-UBA-domain that was 
coupled to GSH-activated sepharose beads. After washes, conjugates were eluted with 
2X SDS and analyzed by western blotting with NEDD8 and ubiquitin antibodies 
(Figure 4.10. a, b). After detection, membranes were washed and stained with 
coomassie blue reagent to visualize the total proteins isolated with the UBDs (Figure 
4.10. c). Our preliminary data show that these UBDs /proteins pull down 
NEDD8/mixed chains when cells are treated with MG132 or heat shock, indicating that 
the chains recognized by these proteins contain NEDD8. 
Under unstressed conditions, a band corresponding to NEDDylated cullins appears from 
the pull-downs with all tested receptors, but not when only GST was used as a control. 
From this experiment it cannot be concluded whether the UBDs recognize cullins or the 
NEDD8 modification. The SCF ligase complex has been co-purified with the 19S cap 
of the proteasome[295]; therefore direct physical interaction between cullins and 
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ubiquitin receptors is not surprising. It is possible that cullins come as part of the SCF 
complex including the ubiquitinated substrate. On the other hand, it is also likely that 
NEDD8 is recognised by the receptors. NEDD8 shares similar three-dimensional 
structure (the β-fold) with ubiquitin, and possesses the Ile44 patch (Leu8, Ile44, Val70) 
as well, which is the platform of recognition for the majority of UBD-containing 
proteins[74]. 
Besides cullins, other NEDDylated proteins have also been detected from the input 
under untreated conditions; while in the pulldowns, only cullins (the most abundant 
NEDD8-conjugates) and a band at ~37 kD are observed most of the time (this is 
probably due to the secondary antibody recognizing the recombinant proteins). An 
interesting exception is the Rpn10 pulldown, where a few other low molecular weight 
bands were detected. These proteins are most likely targeted for degradation under 
normal conditions, and recognized by Rpn10 on the 26S proteasome. 
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Figure 4.9: Expression of the UBA domains or UBD-containing proteins 
GST-tagged UBDs were expressed in BL21-CodonPlus® Competent Cells and purified 
as discussed in the Materials and Methods. Recombinant proteins were stored coupled 
to beads. To monitor the expression of the proteins, equal amounts of beads were boiled 
in 2XSDS, loaded on SDS-PAGE and stained with Coomassie blue reagent.  
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Figure 4.10: NEDD8 is present in the ubiquitin chains recognised by ubiquitin-
binding proteins associated with the ubiquitin-proteasome system. 
H1299 Cells were either treated with 30 µM MG132 for 4 hrs, or heat shocked at a 43oC 
incubator for 1 hour, or left untreated, as indicated. Lysates were incubated with GST-
UBA-domains or full-length proteins coupled to Glutathione Sepharose beads 
overnight. The eluates were mixed with 2X SDS and analysed by western blotting with 
(a) NEDD8- or (b) ubiquitin-specific antibodies. (c) After detection, membranes were 
stained with coomassie blue reagents to visualize the total proteins isolated in the 
pulldowns. 
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Figure 4.11: Schematic representation of the ubiquitin and NEDD8 conjugation 
pathways under homeostatic and stress conditions. 
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4.3. Discussion and future directions: 
Mass spectrometry-based proteomics is a powerful technique that provides a large 
amount of information on proteins and PTMs. Reprocessing of ‘old’ raw data with more 
advanced software tools and expanded databases or searching for a modification that 
has not been looked at before (‘LRGG’) in the dataset provided us with valuable new 
information on NEDD8 chain formation. 
Diglycine modifications on NEDD8 peptides have been found earlier, indicating that 
NEDD8 forms chains[106, 107].  However, the modifier and the type of modification 
have not been addressed before. We applied two mass spectrometry based methods to 
unambigously identify ubiquitination and NEDDylation sites. Our data provide the first 
evidence on the formation of di-NEDD8 (which most likely indicates poly-NEDD8) 
and mixed NEDD8-ubiquitin chains in vivo. As already discussed, while our analysis 
identified K48 and K6 in NEDD8 as ubiquitination and NEDDylation sites respectively, 
and K29 on ubiquitin as NEDDylation site, it is very likely that this type of 
modification applies to other NEDD8 and ubiquitin lysines.  
Despite this success, these methods are inadequate for the detection of sites on substrate 
proteins. This is due to a) the relative low abundance of the NEDDylated peptides and 
b) difficulties in interpreting the resulting MS/MS spectra[294]. Another problem is that 
standard databases do not contain the branched peptides that derive from Lys-C 
digestion; therefore the identification is only possible if a new database is created with 
all the potentially modified substrates. Jeram et al. have developed a database search 
software, SUMmOn for identification of ub/ubl sites after Lys-C digestion[296]. They 
have successfully identified NEDDylation sites in vitro. However, the methodology has 
not been used in vivo. 
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There are other ways to improve large-scale NEDD8 site identification; I am only going 
to discuss one in this thesis. As mentioned above, ubiquitin and NEDD8 both leave the 
diglycine motif on proteins due to the tryptic cleavage after the arginine at position 74. 
To overcome this problem, one could introduce an arginine74 to lysine mutation 
(R74K) on NEDD8, and apply Lys-C digestion to obtain the diglycine signature only on 
substrates that are modified with the R74K mutant of NEDD8 (see on Figure 4.12). One 
could use then the recently developed monoclonal antibody that recognizes the 
diglycine motif to enrich for peptides that contain NEDDylation sites. This is only one 
of the several ways NEDD8 site identification can be and will be improved in the 
following years. 
 
 
 
Figure 4.12: Sequence of NEDD8 and ubiquitin with the C-terminal Lys-C 
cleavage sites. 
 
Large-scale NEDD8 site identification with easily applicable methods will answer 
important biological questions, such as whether NEDD8 modifies proteins directly on 
their acceptor lysine residue, or through intercalation into ubiquitin chains formed prior 
to NEDDylation.  
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Recently a group has also shown evidence on NEDD8 modification on ubiquitin, 
however they did not detect ubiquitin modification on NEDD8 or NEDD8 chains, and 
concluded that NEDD8 might act as a chain terminator (Michael Glickman, oral 
presentation at the ZOMES VII meeting). We have identified ubiquitin and NEDD8 
modification on NEDD8 by mass spectrometry, suggesting that NEDD8 intercalates 
into chains, instead of terminating them. However, our experiment was done in the 
presence of MG132 that induces a vast Ube1-mediated NEDDylation. Under 
physiological conditions such strong trigger probably does not occur, and milder 
NEDD8 engagement into the ubiquitin pathway might result in only a single NEDD8 
modification on ubiquitin chains, similarly what was detected in S. cereviseae. In this 
case, NEDD8 might indeed play role in chain termination, which could allow the 
recovery of the free ubiquitin pools that are depleted upon stress. Therefore, it would be 
interesting to test the type of branched peptides that one can detect from heat shock 
treated cells, which results in a milder (and more physiological) effect on NEDD8 
activation.  
Some groups have also detected unanchored NEDD8-ubiquitin chains in S. cereviseae 
(Thimo Kurz, personal discussion and Michael Glickman, oral presentation at the 
ZOMES VII meeting). Whether NEDD8 modifies substrates through the ubiquitin 
pathway or this type of NEDDylation results in accumulation of unanchored chains (or 
both possibilities exist at the same time) need to be further addressed. There have been 
several reports on free polyubiquitin chains. They are generated during ubiquitin 
biosynthesis, by DUBs that release chains from the substrates or they can be synthetized 
by ubiquitinating enzymes[297]. Unanchored Lys63 polymers have been shown to be 
important for signal transduction, acting as transient platform for protein 
interactions[298]. It would be also important to determine the biological outcome of the 
unanchored mixed chain formation, such as their recognition by cellular receptors. It is 
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likely that UBD-containing proteins bind to them. NEDD8 intercalation to free chains 
might provide a different platform for biological processes, or alter half-life of the 
chains that are normally quickly disassembled by DUBs. 
The research on ubiquitin protein modification has revealed an exquisite and diverse 
functional output that depends on the type of chain formation of the same modifier 
(K48, K63, K11, linear ubiquitin chains) [37, 299]. Therefore, it is very likely that the 
identified types of NEDD8 modification under stress conditions create a new signal 
(poly-NEDD8 chains) and/or alter the biological outcome of the ubiquitin signal.  
The well-established role for NEDD8 is the indirect regulation of protein ubiquitination 
through modification of cullins and the control of CRL activity. Our data now provide 
evidence for a direct role of NEDD8 in controlling the ubiquitin signal output, as the 
NEDD8 conjugates are also ubiquitinated through formation of mixed chains.  
Therefore, based on this mechanism and on the identification of K48 both in NEDD8 
and ubiquitin as a chain formation site, and the mixed chain interaction with the UPS,  a 
possible role for NEDD8 could be the control of the rates of transport, recognition 
and/or degradation of ubiquitinated proteins. However, as the biological output of 
ubiquitin modification is extended well beyond protein degradation, additional 
regulatory functions for NEDD8 may exist.  
We have used recombinant UBA domains and full-length proteins in order to uncover 
whether the mixed chains signal to the UPS. All of the tested proteins/domains pulled 
down NEDD8 conjugates to different extend. From this assay, many conclusions can be 
drawn and even more questions can be raised that I am going to discuss below. When 
interpreting data from such pulldown experiments, it is important to keep in mind that 
isolated domains might behave differently to the full-length proteins. Therefore the data 
obtained is interpreted as a preliminary observation that has to be further investigated.  
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Whether or not the domains can bind directly to NEDD8 or the interaction is through 
ubiquitin remains to be determined. It has been shown that UIMs (ubiquitin interacting 
motifs) of certain proteins recognize both NEDD8 and ubiquitin[103]. Interestingly, in 
yeast two-hybrid systems 30% of Ubiquitin Binding Domains (UBDs) appeared to bind 
NEDD8 as well [300]. In order to gain insight into the nature of the recognition, further 
biochemical studies have to be performed. One possible way is to create short NEDD8 
chains or mixed chains and screen them in yeast two-hybrid assays with a library 
containing UBA-domains. This is going to be investigated in Koraljka Husnjak’s lab in 
the future. Another possibility is to measure the affinity of UBD-containing proteins 
toward recombinant NEDD8/mixed chains, and compare them to ubiquitin chains of 
different linkage. It would be interesting to find out whether there are proteins that have 
higher specificity towards NEDD8, than ubiquitin, or whether receptors’ affinity 
towards ubiquitin chains is altered when NEDD8 is intercalated? These possibilities 
suggest that recognition and processing of the mixed chains by the 26S proteasome 
would be altered, and would also probably affect signaling involved in other cellular 
processes. In this thesis, we only investigated NEDD8 binding to proteasome receptors. 
Since NEDD8 is involved in a variety of cellular processes, it would be interesting to 
test the affinity of other UBD-containing proteins, such as the ones involved in DNA 
damage, towards this ubl. 
I find it highly relevant to mention some of the new observations that other groups 
made on the same subject. Michael Glickman has shown their new finding on NEDD8-
ubiquitin chains and their recognition by proteasome receptors and shuttle proteins at 
the ZOMES VII meeting on “Ubiquitin family proteins and their cognate PCI 
complexes” in September, 2012. First of all, they have obtained the structure of ScRub1 
(NEDD8) by NMR, which appeared to be fully superimposable to that of the ubiquitin. 
The conserved Ile44 patch is identically positioned to the ubiquitin patch, suggesting 
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direct recognition by UBA-domains. Next, they mapped binding of domains to Rub1 by 
NMR CSR; and found that Rad23 and Dsk2 recognise Rub1 very similarly to ubiquitin. 
However, Rpn10, the ubiquitin receptor on the 26S proteasome showed higher affinity 
towards ubiquitin. 
Adaptors for NEDD8 have also been identified, such as the NEDD8 interacting protein 
NUB1 (NEDD8 Ultimate Buster 1) that is suggested to play role in recruiting 
NEDDylated substrates and NEDD8 monomer to the 26S proteasome for 
degradation[115, 116]. An alternative explanation for the accumulation of NEDDylated 
substrates upon stress is that they are normally targeted to the proteasome, possibly 
through modification of NEDD8 with K48 ubiquitin chains. The observation that no 
significant depletion of free NEDD8 is detected upon stress while NEDD8 conjugation 
is dramatically increased, is consistent with the idea that NEDD8 itself  may be a 
substrate for proteasomal degradation. 
Another big question, apart from how NEDD8 is recognised by the proteasome, is 
whether and how DUBs on the degradation machinery can recognise and/or process the 
NEDD8/ubiquitin mixed chains. If they do so, is NEDD8 removal as efficient as 
ubiquitin? There have been three proteins identified on the proteasome that possess 
DUB activity: Rpn11, Uch37 and Usp14. None of them has been shown to have 
deNEDDylating activity. The COP9 signalosome, the protein complex dedicated for 
deNEDDylation has been suggested to be transiently associated with the proteasome, or 
even is able to replace the lid of the degradation machinery[133, 134]. These findings 
however are debated in the field.  
There have been ~ 90 DUBs identified so far that are not associated with the 26S 
proteasome and are involved in diverse cellular processes. Some of the ubiquitin C-
terminal hydrolases (UCHs) show dual specificity towards NEDD8 and ubiquitin 
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(UCH-L3, UCH-L1, PfUCH54). In in vitro studies, ovarian tumor-related proteases 
(OTUs) appear to bind to NEDD8, but do not possess deNEDDylating activity 
(personal discussion with David Komander). Among the large class of ubiquitin-
specific proteases (USPs), only Usp21 has been reported to have NEDD8 cross-
reactivity[301]. However, a later study has not detected NEDD8 cleavage in the 
presence of Usp21[114]. Moreover, based on structural studies, the authors determined 
amino acids on NEDD8 and USPs that prevent NEDD8 from being targeted by these 
types of proteases. Interaction between ubiquitin Arg72 residue and the USP domains is 
essential for processing ubiquitin. NEDD8 possesses an alanine residue at the 72 
position, therefore USPs do not have affinity toward this ubl. Interestingly, amino acids 
on the N-terminus of NEDD8 (that are localized on the β1 and β2 strands), namely 
Lys4, Glu12 and Glu14 also preclude USP binding, due to steric clashes and charge 
repulsion[114].  
Previous studies[102, 103, 260, 261] have shown that many ubiquitin E2s can form 
thiolester bond with NEDD8 in vitro and shared E3 ligases between NEDD8 and 
ubiquitin exist. It is becoming evident that most of the ubiquitin E2 and E3 enzymes do 
not discriminate between the two posttranslational modifiers. However, a large portion 
of deubiquitinating enzymes appears to have specificity towards ubiquitin. NEDD8 
intercalation into the polyubiquitin signal might inhibit the isopeptidase activity of 
DUBs that cannot cleave NEDD8 from mixed chains. The biological relevance of the 
NEDD8 mixed chain formation can be addressed by testing how these chains are 
processed by DUBs that are involved in important regulatory mechanisms and what is 
the consequence of the supposititious inhibition in DUB activity by NEDD8 
intercalation into ubiquitin chains. Usp5 has been reported to cleave unanchored 
ubiquitin chains from the proximal end. It would be interesting to test whether it can 
disassemble the potential ubiquitin-NEDD8 unanchored chains as well. 
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To sum up, in this project we have characterized the chains formed by the ubiquitin 
conjugation cascade. We identified that NEDD8 is present in polyubiquitin signals. We 
have also determined that the mixed chains are recognized by ubiquitin binding 
domains. Based on this observation, recombinant UBDs could be used in the future to 
isolate NEDD8-ubiquitin mixed chains for further studies. For instance, endogenous 
NEDD8 conjugates could be pulled down with the recombinant protein Plic-2 after heat 
shock or other cellular stimuli and subjected to MS-analysis. Moreover, ubiquitin or 
ubiquitin/NEDD8 mixed chains could be specifically isolated and their properties could 
be compared in biochemical assays (e.g. presenting them to the 26S proteasome and 
monitoring the rates of substrate degradation). In addition, based on our preliminary 
data, Rpn10 appears to be a right tool to isolate NEDDylated proteins under 
homeostatic conditions for proteomics studies. 
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Chapter 5: Role of the NEDP1 
deNEDDylating enzyme in DNA-
damage induced apoptosis 
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5.1. Introduction 
5.1.1. NEDP1 and its orthologs 
The NEDP1 deNEDDylating enzyme is highly conserved throughout evolution (see 
Figure 5.1), and has been studied in multiple organisms, including Drosophila 
melanogaster (DEN1), S. pombe (Nep1 and Nep2), and humans (NEDP1/SENP8). 
It is a cysteine protease (the catalytic cysteine being Cys163), and contains the His-Asp-
Cys catalytic (triad) residues also present in sentrin-specific proteases (SENPs) and the 
yeast Ulp1 (Figure 5.2). Interestingly, it does not share sequence homology to ubiquitin-
specific proteases, and is highly specific towards NEDD8[90, 302]. It processes neither 
SUMO, nor ubiquitin with the C-terminal extension. Structural studies revealed that the 
isopeptidase undergoes a conformational change upon NEDD8 binding.  The residues 
on NEDD8 that are important for NEDD8-ubiquitin discrimination are engaged in 
catalysis when a flexible loop centred on Q96 in NEDP1 swings over the C-terminus of 
NEDD8, and locks it into an extended β-structure. The Ala72 residue at the C-terminus 
of NEDD8 is essential for recognition and processing by NEDP1. Since this residue is 
not conserved in ubiquitin (Arg72), this amino acid provides the molecular determinant 
for NEDP1’s specificity towards NEDD8[90, 303]. 
NEDP1 is able to process NEDD8 precursor immediately after the diglycine motif, 
leaving the mature, conjugable NEDD8 form. It is also capable of removing NEDD8 
from substrates. It has been shown to deNEDDylate cullins in vitro and in vivo in 
overexpression experiments, although its activity to deNEDDylate cullins under 
physiological conditions is debated. For example nep1 and nep2 (the NEDP1 homologs 
in S. pombe) deletions do not seem to affect cullin NEDDylation, while deletion of the 
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CSN complex clearly result in increased cullin NEDDylation. However, in the strains 
where the NEDP1 homologs are deleted, high-molecular weight NEDDylated species 
accumulate, indicating the presence of other substrates for NEDP1’s deNEDDylating 
activity. The same phenomenon was observed in Drosophila melanogaster: den1 
deletion does not affect endogenous Cul1 and Cul3 NEDDylation, while other 
NEDDylated proteins accumulate[304]. Recently, a few more groups independently 
found that non-cullin NEDDylated substrates accumulate upon deletion of NEDP1 
homologs in different species, such as Arabidopsis thaliana and Aspergillus nidulans 
(ZOMES VII meeting, personal discussions). 
Overexpressed NEDP1 has been shown to deNEDDyate p53[102], full-length p73[144], 
L11[148], the caspase-7 ortholog in Drosophila, drICE[104] and more recently E2F-
1[150, 151]. However, BCA3 is the only physiological target for NEDP1 that has been 
identified so far under entirely endogenous conditions[146].  
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Figure 5.1: NEDP1 is highly conserved between species. 
Sequence alignment between Homo sapiens NEDP1 (accession number: 
NP_001159812.1), Macaca mulatta (XP_001089430.1), Mus musculus 
(NP_001165542.1), Rattus norvegicus (NP_001012355.1), Danio rerio 
(NP_001070633.1), Drosophila melanogaster Den1 (NP_001163126.1), 
Caenorhabditis elegans ulp-3 (NP_001023477.1), Schizosaccharomyces pombe nep1 
(NP_596375.2) and nep2 (NP_595608.1) was performed using ClustalX 2.0.12 
software. An * (asterisk) indicates positions which have a single, fully conserved 
residue.  A : (colon) indicates conservation between groups of strongly similar 
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properties.  A . (period) indicates conservation between groups of weakly similar 
properties. The residues are coloured according to their physicochemical properties 
(red: small + hydrophobic; blue: acidic; magenta: basic; green: hydroxyl + sulfhydryl + 
amine + G; grey: others). 
 
 
 
Figure 5.2: Crystal structure of the NEDP1-NEDD8 complex. 
Structure was obtained from the Protein Data Bank (www.pdb.org, accession number: 
2BKR) and visualized and modified in MacPymol. NEDP1 is shown in green, NEDD8 
is in red, and the blue residues highlight the catalytic triad: H109, D119 and C163. 
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Since NEDP1 is highly specific for NEDD8 but its physiological role is not known, our 
lab has been interested in characterizing the enzyme. Due to the fact that NEDP1 is 
highly conserved between species, our lab has decided a few years ago to study the role 
of NEDP1 in the round worm, C. elegans, in collaboration with Anton Gartner’s lab. 
Ulp3 was identified to be the worm ortholog of NEDP1 by reciprocal Blast analysis. 
We tested the enzyme and found that it possesses both NEDD8 processing and 
deNEDDylating activity (Figure 5.3-5). Recombinant Ulp3 can process NEDD8 from a 
fusion protein where ubiquitin is fused at the C-terminus of NEDD8, and overexpressed 
Ulp3 is able to deNEDDylate L11 in human cells. The processing and deNEDDylating 
activity depends on the conserved catalytic cysteine residue, since mutation on Cys167 
(Ulp3 Cys) inhibits both activities (Figure 5.4-5.). 
The ulp-3 deletion mutant has been obtained from the Japanese C. elegans knockout 
consortium. Given the Gartner’s lab expertise in DNA damage-induced apoptosis and 
the existing knowledge of the response of the NEDD8 pathway to stress, we decided to 
investigate the effects of the ulp-3 deletion in the DNA damage response pathway. My 
project addressed the role of NEDP1 in DNA-damage induced apoptosis in human cell 
lines. 
In the following parts of this chapter I will first introduce the DNA damage-induced 
apoptotic pathways in worms and humans, and then give a summary on the 
characterization of ulp-3, a work that was done by Aymeric Bailly; followed by my 
results on NEDP1. 
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Figure 5.3: Sequence alignment of human NEDP1 and C. elegans ulp-3 
Sequence alignment between Homo sapiens NEDP1 (accession number: 
NP_001159812.1) and Caenorhabditis elegans Ulp-3 (NP_001023477.1) was 
performed using ClustalX 2.0.12 software. The two orthologs possess 27 % sequence 
identity. The conserved catalytic triad residues involved in protease activity are marked 
with arrows. An * (asterisk) indicates positions which have a single, fully conserved 
residue.  A : (colon) indicates conservation between groups of strongly similar 
properties.  A . (period) indicates conservation between groups of weakly similar 
properties. The residues are coloured according to their physicochemical properties 
(red: small + hydrophobic; blue: acidic; magenta: basic; green: hydroxyl + sulfhydryl + 
amine + G; grey: others). 
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Figure 5.4: Ulp3 is a deNEDDylating enzyme, and its activity depends on the 
catalytic cysteine. 
MBP-His-NEDD8-Ub substrate was incubated with wildtype Ulp3, Ulp3 catalytic 
cysteine mutant (Ulp3 Cys) and NEDP1 for the indicated time intervals in vitro. 
Proteins were analysed on SDS-PAGE gel with coomassie staining. 
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Figure 5.5: Ulp3 deNEDDylates L11 in cells, in a catalytic cysteine-dependent 
manner. 
H1299 cells were transfected with the indicated constructs (5 µg NEDP1 or Ulp-3, 5 µg 
of L11 and 2 µg His-NEDD8 or His-Ub). 2 days after transfection, NEDDylated 
proteins were isolated with Ni2+ beads and analysed by western blotting. WT Ulp3 - but 
not the catalytic mutant- deNEDDylates L11 similarly to the human NEDP1, and does 
not affect ubiquitin conjugates. 
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5.1.2. DNA damage-induced apoptosis in worms and humans 
Caenorhabditis elegans has been extensively used as a multi-cellular model organism to 
investigate the DNA damage response, since it is easy to grow, manipulate and it 
recapitulates the DNA damage response present in higher eukaryotic cells. The basic 
genetic regulation of apoptosis has been uncovered mainly through studies on C. 
elegans, taking advantage of the invariant development of the worm that allows tracing 
the fate of every single cell[305]. The induction of apoptosis in germ cells in the 
nematode C. elegans by genotoxic stress was first reported in 2000[306]; and since then 
it has been extensively studied.  
CEP-1 (C. elegans-p53), the only p53-like protein in C. elegans has been shown to be 
required for DNA damage-induced apoptosis, and is induced by a checkpoint signaling 
pathway[307]. Once activated, CEP-1 induces the transcription of egl-1 and ced-13, 
which encode for two pro-apoptotic BH3-only proteins that act upstream of the genes 
ced-9, ced-4 and ced-3[308]. ced-9 encodes for a Bcl-2-like cell death inhibitor, ced-4 
for an Apaf-1-like adaptor protein and ced-3 for a protease that is related to the caspase 
family of proteins (Figure 5.6 )[309-311]. 
While the core apoptotic machinery is similar between worms and humans, there are 
some fundamental differences as well. The pathway is more complex in mammals, with 
a number of BH3-only domain and Bcl-2 (B-cell lymphoma 2) proteins playing role in 
apoptosis along with multiple caspases. Basically, in mammals Bcl-2 inhibits apoptosis 
by preventing the release of cytochrome c from mitochondria that activates Apaf-1 
(apoptotic protease-activating factor 1). Once cytochrome c is released, it binds to the 
WD40 repeats of Apaf-1 to facilitate assembly of the apoptosome in the presence of 
dATP/ATP. The apoptosome is a wheel-like complex that recruits procaspase-9 to form 
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a functional complex that is able to activate procaspase-3[312]. In worms however, 
cytochrome c is thought to have no role in apoptosis, and CED-4 is mainly inhibited by 
physical interaction with CED-9 that is disrupted upon egl-1 activation. However, there 
are indications that the regulation of CED-4 may be more complex than previously 
thought[313]. 
 
Figure 5.6: Genetic pathway in C. elegans, leading from DNA damage to apoptosis. 
The related mammalian proteins are in brackets.  
 
Aymeric Bailly provided genetic evidence on the importance of ulp-3 (NEDP1 homolog 
in C. elegans) in the DNA damage response. The characterisation of the mutant showed 
that it is viable and develops normally with no obvious defects. However, ulp-3 
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depleted worms develop less apoptotic cells in their germ line upon ionizing irradiation, 
compared to the wild-type animals, similarly to a cep-1 deleted strain. Further 
characterisation on the ulp-3 deleted strain has shown that the defective apoptotic 
response is not due to a DNA repair defect (as determined by comparing the sensitivity 
of the ulp-3 strain to IR treatment to that of the hpr-17 (homologue of pombe RAD17) 
mutant worms that are defective in DNA repair). CEP-1 activity was also not severely 
affected by the deletion of the NEDP1 ortholog. These data suggest that ulp-3 
specifically affects DNA damage-induced apoptosis in the germ line, and acts parallel 
or downstream of cep-1. 
The aim of my project was to test the conservation of the role of Ulp-3 in the DNA 
damage-induced apoptosis in human cells and to investigate whether it acts downstream 
of p53. 
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5.2. Results 
5.2.1. nedp1 is induced upon treatment with chemotherapeutic 
agents 
Studies from our group showed that the protein level of NEDP1 is increased upon 
treatment of human cells with low doses of actinomycin D (ActD)[148]. We decided to 
confirm this data, and investigate the response of nedp1 gene expression to ActD and 
another chemotherapeutic drug, doxorubicin (Dox) as well. Dox causes DNA damage 
by intercalation; therefore it is relevant to our study. MCF7 cells were treated with 1 
µM doxorubicin or 5 nM ActinomycinD for the indicated time periods. RNA was 
isolated and qPCR analysis was performed to detect gene expression of nedp1. We 
found that the expression is increased upon treatment with either agent (Figure 5.7). 
Recently, a paper from Watson et al., 2009 also showed the response of NEDP1 to 
doxorubicin and neocarzinostatin (NCS), and claimed that SENP8 plays an important 
role in p53 induction by inhibiting Mdm2, in response to the drug treatments[314]. 
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Figure 5.7: nedp1 is induced upon doxorubicin and ActD treatment. 
MCF7 cells were treated with (a) 1 µM doxorubicin or (b) 5 nM actinomycin D for the 
indicated time intervals. Quantitative real-time PCR for nedp1 was carried out as 
described in Materials and Methods. The experiments were performed in triplicates; 
data are represented as mean +/-STDEV. T-test was performed for statistical 
significance between the 0h time point and later time points. p<0.05 indicates that the 
difference is statistically significant. 
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5.2.2. NEDP1 is induced upon ionizing irradiation on the mRNA 
and protein level 
Previous data from Aymeric Bailly has shown that ulp-3 depleted worms develop less 
apoptotic cells in their germ line upon ionizing irradiation, compared to the wild-type 
animals. 
We were interested to test whether the human ortholog responds to IR. We exposed 
MCF7 cells to 7 or 10 Gy of IR. 4 or 24 hrs after exposure, cells were harvested. mRNA 
was isolated for qPCR analysis, which showed an induction in the mRNA level of the 
protease (Figure 5.8 a). 
To determine the effect of IR on the NEDP1 protein levels, we exposed cells to 7 Gy 
irradiation, and lysed them in 2X SDS after 0, 4 and 24 hrs. Western blot analysis using 
a p53-specific antibody as a control showed that the irradiation was efficient, the protein 
level increased after 4 hrs and dropped at 24 hrs. The NEDP1 levels were increased but 
at a late time point (~24 h) (Figure 5.8.b). 
Late induction in gene expression and stabilization of the gene product is a common 
characteristic of apoptotic genes. Our data indicate that the deNEDDylating enzyme 
NEDP1 responds to chemotherapeutic drugs and ionizing irradiation, and points 
towards a potential role in the DNA-damage response. 
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Figure 5.8: NEDP1 responds to ionizing irradiation. 
(a) MCF7 cells were irradiated with 10 Gy and harvested at the indicated time. 
Quantitative real-time PCR for nedp1 was carried out as described in Materials and 
Methods. The experiments were performed in triplicates; data are represented as mean 
+/-STDEV. T-test was performed for statistical significance. p<0.05 indicates that the 
difference is statistically significant. (b) MCF7 cells were lysed 0, 4 or 24 hrs after 
irradiation with 7 Gy and extracts were analysed by western blotting with the indicated 
antibodies. 
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5.2.3. Bioinformatic characterisation of the 5 NEDP1 transcript 
variants and prediction of the p53 binding site 
Since ulp-3 and cep-1 deletions result in the same phenotype in response to DNA-
damage, but Ulp-3 is not required for induction of CEP-1-dependent genes, we reasoned 
that the deNEDDylating enzyme might be itself a target for CEP-1. Therefore we 
decided to test whether p53 is a transcription factor for NEDP1 in mammalian cells. 
First we performed a bioinformatic analysis on the transcript variants of NEDP1, and 
predicted the p53 binding site. 
The NEDP1 gene is located to chromosome 15. Alternative splicing results in 5 
transcript variants. Sequence alignment between the mRNA variants showed that they 
are only different in their 5’UTR (Figure 5.9). All splice variants encode the same 
protein. 
Transcription factor binding sites for the senp8 gene were predicted with MatInspector 
software (www.genomatix.de). MatInspector uses a large library of matrix descriptions 
for transcription factor binding sites to identify matches in DNA sequences. Several 
transcription factors were predicted to bind to NEDP1 promoter including p53, the well-
known transcription factor involved in DNA damage response. The software predicted 
three p53 binding sites. We therefore designed ChIP qPCR primers that amplify DNA 
fragments around the following predicted p53-binding site: 
GAGGCAAGATGTTGGCATGGGGG. This binding site is located -334 bp from the 
transcription start site (TSS), upstream of all the splice variants, as shown on Figure 
5.10.  
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Figure 5.9: Sequence alignment between the parts of the 5’UTRs that are different. 
The sequence alignment between the mRNA variants the variants (1.: accession 
number: NM_001166340; 2.: accession number: NM_001172111.1; 3.: accession 
number: NM_001172109; 4.: accession number: NM_001172110.1; 5.: accession 
number: NM_145204.3) was performed by ClustalX. 
 
 
Figure 5.10: Schematic representation of the nedp1 splice variants and the location 
of the predicted p53 binding site. 
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5.2.4. Chromatin Immunoprecipitation experiments show p53 
recruitment to the nedp1 promoter 
We found that nedp1 gene expression increases upon ActD, Dox and IR treatment. In 
order to test whether p53 is a regulator of the nedp1 gene expression, we investigated 
the recruitment of p53 to the predicted binding site of the nedp1 promoter by chromatin 
immunoprecipitation experiments. First, we treated MCF7 cells with ActD for the 
indicated time intervals. After harvesting, DNA was cross-linked and sheared to ~500 
bp length fragments. p53 and IgG antibodies (control) were used for 
immunoprecipitation. ChIP primers designed to nedp1 and bax promoter were used in 
qPCR reactions to determine whether p53 is associated with the promoters. BAX is a 
proapoptotic protein, a member of the Bcl2 family. Bax is a p53 target gene and its 
expression is upregulated upon DNA damage; therefore we used bax as a positive 
control in our experiment. We observed the recruitment of p53 both to the bax and 
nedp1 promoters, indicating that p53 is indeed a transcription factor that potentially 
regulates nedp1 gene expression. We next tested whether p53 is recruited to the nedp1 
promoter upon ionizing irradiation as well. This time we used HCT116 cell line, 
containing wild-type p53, and a p53-deficient derivative, as a negative control. Cell 
lines were irradiated with 7 Gy, and harvested 0, 1, 3, 5 and 8 hrs after the treatment. 
Chromatin immunoprecipitation was performed with p53 antibody, and the associated 
promoters were detected with bax and nedp1 primers in a qPCR reaction. Consistent 
with the data obtained with ActD treatment, p53 was immunoprecipitated on the nedp1 
promoter upon IR. These data indicate that p53 can act as a transcription factor for 
nedp1 and the recruitment of p53 on nedp1 is comparable to that for bax (a well-
described pro-apoptotic p53 target gene). 
The experiments were performed with the help of Bidesh Mahata. 
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Figure 5.11: p53 occupies the nedp1 promoter upon ActD treatment and IR 
(a) MCF7 cells were treated with 5 nM ActD for the indicated time intervals. p53 and 
IgG antibodies (control) were used for immunoprecipitation. ChIP primers designed to 
nedp1 and bax promoter were used in qPCR reactions to determine whether p53 is 
associated with the promoters. (b) HCT116 (+/+) or (-/-) cells were exposed to 7 Gy IR 
for the indicated time intervals. After immunoprecipitation with p53 antibody, the 
isolated DNA fragments were tested in a qPCR reaction with nedp1 and bax specific 
primers. 
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5.2.5. p53 is not essential for nedp1 gene induction upon IR 
Since p53 was not the only transcription factor predicted by MatInspector, we wanted to 
know whether it plays an essential role in nedp1 gene induction upon IR. We addressed 
this question by using the two HCT116 cell lines that are isogenic except for p53 (either 
p53+/+ or p53-/-). We exposed cells to 7 Gy of IR, and monitored the gene expression 
by qPCR 8 hrs after irradiation. We also monitored changes of a well-established p53 
target gene (p21 expression), as a positive control. The increase in p21 gene expression 
upon IR was p53 dependent, since the induction could not be observed in the cell line 
lacking p53. However, nedp1 was still induced in HCT116 p53-/- cell line, suggesting 
that p53 is not the main transcription factor for this gene. In the absence of p53, other 
factors can induce nedp1 expression. 
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Figure 5.12: nedp1 is induced in a p53-independent manner 
HCT116 p53 negative (-/-) and positive (+/+) cells were irradiated with 7 Gy and 
harvested 0 and 8 hrs after irradiation. The changes in (a) nedp1 and (b) p21 mRNA 
levels were detected by quantitative real-time PCR with specific primers. T-test was 
performed for statistical significance between the gene inductions in the different cell 
lines. p<0.05 indicates that the difference is statistically significant. 
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5.2.6. NEDP1 knockdown results in impaired caspase 3/7 
activation upon IR, but not upon staurosporine treatment 
Ionizing irradiation triggers DNA damage-induced apoptosis. Staurosporine is a 
relatively non-selective protein kinase inhibitor that induces cell death in a non-
genotoxic manner. Both treatments result in induction of the effector caspases. In order 
to test whether NEDP1 is specific for the DNA damage-induced apoptosis, we 
measured caspase 3/7 activity induction upon IR or staurosporine treatment in a 
luminescence assay, in control or NEDP1 knockdown conditions.  
HCT116 cells were transfected twice within a period of 5 days either with NEDP1 or 
NT siRNA. 6 hrs before harvesting, cells were either left untreated, or exposed to 7 Gy 
ionizing irradiation or 1 µM staurosporine. Caspase activity was measured using the 
luminescence Caspase-Glo 3/7 Assay (Promega), according to the manufacturer’s 
instructions. We observed a ~3- and 2,5-fold induction in caspase activity upon IR and 
staurosporine treatment, respectively. Knockdown of NEDP1 compromised caspase 
induction in response to IR while it did not have any effect on staurosporine-mediated 
caspase activity. This preliminary observation indicates that NEDP1 is specifically 
required for the DNA damage induced apoptosis; consistent with the data obtained in C. 
elegans. 
A member of the lab has also performed an experiment to quantify apoptotic cells after 
IR and found that NEDP1 siRNA protects cells from cell death. HCT116 cells were left 
untreated or treated with NEDP1 siRNA and then exposed to IR. Cells were stained 
with Annexin V and the number of Annexin V positive cells were quantified by flow 
cytometry.  The dye detects the externalization of phosphatidylserine residues on the 
outer plasma membrane of apoptotic cells[315]. We have found that the number of the 
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apoptotic cells decreased in the absence of NEDP1 (data not shown). This result 
indicates that the phenotype we obtained in C.elegans, where ulp-3 deletion prevents 
the formation of apoptotic corps in the germ line after IR treatment is also conserved in 
mammalian cells. 
 
Figure 5.13: NEDP1 knockdown is required for caspase 3/7 activation upon IR, 
but not upon staurosporine treatment. 
HCT116 cells were treated with NT or NEDP1 siRNA for 5 days. 6 hrs before 
harvesting, cells were either left untreated, or exposed to 7 Gy ionizing irradiation or 1 
µM staurosporine. Caspase activity was measured using the luminescence Caspase-Glo 
3/7 Assay (Promega). The experiment was performed in triplicates, data represent mean 
+/- STDEV. T-test was performed for statistical significance for the caspase activity 
induction with NT or NEDP1 siRNA. p<0.05 indicates that the difference is statistically 
significant. While NEDP1 siRNA significantly reduces effector caspase activation upon 
IR, it does not significantly affect staurosporine-induced apoptosis. 
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5.2.7. Testing the role of NEDP1 in caspase 8 and 9 assays 
induction 
As mentioned in Chapter 1.10, there are two main apoptotic pathways, the extrinsic 
(death receptor) and the intrinsic (mitochondrial) cascade. They both converge on the 
same execution pathway. Caspase-8 and -9 are the initiator caspases for the extrinsic 
and intrinsic cascade, respectively. We tested which pathway is NEDP1 involved in by 
measuring caspase 8 or 9 activity after doxorubicin treatment in the presence and 
absence of the deNEDDylating enzyme. 
A 5-days double treatment of NEDP1 or NT siRNA was performed in HCT116 cells. 
6hrs before harvesting, cells were either left untreated, or treated with 1µM doxorubicin. 
Caspase activity was measured using Caspase-Glo 8 or 9 Assays (Promega), according 
to the manufacturers instructions (Figure 5.14). We have also performed the experiment 
with IR-treated cells and measured Caspase 8 and 9 activities 15 hrs after IR (data not 
shown). 
NEDP1 knockdown did not significantly affect caspase induction in any cases. This 
result might suggest that NEDP1 acts downstream from the initiator caspases, possible 
directly or indirectly on the effector caspases. 
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Figure 5.14: NEDP1 knockdown doesn’t compromise caspase 8 or 9 induction. 
A 5-days double treatment of NEDP1 or NT siRNA was performed in HCT116 cells. 6 
hrs before harvesting, cells were either left untreated, or treated with 1 µM doxorubicin. 
Caspase activity was measured using the luminescence-based Caspase-Glo 8 or 9 
Assays (Promega). The experiment was performed in triplicates, data represent mean 
+/- STDEV. 
5.2.8. NEDP1 knockdown results in accumulation of NAE-
dependent, yet to be identified NEDD8 substrates 
To date, targets for NEDP1 under entirely endogenous conditions have not been 
identified. In order to understand the role of the enzyme, we need to find targets for its 
deNEDDylating activity. First we wanted to monitor protein NEDDylation upon 
knockdown of NEDP1. We therefore treated U2OS cells with siNEDP1 for 5 days (with 
the double-transfection procedure described in the Methods), lysed them with 2X SDS, 
and detected the NEDD8 conjugates by western blotting. Indeed, knockdown of NEDP1 
resulted in the increase of distinct NEDD8 bands; mainly in the molecular size range 
lower than cullins. Since we have shown that not only NAE, but also Ube1 can activate 
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NEDD8, we were interested to test whether the substrates controlled by NEDP1 are 
NEDDylated through the canonical or the ubiquitin-conjugation pathway. We 
performed the knockdown experiment in the presence of MLN4924 or siUbe1, and 
found that NEDD8 modification of NEDP1 substrate proteins are promoted entirely by 
the canonical (NAE-mediated) NEDD8 conjugation pathway. 
 
Figure 5.15: NEDP1 substrates are NEDDylated through the canonical NEDD8 
pathway. 
U2OS cells were transfected with the indicated siRNAs, then treated or not with 1 µM 
MLN4924 for 16 hrs. Cell extracts were analyzed by western blotting. 
 
 194 
5.2.9. Doxorubicin treatment does not result in global NEDD8 
response 
In order to see how NEDD8 responds to DNA damage, we have also performed a 
western blot analysis on samples derived from U2OS cells that were treated or not with 
the DNA damaging agent doxorubicin. We did not detect any obvious change in the 
NEDDylation profile in response to the drug, suggesting that DNA damage does not 
result in a global NEDD8 response that can be detected by western blotting. 
 
Figure 5.16: NEDD8 does not respond globally to doxorubicin treatment. 
U2OS cells were treated with 1 µM doxorubicin for 16 hrs before being lysed and 
analyzed by western blotting. 
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5.2.10. Cul4A and Cul1 NEDDylation are not affected by NEDP1 
knockdown 
Since the substrates controlled by NEDP1 are NAE-dependent, we wanted to test 
whether the main NAE targets, cullins are also affected by NEDP1 siRNA. Cul1 and 
Cul4A have been reported to be involved in DNA damage responses. Moreover, in C. 
elegans, the SCF ligase complex has been shown to control apoptosis through 
regulating CEP-1[124]. Therefore we reanalysed the samples from Figure 5.15 and 
compared the NEDDylation status of the cullins in controlled, MN4924-or siNEDP1 
treated conditions. Our data showed that NEDP1 knockdown did not affect 
NEDDylation of Cul4A and Cul1, while MLN4924 as expected completely inhibited 
them. 
It would be interesting to test how NEDP1 siRNA affects CRL activity, not only their 
NEDDylation status. The extracts could be analysed with antibodies specific for CRL 
substrates, such as p21 or Cyclin E for Cul1 and DDB2 for Cul4A. 
 
Figure 5.17: NEDP1 knockdown doesn’t affect Cul4A and Cul1 NEDDylation. 
U2OS cells were transfected with the indicated siRNAs, then treated or not with 1 µM 
MLN4924 for 16 hrs. Cell extracts were analyzed by western blotting. 
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5.3. Discussion and future directions 
We have shown that NEDP1 is induced upon DNA damage and required for the 
activation of the effector caspase 3 and 7. We have also found that p53 can act as a 
transcription factor for nedp1, however its role in nedp1 induction is not indispensible. 
NEDP1 most likely affects a downstream protein of the cascade, or parallel to the 
intrinsic apoptotic pathway. 
Since the core apoptotic pathway in worms and humans is conserved, we decided to 
look for a target for the deNEDDylase activity of NEDP1 within the orthologs of CED-
9, CED-4 and CED-3. We have tested if Bcl-2 (~CED-9), Apaf-1 (~CED-4) and 
caspase 2, 3 and 7 (~CED-3) are NEDDylated. We have created an HCT116 cell line 
stably expressing low levels of His6NEDD8, and isolated NEDDylated proteins from 
untreated, IR or siNEDP1 treated cells. After Ni2+-purification, we analysed the samples 
with Bcl-2, Apaf-1 and caspase 2,3,7 specific antibodies. However, we failed to detect 
the endogenous proteins from the pulldowns in the conditions used. NEDP1 might not 
act directly on any of these proteins, but rather affects the pathway indirectly. Since the 
formation of the apoptosome is crucial for the activation of effector caspases, it would 
be interesting to test in a gel filtration assay whether knockdown of the deNEDDylating 
enzyme disrupts the complex. 
During my PhD, Broemer et. al has shown that DEN-1 (NEDP1 ortholog in 
Drosophila) activates the effector caspase drICE by removing NEDD8 from the 
protein[104]. The NEDDylation of drICE was later shown to be Ube1-dependent. 
Whether or not endogenous DEN-1 has an effect on the caspase-7 ortholog was not 
investigated in the paper. 
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In order to find endogenous targets for NEDP1’s deNEDDylase activity, the best would 
be to use an unbiased approach, such as mass spectrometry-based proteomics. The 
method for the identification of NEDDylation sites with a R74K NEDD8 stable cell line 
mentioned in Chapter 4.3 could be used in a SILAC experiment. A labelled cell 
population could be treated with siRNA or shRNA for NEDP1, and the regulated 
proteins/ NEDDylation sites could be identified by mass spectrometry. Since NEDP1 
knockdown results in the accumulation of lower molecular weight NEDD8 conjugates, 
recombinant Rpn10 might be also a good tool to isolate them under endogenous 
conditions. However, only partial NEDP1 knockdown can be achieved with the siRNA 
approach. Therefore it would be advantageous to isolate NEDDylated proteins from 
worms from a ulp-3 deletion background, and compare them to wild-type animals in a 
SILAC experiment[316]. 
NEDP1 might not affect directly the core apoptotic pathway. In mammalian cells, there 
are many additional factors that play role in regulating the signalling cascades that lead 
to apoptosis. The transcription factor E2F-1 has been shown to be induced in response 
to DNA damage[317], and is important for the activation of the p73 proapoptotic target 
gene[318]. Two recent studies demonstrated that E2F-1 is posttranslationally modified 
by NEDD8[150, 151]. Aoki et al has also shown that knockdown of NEDP1 attenuated 
p73 expression induced by E2F-1 and abolished apoptosis. This result fits to our 
observations that the deNEDDylating enzyme is required for DNA damage-induced 
apoptosis and might explain the phenotype in mammalian cells, but not in C. elegans. 
The worm ortholog of E2F-1, EFL-1 is not required for DNA damage-induced germ 
cell apoptosis[319], therefore the apoptotic defect cannot be explained by the 
suppositional EFL-1 inhibition by ulp-3 deletion. 
It is also a possibility that the NEDD8 accumulation seen on the western blot after 
NEDP1 knockdown does not represent NEDDylated substrates, but indicates the 
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appearance of unanchored chains in the cells. As discussed in the Introduction and 
Chapter 4.3, these free chains can play important biological roles such as providing 
platforms for protein interactions. NEDP1 might control the formation of such polymers 
by eliminating them. It would be interesting to test whether NEDP1 is able to 
disassemble NEDD8 chains from the proximal end, like it was shown in the case of 
Usp5 and free ubiquitin chains. 
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Chapter 6: Final discussion 
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The work described in this thesis expanded the scope of NEDD8 conjugation. 
Historically, NEDD8 has been thought to influence the ubiquitin system via the 
regulation of CRLs through a covalent modification that is mediated by a specific set of 
NEDD8 activating and conjugating enzymes. This is thought to be the exact function of 
NEDD8 that is targeted therapeutically by MLN4924. However, as described in this 
thesis, we have discovered a more profound interplay between NEDD8 and ubiquitin, 
where the ubiquitin E1 activating enzyme Ube1 activates NEDD8 under stress 
conditions such as proteasome inhibition, heat shock and oxidative stress. NEDD8 
engagement into the ubiquitin conjugation system results in mixed chain formation that 
is recognized by ubiquitin receptors. This discovery has expanded the function of 
protein regulation by NEDD8 beyond CRLs, and also raised many questions. What is 
the biological function of Ube1-mediated NEDDylation? What are the targets? How are 
the NEDD8/ubiquitin mixed chains recognized and processed in cells? 
Determining the biological consequences of Ube1-mediated NEDDylation would not 
only be interesting, but might be therapeutically relevant. The proteasome inhibitor 
velcade has been used in clinics for the treatment of multiple myeloma and mantle cell 
lymphoma. Moreover, it is likely to be used for other applications in the future, for 
instance to deplete normal antibody-producing plasma cells in transplant patients to 
prevent from antibody-mediated rejection. Therefore, it would be important to 
determine the consequence of elevated NEDDylation in patient treatment, or how it 
might affect combinatorial therapy with other drugs. For instance, we showed that the 
combination of MG132 and MLN4924 results in an even more enhanced Ube1-
mediated NEDDylation. By inhibiting NEDDylation of cullins, the major NEDD8 
targets, MLN4924 “frees up” a large proportion of conjugable NEDD8 that is used by 
Ube1 if a trigger occurs. Paradoxically, inhibition of the canonical NEDD8 conjugation 
cascade results in increased NEDDylation by the alternative pathway under certain 
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circumstances. MLN4924 is now in clinical phase II trial for the treatment of acute 
myeloid leukemia, and reports on potential applications for the treatment of other types 
of cancer have been appearing recently. Whether the increase in Ube1-mediated 
NEDDylation on non-cullin substrates by MG132 and MLN4924 would have any effect 
(positive or negative) on cancer treatment has to be determined.  
In addition to cancer therapy, Ube1-mediated NEDDylation can be linked to disease 
conditions that involve decreased proteasome activity. The ubiquitin proteasome system 
plays a key role as a quality control pathway that removes misfolded, or damaged 
proteins. The cellular insults studied in this thesis, heat shock and oxidative stress, have 
a well-defined effect on generating misfolded or oxidised damaged proteins and their 
removal by the UPS is critical for the cells to recover from these insults[320]. What is 
also evident is that the age-related decrease in proteasome activity observed in many 
tissues is associated with the accumulation of misfolded and/or oxidised damaged 
proteins. These observations are linked to the development of pathology including 
cardiac dysfunction, cataract formation and neurodegenerative diseases such as 
Alzheimer’s and Parkinson’s[320]. NEDD8 and ubiquitin also accumulate under 
pathological conditions in areas of protein aggregation such as Lewy bodies in 
Parkinson’s disease, Rosenthal fibres in astrocytomas and Mallory bodies in alcoholic 
liver disease [321, 322]. Our studies provide a possible mechanistic link of how 
perturbations in proteasomal activity could result in the accumulation of NEDD8 
conjugates observed in many pathological conditions.  
We have characterized NEDD8 in another therapeutically relevant stress response, the 
DNA damage-induced apoptosis. Our group in collaboration with Anton Gartner’s lab 
has found that the C. elegans ortholog of the deNEDDylating enzyme NEDP1, ulp-3 is 
required for DNA damage-induced apoptosis in the germ line. We have shown that the 
role of NEDP1 is conserved between worms and humans: NEDP1 is induced in 
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response to IR in the mRNA and protein levels, and is required for the induction of 
effector caspase activity. Annexin V staining has also confirmed that NEDP1 siRNA 
protects cells from cell death after IR, consistent with the phenotype observed in C. 
elegans. We found p53 as a potential transcription factor controlling nedp1 gene 
expression, however, it is not required for nedp1 induction upon IR. We determined that 
NEDP1 is specifically required for DNA damage-induced apoptosis, as NEDP1 siRNA 
had no effect on caspase 3/7 activity induced by staurosporine, a non-genotoxic agent 
that induces apoptosis. 
Even though NEDD8 does not respond globally to DNA damaging agents such as 
doxorubicin treatment or IR (as observed from western blots), knockdown of NEDP1 
results in the accumulation of NEDD8 conjugates that are dependent on NAE. As 
discussed in chapter 5.3, these conjugates have to be further investigated. First of all, it 
would be interesting to know whether they are unanchored NEDD8 chains, or substrate 
proteins. All of the bands detected on the western blot are lower molecular weight than 
cullins, suggesting that NEDP1 controls NEDDylation of non-cullin substrates. The 
lower molecular weight bands have been suggested to be degraded cullin complexes, a 
hypothesis that needs to be tested. However, since NEDP1 possesses little 
deNEDDylating activity towards cullins in vivo in model organisms, its targets most 
likely are other NAE-dependent NEDD8 substrates. For the identification of NEDP1 
targets, an unbiased, site-specific proteomics approach would be the most suitable, 
preferably performed in a model organism on a NEDP1 knockout genetic background. 
The data from the C.elegans studies show that NEDP1 is not an essential gene, which 
allows proteomic studies on the NEDP1 knockout background. 
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NEDDylation has become a rapidly expanding field since the development of the NAE-
inhibitor MLN4924. The utilization of MLN4924 makes it possible to study the 
classical NEDD8 pathway in diverse tumors and animal model systems in context with 
cancer therapy. The number of studies appearing since MLN4924 is available for 
research use is increasing, and they indicate a very complex regulation of protein 
homeostasis by a single modification, NEDD8. Until recently, NEDD8 has been 
thought to conjugate exclusively to cullins and a handful of other substrates. So far, 
there have been only a few substrates identified under endogenous conditions to be 
NEDDylated by the canonical NEDD8 pathway: cullins and VHL. Additionally, 
NEDD8 modification on p53 and HIF1α has been shown to be mediated by both the 
NAE and Ube1. However, we observed that proteins distinct from cullins are also 
regulated by MLN4924, such as the ones that appear on the western blot after NEDP1 
knockdown.  
In addition, we have discovered that there are NEDD8 substrates that depend on the 
ubiquitin conjugation cascade, further expanding the NEDD8 proteome. Since for a 
long time the only well-established role for NEDD8 was the regulation of CRLs, and 
Hjerpe et al. has shown that Ube1 activates NEDD8 when the ubl is 
overexpressed[260], the Ube1-mediated NEDD8 conjugation has been so far referred to 
as “erroneous conjugation of NEDD8”, “misactivation” or “faulty neddylation”[323, 
324]. These labels indicate that the scientific community regards the mechanism as an 
artifact; regardless we showed that the NEDD8 activation by Ube1 occurs 
endogenously, under physiological stress conditions. In my opinion this novel type of 
NEDDylation should not be labeled as an error, it should rather be investigated open-
mindedly. I would rather term the phenomenon as alternative, non-canonical or Ube1-
mediated NEDDylation. I do agree to avoid overexpression whenever it is possible, and 
interpret the data obtained from overexpression experiments with caution. When a new 
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NEDD8 target is found, the manner of NEDDylation should be determined and 
classified as NAE-/or Ube1 target. However, Ube1 targets should not be regarded as 
experimental artifacts. Even though we don’t have a proof that this type of 
NEDDylation is biologically significant, we cannot exclude it either. 
The number of groups studying NEDD8-ubiquitin chains and Ube1-dependent 
NEDDylation is rapidly increasing. Research in the last few years has opened a door to 
a greater understanding of protein regulation by NEDD8, and left the research 
community with numerous exciting mechanistic and functional questions to be 
answered. Taken together, our studies indicate that the function of NEDD8 extends 
beyond the regulation of Cullin Ring Ligase complexes. The new challenges in the field 
are: 1, to determine non-cullin substrates for the canonical NEDD8 pathway and 
NEDP1 2, determine substrates for NEDDylation through the ubiquitin enzymes and 
identify the enzymes that control the non-canonical pathway 3, investigate the 
biological relevance of the non-canonical NEDD8 conjugation (for example how the 
degradation machinery recognizes and most importantly deals with the mixed chains). 
 
When the yeast NEDD8, Rub1 was found to be conjugated to cdc53 in Saccharomyces 
cerevisiae, the discovery was initially greeted cautiously. The reason for it was that 
Rub1 deletion mutants in budding yeast were ‘distressingly healthy’. Only later on, 
when studied in different genetic organisms, the functional importance of the NEDD8 
pathway became evident[325]. Maybe the same ‘enlightenment’ will come in 
connection with the Ube1-mediated NEDDylation, once we find the right tool to study 
it? 
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